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 Pluripotent embryonic stem cells (ESCs) possess an unlimited capacity for 
self-renewal. This property of ES cells is both defining and unique. Harnessing this 
potential of ESCs would provide tremendous opportunity in the field of regenerative 
medicine and its attempts to combat degenerative diseases such as Parkinson’s, 
muscular dystrophy, etc.  
 In 2006, Shinya Yamanaka was able to demonstrate that the ectopic 
expression of four proteins could reverse the process of differentiation and provide 
somatic cells with the characteristics ESCs. One year later, James Thompson’s group 
proved the same feat could be accomplished in human somatic cells using a different 
set of four proteins, including Nanog. The prospect of converting one’s own cells 
into a stem cell which could subsequently differentiate and repopulate an area of the 
body afflicted by gross degeneration was revolutionary. In the years following 
Yamanaka’s and Thompson’s discoveries, however, there has been little insight 
gained into how these proteins are regulated post-translationally. 
 In this study, four proteins which had previously been identified by 
Yamanaka as being ‘pluripotency factors’ were used as baits in order to ascertain a 
protein-protein interaction network. This network was subsequently interrogated 
using various chemical compounds and small molecules in order to dissect the signal 
transduction pathways feeding into pluripotency, as well as, post-translational 
modifications regulating the factors themselves. 
 In this way, the chemical inhibitor H89 was found to decrease the presence of 
Nanog phosphorylation and possibly its dimerization resulting in the Nanog protein 
being destabilized and targeted for degradation. Inversely, the pan-cullin inhibitor 
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MLN4924 was identified to increase the abundance of both phosphorylated Nanog 
and total Nanog protein. In an attempt to identify the Cullin Ring Ligase (CRL) 
responsible for the degradation of Nanog protein in ESCs, each cullin identified in 
the protein interaction network was inhibited using specific shRNAs. Quantitative 
fluorescence microscopy was performed and identified that inhibition of CUL3 
increases Nanog protein levels, suggesting that a CUL3-based CRL may be 
responsible for the post-translation regulation of Nanog.  
Additionally, the quantitation of Sox2 protein levels in CUL4B shRNA cell 
line demonstrates that Sox2 protein levels may be regulated by a CUL4B-based 
CRL. Further studies will reveal whether or not CUL4A depletion also results in 
elevated Sox2 protein levels. If not, this would include the pluripotency factor Sox2 
among the recently identified CUL4B-isoform-specific substrates for degradation 
and possibly provide the basis for a hypothesis of developmentally regulated 
substrate specificity.  
In addition to MLN4924, several other small molecules were identified as 
being able to increase phospho-Nanog protein levels in this study. Among them were 
the cell permeable peptides Ht-31 and PKI (14-22) amide. These peptides were found 
to both stabilize phospho-Nanog and produce ES cell colonies that uniformly express 
the Nanog protein. The development of a growth medium containing these peptides 
in order to maintain homogeneous pluripotent ES cells is currently in progress and 
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CHAPTER 1: Introduction 
  
 The body of work presented in this thesis encompasses a wide range of 
topics. As a result, a review of the literature for each topic will be presented in this 
Chapter. In the first section (1.1), I will describe the developmental stage from which 
pluripotent mouse embryonic stem cells are derived a well as their maintenance in 
culture. In the second section (1.2), I will present the discovery of pluripotency 
factors in mouse embryonic stem cells and their ability to confer the pluripotent 
embryonic stem cell phenotype. In the third section (1.3), I will provide an update on 
protein-protein interaction networks for pluripotency factors obtained using an IP-
LC-MS/MS strategy. In the fourth section (1.4), I will detail the post-translational 
regulation of protein abundance in cells by the ubiquitin proteasome system. In the 
fifth section (1.5), I will present the Cullin-RING ligase family of E3 ubiquitin 
ligases and the mechanism by which they target their specific substrates for 
degradation by the 26S proteasome. In the sixth section (1.6), I will provide an 
overview of chemical compounds and small molecules that have been discovered to 
provide a control over the various cell fate decisions made by pluripotent stem cells.  
 
1.1       The derivation and culture of mouse embryonic  stem cells 
The initial stages of mammalian reproduction involve the establishment of a 
fertilized egg, that is, the fusion of an oocyte and a sperm cell. This cell is now 
classified as a totipotent stem cell. Totipotent is the term assigned to cells that can 
give rise to all the different types of cells in the body and construct an entire 
organism (Mitalipov and Wolf, 2009). In the subsequent rounds of cell division, cells 
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maintain their totipotency until they reach the blastocyst stage of development (Do et 
al., 2007). The blastocyst is an early stage embryo comprised of approximately 50 to 
100 cells and containing a cluster of cells called the inner cell mass (ICM).  
These embryonic stem cells in the ICM are pluripotent and have an 
apparently unlimited capacity for self-renewal (Suda et al., 1987). Pluripotent is the 
term assigned to cells that are derived from the ICM of the early developing embryo 
(blastocyst) and give rise to any cell type found in the three primary germ layers of 
the embryo (endoderm, mesoderm and ectoderm), as well as germ cells (Beddington 
and Robertson, 1989; Gardner and Brook, 1997; NIH – Report on Stem Cells, 2001; 
Nichols, 2001; Hubner et al., 2003; Toyooka et al., 2003). Unlike totipotent cells, 
pluripotent stem cells do not contribute to the formation of the placenta or extra-
embryonic membranes. 
At this stage of embryonic development, the previously totipotent stem cells 
have differentiated and formed a layer of trophoblast cells enveloping a mass of 
embryonic stem cells. An important function of the trophoectoderm layer of the 
blastocyst-stage embryo is the secretion of the cytokine Leukemia Inhibitory Factor 
(LIF). The stem cells residing within the ICM widely express the LIF receptor and 
rely heavily on LIF-dependent signaling in order to maintain their pluripotency 
through the activation JAK/STAT and MAPK signalling cascades (Burdon et al., 
1999; Niwa et al., 1998; Smith 2001).  
In 1981, Evans and Kaufman became the first to report the establishment of 
mouse pluripotent stem cells in culture (Evans and Kaufman, 1981). Figure 1.1 
illustrates the developmental stage from which pluripotent stem cells are derived as 




Figure 1.1: Illustration of the origin and potential of pluripotent stem cells. 
Image taken from www.stemcellresearchfoundation.org.  
 
 As a consequence of removing stem cells from the ICM and placing them in 
culture, however, is that they are deprived of the supply of LIF that the 
trophoectoderm layer naturally provides. Therefore, stem cells were required to be 
maintained on primary mouse embryonic fibroblasts (MEFs) which would secrete 
LIF into the culture medium and inhibit differentiation. The identification of LIF’s 
ability to maintain mouse embryonic stem cells’ pluripotential in culture enabled the 
culturing the cells in feeder-free conditions (Smith et al., 1988; Williams et al., 1988; 
Peace and Williams, 1990; Nichols et al., 1990). Subsequent modifications and 
improvements in culture techniques have made the routine maintenance and 
differentiation of pluripotent mouse embryonic stem cells in monolayer culture 
possible (Smith et al., 1992; Nichols et al., 2006).  
The ability to maintain pluripotent stem cells as monolayers in culture 
provided several advantages for fundamental research. The main advantage was the 
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removal of the MEF feeder layer which made embryonic stem cell cultures a 
heterogeneous population of different cell types. As a result, it was difficult to use 
stem cell cultures to perform certain types of experimental studies, i.e., quantitative 
mass spectrometry, IP-LC-MS/MS, to name a few.  
Another advantage is that the growth of a uniform monolayer of stem cells 
made reliable small molecule screening studies possible. In a monolayer culture, 
each cell is exposed to exactly the same concentration of compound for exactly the 
same amount of time thereby ensuring a uniform response by the cells and less 
variation between the conditions being tested. In the case of chemically inducing 
stem cells to differentiate into a particular cell type, for example, a monolayer culture 
system ensures that the required differentiation transcriptional programs are activated 
uniformly and in the maximum number of cells. This optimized level of control over 
cell fate decisions is simply not possible in a traditional spheroid culture system.  
In addition, a monolayer culture system allows for the individual responses of 
each cell in the population to a particular perturbation to be accurately visualized and 
quantified using fluorescence-based confocal microscopy assays. Thus, enabling 
highly sensitive measuring and monitoring of the various cell fate decisions being 
made by cells throughout entire populations of stem cells.  
 
1.2 Pluripotency factors in mouse embryonic stem cells 
 In addition to their ability to generate all tissue-specific cell types of the  
body, embryonic stem cells can also reprogram differentiated cells when they are  
fused to a somatic cell (Tada et al., 2001). This observation made by Tada et al., 
2001, indicated that embryonic stem cells contain unknown factors that can confer  
pluripotency to somatic cells and drew the interest of researchers in the field of  
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regenerative medicine. Among them, was Shinya Yamanaka from the Institute for  
Frontier Medical Sciences at the University of Kyoto in Japan who has contributed  
significantly to this field (Mitsui et al., 2003; Maruyama et al., 2005; Takahashi et  
al., 2006; Takahashi et al., 2007; Okita et al., 2007). After having characterized  
several genes which are specifically expressed in embryonic stem cells, Yamanaka  
selected 24 of these genes for further testing of their ability to confer pluripotency to  
mouse embryonic fibroblasts (Takahashi et al., 2006). 
Takahashi and Yamanaka reported the ability to reprogram mouse fibroblasts 
via retroviral transduction of four transcription factors, Oct4, Sox2, KLF4 and cMyc 
(Takahashi and Yamanaka, 2006). The following year, they demonstrated the 
ability to reprogram adult human skin cells using the same four defined factors 
(Takahashi et al., 2007). Another group reported the ability of a different 
combination of four factors, (Nanog, Oct4, Sox2 and Lin28) were sufficient to 
reprogram human foreskin fibroblasts to pluripotent stem cells, (Yu et al., 2007).  
The study by Yu et al., 2007 revealed that the four factors used by  
Yamanaka were not exclusive. This led to the relentless pursuit of undiscovered  
pluripotency-inducing factors in an attempt to further define the exact composition of 
the mysterious cocktail of factors contained within the stem cell nucleus that was  
first described by Tada et al., 2001 more than a decade ago. 
A summary of the various methods routinely used by scientists to generate 
induced pluripotemt stem cells (iPSCs) from somatic cells using Yamanaka’s four 




Figure 1.2: Methods of generating induced pluripotent stem cells (iPS). 
Image in TOP panel taken from Okita et al., 2007. Image in the BOTTOM panel taken from 
Lowry and Plath, 2008. 
 
In the years that have followed these landmark publications, multiple groups 
have reported the ability to reprogram mouse and human somatic cells using 
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different factors such as Esrrβ, Nr5a2 (Feng et al., 2009; Heng et al., 2010), different 
numbers of factors such as Sox2 and Oct, Oct4 alone (Huangfu et al., 2008; Kim et 
al., 2009), using a plasmids (Okita et al., 2008; Stadtfeld et al., 2008; Woltjen et al., 
2009; Kaji et al., 2009), in combination with small molecules (Shi et al., 2008; 
Maherali et al., 2009) and by direct delivery of the proteins themselves using defined 
factors (Li et al., 2009; Kim et al., 2009). These rapid developments are the result of 
the intense pursuit of patient-specific iPSCs for the treatment of degenerative 
diseases such as Parkinson’s or Alzheimer’s. 
The work of Yamanaka has resulted in the establishment of an entirely new 
branch of biology. More importantly, it has challenged our fundamental beliefs 
about mammalian development which has always been thought to occur linearly 
and in one direction (Beddington and Robertson, 1989; Gardner and Brook, 1997).  
We now know that this process can be reversed and we have refined our definition of  
a pluripotency factor. A pluripotency factor can currently be defined as any protein  
that can maintain the pluripotency of an embryonic stem cell and can also confer  
pluripotency to a somatic cell. 
  
1.3 Protein-protein interaction mapping using LC-MS/MS 
While much work has been done to characterize the genes either expressed 
exclusively or upregulated in embryonic stem cells, very few datasets have been 
published with regards to the protein-protein interactions in which pluripotency 
factors are involved. Exactly how Yamanaka’s four reprogramming factor proteins 
confer pluripotency to somatic cells remains somewhat elusive. Considering that the 
majority of pluripotency factors are transcription factors, it is generally assumed that 
they confer pluripotency to somatic cells by activating the transcription of other 
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embryonic stem cell-specific genes. In this way, they change both the transcriptional 
and proteomic composition of the cell from a tissue specific mixture to one that is 
characteristic of a pluripotent cell. This view of reprogramming may be a gross over-
simplification especially when considering that one of the initial factors reported as 
being capable of reprogramming human cells was not a transcription factor at all, i.e., 
the mRNA binding protein Lin28 (Yu et al., 2007). Two of the more recently 
identified reprogramming factors are the hormone responsive transcriptional 
repressors and co-activators Esrrβ and Nr5a2 (Feng et al., 2009; Heng et al., 2010). 
These reports suggest that the transcriptional repression of certain sets of genes may 
be equally as important as the activation of the Oct4, Sox2 and Nanog core 
transcriptional circuitry in ES cells. Furthermore, these factors suggest that the 
transcriptional activation and repression mechanisms required for the induction of 
pluripotency are further integrated with extracellular signaling. 
One approach to deciphering the mechanisms by which reprogramming 
occurs is to understand the protein-protein interactions of these factors. Identifying 
the protein interaction networks of key pluripotency factors such as Nanog would 
provide a view of the Nanog-imposed stem cell state beyond its ability to bind to 
DNA. Furthermore, identification of the protein interaction networks of multiple 
pluripotency factors provides insight as to whether or not these networks converge or 
if they are unique. These networks may possibly reveal a much larger and more 
complex set of inter-dependent signalling pathways that govern pluripotency.  
Since 2006, the view of pluripotency factors and their contribution to the 
pluripotent stem cell state has been primarily restricted to the nucleus and the 
transcriptome (Chambers, 2004; Boyer et al., 2005; Ivanova et al., 2006; Loh et al., 
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2006; Matoba et al., 2006; Babaie et al., 2007; Kim et al., 2008). By comparison, 
there have been only two published reports of protein-protein interaction mapping 
studies using multiple baits in mouse embryonic stem cells (Wang et al., 2006 and 
Van den Berg et al., 2010). The first was the interaction network ascertained for 
Nanog and four other factors by the Orkin lab at Harvard University (Wang et al., 
2006). Using immunopurification of epitope tagged pluripotency factor proteins 
followed by liquid chromatography coupled with tandem mass spectrometry (IP-
LC/MS/MS), a protein interaction network dubbed ‘The Roadmap to Pluripotency’ 
was created (Wang and Orkin, 2008). This ‘roadmap’ would shape stem cell 
researchers’ views about the protein interactions governing pluripotency and 
reprogramming in the years to come. 
The second IP-LC/MS/MS-based approach to mapping pluripotency factor 
interactions was published by Van den Berg in 2010. Unlike Orkin’s Nanog-centered 
interaction network, Van den Berg and colleagues built an interaction network 
centered around another master regulator of pluripotency, Oct4. In this publication, 
epitope-tagged pluripotency factors were stably expressed from a plasmid and 
nuclear extracts were used as the starting material for all purifications. This very 
different snapshot of pluripotency factor interactions provided a much broader view 
of the pluriproteomic landscape than its predecessor. 
Recently, however, a very different view of the protein-protein interaction 
landscape for Oct4 was obtained by using whole cell lysates as the starting material 
for IP-LC-MS/MS experiments (Pardo et al., 2010). In this study, the CUL4B protein 
was reported as an interactor with the Oct4 protein interaction network. Although not 
highlighted by the authors of the study, this marked the first time that an essential 
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component of a Cullin-based E3 ligase was identified as interacting with a master 
pluripotency factor. Since Cullin RING E3 Ligases (CRLs) are key complexes 
involved in the ubiquitination of specific substrate proteins, the identification of a 
cullin protein with Oct4 implies that post-transcriptional mechanisms are involved in 
the maintenance of pluripotency in ES cells. 
One year later, another study would identify CUL4B as being part of the Oct4 
protein-protein interaction network in nuclear lysates (Cheong et al., 2011). The 
authors of this study concluded that the Oct4-CUL4B interaction identified by IP-
LC-MS/MS in the nucleus of mESCs may be due to both proteins independently 
interacting with beta-catenin (Takao et al., 2006; Tripathi et al., 2007).  
The reported protein interaction landscape for Sox2 in mESCs undergoing 
differentiation (Mallanna et al., 2010) revealed that there are several proteins 
interacting with both Sox2 and other master pluripotency factors Nanog, Oct4 and 
Esrrβ (Wang et al., 2006; Liang et al., 2008; Van den Berg et al., 2010; Pardo et al., 
2010 and Van den Berg et al., 2008, respectively).  
Figure 1.3 shows a Cytoscape diagram integrating all of the IP-LC-MS/MS 
protein-protein interaction networks reported in the literature to date for 10 different 
pluripotency factors in mESCs. 
As highlighted by Mallanna and Rizzino (2012) and shown in Figure 1.3, the 
shared interactors identified between these key pluripotency factors implies a high 





Figure 1.3: The published protein–protein interaction datasets for 10 different 
pluripotency factors in mESCs. Using Cytoscape, the interaction networks for 10 different 
pluripotency factors were merged together in order to generate an integrated protein interaction 
network for mESCs. The interactors identified for Nanog, Oct4, Esrrβ, Sall4, Zfp281, Rex1, Dax1, 
Tcfcp1l1 and Nacc1 in mESCs (coloured in blue) (Wang et al.,2006; Liang et al., 2008; Pardo et al., 
2010; Van den Berg et al., 2010) were integrated with the interactors identified for Sox2  undergoing 
early-stage differentiation (coloured in red) (Mallanna et al., 2010). Image taken from Mallanna and 




Such a highly connected network of protein interactions involved in the 
maintenance of pluripotency must be tightly regulated. This is particularly true for 
the master pluripotency factors themselves since it has been documented that a 2-fold 
increase in either Sox2 or Oct4 results in the differentiation of mESCs rather than the 
maintenance of pluripotency (Niwa et al., 2000; Chew et al., 2005; Kopp et al., 
2008). Furthermore, the successful reversal of the differentiation process is also 
highly dependent upon a seemingly delicate balance in the levels of pluripotency 
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factor expression during reprogramming (Eminli et al., 2008; Papapetrou et al., 
2009; Cox and Rizzino, 2010). Therefore, the identification of proteins involved in 
maintaining this balance would provide valuable insight into how pluripotency can 
be re-acquired by somatic cells as well as how this potential is both maintained and 
lost in ES cells. 
As previously mentioned, the studies by both Pardo et al., 2010 and Cheong 
et al., 2011 identified CUL4B as an interactor with Oct4. However, neither study 
investigated the possible role of a CUL4B CRL being involved in the degradation of 
the Oct4 protein or any other master pluripotency factor within the network.  
Furthermore, the Cheong et al., 2011 dataset identified proteins involved in nuclear 
import and export (Kpna2 and Rcc1) as interacting with Oct4.  While Oct4 and 
Kpna2 have been previously reported to interact (Li et al., 2008), the identification of 
Rcc1 was novel to the Cheong et al., 2011 study. The cargo being imported to and 
exported from the nucleus of mESCs by these proteins have not been identified and 
the authors postulated that these proteins may be working together in order to 
facilitate the import of unidentified proteins involved in the remodeling of chromatin.  
However, the possibility of these proteins being involved in the import/export of 
Oct4 itself or other pluripotency factors was surprisingly not raised in that study. 
The observed interaction between Oct4, Kpna2 and Rcc1 in nuclear extracts 
by Cheong et al., 2011 may provide a key insight into the cytoplasmic export 
observed for another master pluripotency factor Sox2 (Baltus et al., 2009).  In the 
study by Baltus et al, 2009, the cytoplasmic export of Sox2 preceded its 
ubiquitination and degradation by the 26S proteasome. Combined with the fact that 
the Pardo et al., 2010 study was performed on whole cell lysates and is the only other 
13 
 
report of the CUL4B interaction, it is plausible that this cullin protein may form a 
CRL E3 ligase that targets its substrates for degradation in the cytoplasm. Despite the 
shuttling of Sox2 between the nucleus and cytoplasm, however, the Mallanna et al., 
2010 study performed Sox2 IP-LC-MS/MS experiments using nuclear extracts as the 
starting material. Taking into account the Baltus et al., 2009 study, a very different 
snapshot of pluripotency factor regulation could be obtained by performing an IP-
LC-MS/MS study using whole cell lysates rather than nuclear extracts. 
 
1.4 Post-translational regulation of protein abundance by the Ubiquitin 
Proteasome System (UPS) 
 
In order to determine a protein’s abundance in cells or tissues, the mRNA 
transcript level is often quantified and used as an estimate of protein levels and a 
strong correlation between transcription and translation is assumed (Hack, 2004). 
However, several studies have revealed that in some cases there is little to no 
correlation between transcript levels and protein levels in cells and tissues 
(Humphrey-Smith et al., 1997; Gygi et al., 1999; Futcher et al., 1999; Ideker et al., 
2001; Chen et al., 2002; Griffin et al., 2002; Washburn et al., 2003; Hack, 2004). 
Furthermore, one recent study by Helbig et al., 2011 has revealed that in the case of 
certain metabolic enzymes, an inverse correlation exists. There are many possible 
explanations for this lack of correlation between transcription and protein expression 
level. One possible explanation is the rate and the degree to which protein synthesis 
and degradation (i.e., protein turnover) is occurring within cells. Information about 
the level of protein degradation in the cell is simply not captured at the transcriptome 
level of analysis. 
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Protein homeostasis is regulated by cellular protein degradation pathways 
(the lysosomal degradation pathway and the ubiquitin-proteasome pathway). In the 
Ubiquitin Proteasome System (UPS), proteins are modified by the covalent 
attachment of ubiquitin to a lysine residue through a cascade of reactions carried out 
by three enzymes (Etlinger et al., 1977; Hershko et al., 1980; Hershko et al., 1983; 
Ganoth et al., 1988). The first step of this reaction involves the hydrolysis of ATP 
and subsequently the adenylylation of a ubiquitin molecule by a ubiquitin activating 
enzyme (referred to as an E1). This now adenylylated, or ‘activated,’ ubiquitin 
molecule is then transferred to the cysteine residue within the active site of the E1 
along with the adenylylation of a second molecule of ubiquitin (Haas et al., 1982). 
The activated ubiquitin molecule residing within the active site of the E1 is then 
transferred to a cysteine residue within the active site of a second enzyme, a 
ubiquitin-conjugating enzyme (known as an E2). The E2 then collaborates with a 
ubiquitin-conjugating enzyme (termed an E3 ligase) in order to transfer the 
‘activated’ ubiquitin molecule to the target protein to be degraded. Using this 
mechanism, a Lys48 linked polyubiquitin chain containing a minimum of four 
ubiquitin molecules is attached to the substrate protein in order for it to be targeted to 
the 26S proteasome for degradation (Thrower et al., 2000). 
E3 ubiquitin ligases can be divided into three groups based on whether or not 
they contain a HECT (homologous to E6-AP carboxy terminus), RING (Really 
Interesting New Gene) finger or a U-box domain containing protein (Ardley and 
Robinson, 2005). After the formation of a thioester intermediate with ubiquitin, 
HECT E3 ligases transfer ubiquitin directly to the substrate protein (Kee and 
Huibregtse, 2007). RING-finger E3 ligases, however, serve as scaffolds bringing the 
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substrate protein in close proximity with the ubiquitin-charged E2 which transfers 
ubiquitin directly to the substrate (Willems et al., 2004). The RING-finger E3s can 
be further sub-divided into three groups: the Cullin-RING E3 ligases (Willems et al., 
2004; Petroski and Deshaies, 2005; Deshaies and Joazeiro, 2009), RING-finger E3 
ligases in which the RING-finger and substrate binding domains are located within 
the same protein (Sun, 2003) and the U-box (or RING-like) domain-containing E3s. 
While the U-box domain is structurally similar to the RING-finger domain, it does 
not contain the metal-chelating residues which are characteristic features of the 
RING domain (Hatakeyama and Nakayama, 2003). A schematic of the mechanism 
by which ubiquitin is conjugated to proteins by the UPS is illustrated in Figure 1.4. 
 
Figure 1.4: The conjugation of ubiquitin to substrate proteins. The diverse ubiquitin 
conjugation processes performed by the HECT and RING/RING-like (U-box) E3 ligases is shown in 
this figure. The reversible nature of ubiquitin conjugation by De-ubiquitinating enzymes (DUBs) is 
also illustrated. Abbreviations: Ub = ubiquitin; Lys = Lysine; Cys = Cysteine; ATP = Adenosine 
triphosphate; ADP = Adenosine diphosphate; PPi = pyrophosphate. Image taken from Ravid and 




 The covalent attachment of Lys-48 polyubiquitination chains to a protein 
does not always result in its degradation. Instead, this process may be reversed by a 
specialized class of enzymes called de-ubiquitinating enzymes (DUBs) (Wilkinson, 
1997).  DUBs provide an additional level of regulation and control over protein 
abundance in cells prior to protein degradation by the 26S proteasome (Iyer et al., 
2004; Reyes-Turcu et al., 2009). They have several essential roles in the ubiquitin 
proteasome pathway: processing of ubiquitin precursors, ubiquitin recycling, 
proofreading of protein ubiquitination and the disassembly of polyubiquitin chains 
(Amerik and Hochstrasser, 2004; Katz et al., 2010; Burrows and Johnston, 2012).   
 
1.5 Cullin-RING E3 ubiquitin Ligases (CRLs) 
 
The mammalian genome encodes 7cullin proteins: CUL1, CUL2, CUL3, 
CUL4A, CUL4B, CUL5 and CUL7. Cullins are key components of the multi-subunit 
complexes known as Cullin RING Ligases (CRLs) responsible for the ubiquitination 
of proteins and targeting them for degradation (Kipreos et al., 1996; Petroski et al., 
2005; Zheng et al., 2002). With the exception of CUL3-based CRLs, all cullin-based 
E3 RING ligases contain both a substrate recognition subunit (SRS) as well as a 
substrate-specific adaptor protein in order to bind to their respective targets (Willems 
et al., 2004; Angers et al., 2006; Kamura et al., 2004). Each of these adaptor proteins 
specifically binds to their particular cullin through a characteristic cullin-binding 
motif as illustrated in Figure 1.5. In turn, these substrate-specific adaptor proteins 
bind directly to the target protein to be degraded (substrate) thereby conferring 
substrate specificity to the CRL (Craig et al., 1999; Winston et al., 1999; Mahrour et 
al., 2008; Jackson et al., 2009). In the case of CUL3-based CRLs, a BTB/POZ 
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domain-containing protein links this cullin directly to its specific target. (Geyer et al., 
2003; Xu et al., 2003; Pintard et al., 2003; Pintard et al., 2004).  
 
Figure 1.5: The architecture of mammalian CRLs. (A) The basic organization of all CRLs, 
(B) The composition of the 7 different types of multi-subunit CRLs is illustrated. The substrate 
recognition subunits unique to each cullin protein are shown in green. Image was adapted from Eric 
Bennett’s faculty webpage UCSD http://biology.ucsd.edu/faculty/bennett.html.  
 
Cullin proteins are also subject to post-translational modification themselves 
by the small ubiquitin-like modifier Neural precursor cell-expressed developmentally 
down-regulated protein 8/Related to Ubiquitin1 (Nedd8/RUB1) as shown in Figure  
1.6. Nedd8 is conjugated to Cullin proteins by a series of enzymatic reactions 
involving Nedd8-Activating Enzyme (NAE1) along with a Uba3 subunit, an E2 
ubiquitin-conjugating enzyme and an E3-ligase (Rbx1 or DCN1). (Hori et al., 1999; 
Gong et al., 1999; Gray et al., 2002; Kurz et al., 2005; Hochstrasser et al., 2009).    
The conjugation of Nedd8 to Cullin proteins is essential for the function of 
their respective E3 Cullin RING-ligases (CRLs) ability to target substrate proteins 




Figure 1.6: Regulation of CRLs by post-translation modification. Illustration of the 
inhibition of CRL activity by either the prevention of Neddylation by the binding of CAND1 to a 
cullin protein or the removal of Nedd8 by the COP9 Signalosome. The activation of CRLs by the 
enzymes responsible for the Neddylation of cullin proteins is termed the ‘Neddylation System.’ Image 
was adapted from Eric Bennett’s faculty webpage UCSD http://biology.ucsd.edu/faculty/bennett.html.  
 
Inhibiting the neddylation of the Cullin subunits of CRLs would prevent the 
turn-over of their target proteins and provide a means of achieving CRL-regulated 
protein homeostasis in cells. The following three sections will introduce the use of 
small molecules in order to modulate various pathways influencing the cell fate 
decisions made by stem cells. 
 
1.6 Chemical compounds and small molecules for controlling cell fate 
 Stem cell self-renewal provides a continuous supply of newly differentiated 
cells that can re-populate various tissues and organs throughout early development 
and in adulthood (Vickaryous and Hall, 2006). This process is essential for both 
development and the regeneration of tissues throughout an organism’s lifetime. The 
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ability of pluripotent stem cells to form any of the three germ layers (mesoderm, 
endoderm and ectoderm) has raised a considerable amount of interest in the field of 
regenerative medicine in recent years.  In particular, the field of chemical biology has 
focused much of its efforts on the pursuit of chemical compounds and small 
molecules that provide a non-genetic means of controlling stem cell fate decisions 
(Ding et al., 2003; Ding and Schultz, 2004; Schugar et al., 2008; Li and Ding, 2010; 
Peltier et al., 2010; Lyssiotis et al., 2011; Li et al., 2012).  
In order to identify molecules capable of controlling cell fate decisions, it is 
necessary to understand both the process of cell fate choice as it is made during 
development and the underlying biochemical mechanisms responsible for these 
decisions. This section is subdivided into four sections in which I will describe the 
various cell fate decisions that a stem cell makes throughout development (1.6.1), the 
use of small molecules to prevent stem cell differentiation (1.6.2), the molecules that 
have been identified as being able to direct differentiation toward specific lineages 
(1.6.3) and molecules that demonstrate the ability to increase the reprogramming of 
somatic cells to a pluripotent state (1.6.4). 
 
1.6.1 Cell fate decisions during fetal development 
 A tight control over cell fate decisions is essential for proper development of 
the embryo, tissue regeneration in the adult and the prevention of diseases such as 
cancer. In humans, all of the various cell types of the body arise from a single 
totipotent zygote (Vickaryous and Hall, 2006).  
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The specification of these cells into the tissue-specific cell types that 
comprise the entire organism occurs in a co-ordinated series of cell fate choices that 
are determined by both space and time (Hogan, 1999; Gurdon and Bourillot, 2001).  
 
Figure 1.7:   Schematic representation of cell lineage commitment during development.  The cell 
fate decisions made by stem cells at various stages of embryogenesis are illustrated. Green text 
highlights the stage of development represented by current ES model cell lines. Red text highlights the 
consequence of improper cell specification. Blue text highlights that the entire process of development 
can be reversed.  
 
 
Many of the signaling pathways that govern cell type specification and tissue 
patterning in the mammalian embryo have been identified and are selectively 
activated in order to control proper fetal development as well as post-natal tissue 
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homeostasis (Burdon et al., 2002; Bolos et al., 2007; Jiang et al., 2008; Wu and Hill, 
2009).  
 
Chemical compounds and small molecules can be employed as molecular 
probes in order to further dissect the signaling pathways that control cell fate 
decisions. In this way, they can identify new molecular targets involved in the timing 
and specification of stem cells both in culture and in vivo.   
 
1.6.2 Chemical compounds and small molecules that sustain self-renewal 
 The long term maintenance of pluripotent stem cells in culture is a challenge 
for stem cell biologists and has resulted in the pursuit of reagents that promote their 
self-renewal. Since a shortened G1-phase is characteristic of ES cells, it is generally 
assumed that this is necessary in order to avoid exposure to mitogenic stimuli that 
promote differentiation (Burdon et al., 2002; White and Dalton, 2005; Ballabeni et 
al., 2011).  In standard culture conditions of mouse embryonic stem cells, protein 
factors that promote a rapid G1-phase transit during the cell cycle progression are 
used to maintain pluripotency. Namely, these two factors are: LIF (Leukemia 
Inhibitory Factor), a cytokine that activates the STAT3 (Signal Tranducer and 
Activator of Transcription 3) self-renewal pathway through its binding to the gp130 
receptor as well as the MAPK pro-differentiation pathway, and BMP4 (Bone 
Morphogenic Protein 4) which attenuates the MAPK pathway by inducing the 
expression of the Id (Inhibitor of differentiation) proteins (Smith et al., 1988; 
Williams et al., 1988; Niwa et al., 1998; Matsuda et al., 1999; Ying et al., 2003). 
While the use of exogenous factors and serum were generally well-suited for 
research applications, the batch-to-batch variations in LIF activity and serum growth 
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factors yielded inconsistent cellular responses (Ying et al., 2008). Additionally, the 
use of fetal bovine serum in stem cell culture prevented their use in cell-based 
therapeutics. Therefore, an animal product-free method of culturing stem cells was 
required by the field of regenerative medicine. 
 Using a high-throughput chemical screen of heterocyclic compounds on ES 
cells and monitoring their expression of Nanog, Oct4, Sox2 and alkaline 
phosphatase, the first small molecule shown to promote self-renewal of stem cells 
was discovered. That is, Pluripotin, a dual inhibitor of both RasGAP and ERK1 
kinases (Chen et al., 2006). This molecule demonstrated for the first time that stem 
cells cultured in the presence of a chemical compound rather than protein factors 
could contribute to all three germ layers in chimeric mice. 
 In 2008, the fields of chemical biology and stem cell biology were merged 
once again in an attempt to recapitulate the ability of the BMP4 protein to maintain 
self-renewal by inhibiting differentiation (Ying et al., 2003). Small molecules 
inhibiting MEK1 (PD184352) and ERK1/2 (SU540) within the pro-differentiation 
MAPK pathway were used along with the inhibition of GSK-3β (CHIR99021) in 
order to release cyclins from suppression (Ying et al., 2008). Using this cocktail of 
chemical inhibitors, it became possible to cultivate stem cells in absence of serum 
and extrinsic factors for the first time. As a result, stem cells cultured in the presence 
of these inhibitors were more amenable to cell-based regenerative therapies and 






1.6.3 Chemical compounds and small molecules that induce differentiation 
 In contrast to molecules that sustain pluripotency, compounds have been 
identified that induce differentiation of stem cells into specialized tissue-specific 
progenitor cells. A high-throughput chemical screen for compounds that induce ES 
cell differentiation into definitive endoderm identified IDE1 and IDE (Borowiak et 
al., 2009). Although the exact mechanism(s) by which these compounds act is 
unknown, they were found to be more efficient than the commonly used protein 
factors Activin A and Nodal at driving ES cell differentiation into endoderm lineages 
(Borowiak et al., 2009). An additional chemical screen was subsequently performed 
in order to identify compounds that could further direct these chemically-induced 
endoderm cells to commit into the pancreatic lineage (Chen et al., 2009). This study 
identified that the sequential treatment of ES cells with IDE1/IDE2 followed by 
indolactam V was able to induce the differentiation of both mouse and human ES 
cells into pancreatic progenitor cells. These chemically induced pancreatic stem cells 
were found to be capable of repopulating the developing gut and give rise to insulin-
secreting pancreatic cells following their injection into mouse embryos. 
 Several chemical library screens have been performed in recent years and 
have identified novel compounds capable of inducing differentiation of ES cells 
along various lineages. For example, cardiogenic compounds that generate 
progenitor cells capable of repairing myocardial repair in rats (Sadek et al., 2008) 
and the identification of neuropathiazol capable of directing neural progenitor cells 





1.6.4 Chemical compounds and small molecules that facilitate reprogramming 
 
 The demonstrated ability of terminally differentiated mouse and human 
somatic cells to be reprogrammed by the ectopic expression of four transcription 
factors provided the possibility of generating patient-specific stem cells for 
regenerative medicine therapies (Takahashi et al., 2006, Takahashi et al., 2007; Yu et 
al., 2007). However, fully realizing this potential required further development due 
to the highly inefficient method of retrovirus-mediated reprogramming. In the initial 
studies performed by Takahashi et al., 2007 and Yu et al., 2007, only 0.01% of 
transduced somatic cells generated induced Pluripotent Stem Cells (iPSCs) following 
several weeks of repeated infections. Other limitations included the integration of 
viral vectors into the host cell genome as well as the risk of the retroviral promoters 
driving the reprogramming factors being re-activated and causing cancer in the 
patient as observed in the mouse (Okita et al., 2007).  
 In recent years, many of these risks have been eliminated by the use of non- 
viral vectors (Okita et al., 2008) and without any vector integration into the genome 
(Kaji et al., 2009; Stadtfeld et al., 2008) and increased reprogramming efficiency 
using chemical compounds and small molecules (Huangfu et al., 2008; Mikkelsen et 
al., 2008; Maherali and Hochedlinger, 2009; Li et al., 2009). In the study performed 
by Huangfu et al., 2008 the use of Valproic acid, an HDAC inhibitor increased 
reprogramming efficiency using the four factors 400-fold. Furthermore, this 
compound allowed for iPSCs to be generated using only Oct4 and Sox2. A 100-fold 
increase in iPSC colony formation has been reported following an appropriately 
timed treatment with 5-azacytidine, a DNA methyltransferase inhibitor (Mikkelsen et 
al., 2008). Other molecules involved in the reversal of epigenetic modifications and 
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gene silencing have also been identified as facilitating the reprogramming process. 
They are, the histone methyltransferase inhibitors BIX-01294 and Parnate (Shi et al., 
2008; Li et al., 2009). The use of BIX-01294 was found to reverse the epigenetic 
silencing of the Oct4 gene and relieve the requirement for exogenous Oct4 during the 
reprogramming process (Feldman et al., 2006; Kubicek et al., 2007).    
In mouse somatic cells, inhibiting the TGF-β pathway using SB-431542 has 
been shown to increase reprogramming efficiency 30-fold and greatly reduces the 
time required for iPSC generation from weeks to days (Maherali and Hochedlinger, 
2009; Ichida et al., 2009). Human somatic cells, however, require the combined 
treatment using both the TGF-β and MEK inhibitors (SB-431542 and PD0325901) to 
yield a 100-fold increase in iPSC production (Lin et al., 2009).  
 While several advances have been made in increasing the efficiency of 
reprogramming somatic cells, and several molecules capable of replacing the 
requirement of certain factors have been identified, a chemical cocktail capable of 
generating iPSCs alone has yet to be developed. Further investigation of small 
molecules and their ability to further enhance reprogramming efficiency as well as 
replace the various factors required for this process will continue to provide novel 
methods of generating iPSCs free from the marks left on genomic DNA following 
genetic manipulation.  
 
1.7 Thesis outline and structure 
 Presented in this study will be two data chapters each of which having its 
own separate research focus.  
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In Chapter 3: Pluripotency Factor Protein-Protein Interaction Mapping, an IP-
LC-MS/MS strategy using whole cell extracts as the starting material will be 
employed in order to further characterize the protein interactomes of several 
pluripotency factors.  While the protein interactomes for several of the chosen factors 
have been previously identified, those studies provided a snapshot of the interactions 
occurring solely within the nucleus of ES cells. Additionally, the Pardo et al., 2010 
and Cheong et al., 2011 studies identified CUL4B as an interactor with the protein 
interaction landscape in both the cytoplasm and the nucleus, respectively. Therefore, 
the proteomic strategy employed in Chapter 3 of this study aims specifically to 
identify proteins involved in the regulation of pluripotency factors by post-
translational modifications.   
The overall goal of the research presented in Chapter 3 will be to ascertain 
pluripotency factor protein-protein interaction networks that extend beyond the 
nucleus in order give a new perspective on how the highly connected proteomic 
landscape governing “stemness” is regulated by post-translational modifications in 
mouse embryonic stem cells.  
 In Chapter 4: Exploring the Post-Translational Modification of Nanog and 
Sox2 Using Chemical Compounds and Small Molecules, both the stability and the 
interactions of the Nanog and Sox2 proteins will be examined following targeted 
inhibition of the kinases and cullin proteins identified in Chapter 3 of this study. 
While the dimerization, phosphorylation and stabilization of Nanog has been 
identified by Mullin et al., 2008, Wang et al., 2008 and Moretto-Zita et al., 2010, the 
kinase responsible for this phosphorylation has not been identified. Therefore, one of 
the aims of Chapter 4 in this study will be to inhibit all of the kinases identified in 
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Chapter 3 of this study in order to reveal the kinase or kinases responsible for 
phosphorylating Nanog. A compound found to inhibit the phosphorylation and 
stabilization of Nanog will provide a non-genetic means to homogeneously prime an 
entire population of ES cells for subsequent differentiation into any cell type desired.  
At the same time, this compound would serve as a potent anti-cancer therapeutic 
since Nanog is frequently re-expressed in the most aggressive forms of cancer (Jeter 
et al., 2009; Zbinden et al., 2010; Brandner et al., 2010; Meng et al., 2010).  
 Conversely, chemical compounds found to elevate phosphorylated Nanog 
would provide a novel method of stabilizing the specific differentiation-resistant 
phenotype that Nanog confers to ES cells as well as to somatic cells being 
reprogrammed (Chambers et al., 2007; Yu et al., 2007). Specifically, cullin proteins 
identified as part of the pluripotency interaction networks obtained in Chapter 3 of 
this study will be inhibited both chemically using MLN4924 and individually using 
shRNA. The aim of this series of experiments will be to provide insight into whether 
or not Nanog and Sox2 protein levels are regulated by the UPS in embryonic stem 
cells. Further to this end, the inhibition of specific cullin proteins will help to identify 
the specific cullin-RING E3 ligase responsible for targeting these master 
pluripotency factors. The identification of these CRLs will allow for the development 
of targeted inhibitors specifically inhibiting either the degradation of Nanog or Sox2. 
These reagents will allow for the reversible and dosage-dependent activation of the 
core pluripotency transcriptional circuitry without leaving the footprints of genetic 
manipulation upon the cells.  
The overall goal of the research presented in Chapter 4 of this study is to 
identify novel chemical compounds and small molecules that allow for the 
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modulation of the Nanog and Sox2 proteins thus, providing the fields of regenerative 
medicine and oncology with the first specific and targeted reagents controlling both 
the maintenance of pluripotency and the induction of differentiation in cells.  
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CHAPTER 2:  Materials and Methods 
 
2.1 Materials: 
2.1.1 Kits and reagents: 
 2.1.1.1 Kits 
 Spin Miniprep kit      QIAGEN 
 Endo-Free Maxi kit      QIAGEN 
 Protein A/G plus agarose conjugation kit   Pierce 
 NativePAGE™ sample prep kit    Invitrogen  
  
2.1.1.2 Reagents 
 NuPAGE® Novex® Bis-Tris 4-12% gradient gel  Invitrogen 
 NuPAGE® LDS sample loading buffer, 4X   Invitrogen 
 SeeBlue® pre-stained protein standard   Invitrogen 
 BenchMark pre-stained protein marker   NEB 
 SimplyBlue™ Safe Stain (Coomassie)   Invitrogen 
 NativePAGE™ (3-12%) gradient gel    Invitrogen 
 NativePAGE™ 4X sample loading buffer   Invitrogen 
 NativePAGE™ 20X cathode buffer    Invitrogen 
 NativePAGE™ cathode buffer additive   Invitrogen 
 NuPAGE® Transfer buffer     Invitrogen  
 NativePAGE™ 5% G-250 Sample Additive   Invitrogen 
NativeMark™ unstained protein standard   Invitrogen 
anti-FLAG® M2 agarose     Sigma 
 3XFLAG® peptide      Sigma 
LIF (Leukemia Inhibitory Factor), >95%   Sigma 
DMA (N,N-Dimethylacrylamide), 99%   Sigma 
 anti-HA High Affinity Matrix    Roche 
 Protein A/G Plus agarose     Pierce 
 NuPAGE® MOPS running buffer     Invitrogen 
NuPAGE® MOPS Transfer buffer    Invitrogen 
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SuperSignal™ West Pico/Femto Chemiluminescent   
Substrate       Pierce 
Amicon® Ultra-0.5mL, centrifugal spin columns for    
protein concentration and purification, (YM-3).  Millipore 
GMEM (Glasgow Minimal Essential Medium)  Sigma 
HyClone Fetal Bovine Serum, defined, 40 nm-filtered  Thermo 
Puromycin       InvivoGen 
DAPI (4’, 6-Diamidino-2-phenylindole dihydrochloride) Sigma 
ESGRO COMPLETE™ Gelatin solution, Ultrapure water  
with 0.1% Gelatin      Millipore 
Sepharose CL-4B      Sigma 
NP40 (Igepal CA-630)     Sigma 
Glycerol       Merck 
DTT (Dithiothreitol)          Melford Labs Ltd. 
Benzonase Nuclease HC, purity >90%    Novagen 
Lipofectamine™ 2000 Reagent, 1mg/mL   Invitrogen  
OptiMEM serum-free medium    Invitrogen 
Complete, EDTA-free Protease inhibitor Cocktail tablets Roche 
Phosphatase Inhibitor Cocktail Set II, 100X    Calbiochem 
0.2 µm vacuum filtration unit     Nalgene 
Lab-Tek® II Chamber Slide™ 8 well Glass Slide   ThermoFisher   
Cover Glass No.1, 24mm x 60mm    Corning   
 Paraformaldehyde, 16% (w/v) aq. soln., methanol-free Alfa Aesar  
 Triton® X-100 (Polyethylene glycol tert-octylphenyl ether) Fluka  
 Bovine Serum Albumin (BSA) (Fraction V)   Fisher   
 ProLong® Gold antifade reagent    Invitrogen 
 10% Normal Goat Serum, Ready-to-use   Invitrogen  
 Streptavidin, Alexa Fluor® 555 conjugate   Invitrogen 
10X Phosphate –buffered saline (10X PBS)   Invitrogen  







137mM NaCl, 2.7mM KCL, 4.3 mM Na2HPO4, 1.47mM KH2PO4 
 
PBS-T: 




50 mM Tris base, 150 mM NaCl. pH adjusted to 7.6 
 
TBS-T: 
50 mM Tris base, 150 mM NaCl. pH adjusted to 7.6, 0.1% (v/v) Tween20 
 
IP Lysis buffer: 
50 mM Tris-HCL pH 7.5, 250 mM NaCl, 5 mM MgCl2, 0.1% (v/v) NP40,10% (v/v) 
Glycerol, 1 mM DTT, Benzonase nuclease HC 1µL/mL of lysis buffer, 1X Complete 
Protease, Inhibitor Cocktail, 1X Phosphatase Inhibitor Cocktail Set III. 
 
IP wash buffer 1: 
50 mM Tris-HCL pH 7.5, 250 mM NaCl, 5 mM MgCl2, 0.01% (v/v) NP40,10% 
(v/v) Glycerol, 1 mM DTT, Benzonase nuclease HC 1µL/mL lysis buffer, 1X 




IP Wash Buffer 2: 
50 mM Tris-HCL pH 7.5, 250 mM NaCl, 5 mM MgCl2, 1 mM DTT, Benzonase 
nuclease HC 1µL/mL lysis buffer, 1X Complete Protease, Inhibitor Cocktail, 1X 
Phosphatase Inhibitor Cocktail Set III. 
 
3XFLAG 5mg/mL Peptide Stock Solution:  
Entire contents of 1 vial containing 5mg of 3XFLAG peptide were resuspended in 
1mL of buffer containing 50mM Tris-HCl, pH 7.4 and 150mM NaCl. Solution 
aliquotted and stored at -20°C. 
 
3XFLAG 200µg/mL peptide elution solution: 
5mg/mL 3XFLAG stock solution diluted to a final working concentration of 
200µg/mL in Wash Buffer 2. 
 
Western blot blocking buffer: 
5% (w/v) skimmed milk powder dissolved in TBS-T or PBS-T. 
 
Western blot antibody buffer: 
1% (w/v) skimmed milk powder dissolved in TBS-T or PBS-T. 
 
Western blot washing solution: 





Native Anode buffer solution: 
NativePAGE™ Running buffer, 20X was diluted to 1X in ddH2O. 
 
Native Dark Blue Cathode buffer solution: 
10 mL of NativePAGE™ [20X] Cathode additive was added to 900 mL of 1X 
NativePAGE™ Running buffer.   
 
Native Light Blue Cathode buffer solution: 
1 mL of NativePAGE™ [20X] Cathode additive was added to 999 mL of 1X 
NativePAGE™ Running buffer. 
 
NativePAGE™  reducing solution: 
4X NuPAGE® LDS sample loading buffer was diluted to 1X with ddH2O and  
50 mM DTT was added. 
 
NativePAGE™  alkylating solution: 
4X NuPAGE® LDS sample loading buffer was diluted to 1X with ddH2O and  
50 mM DMA was added. 
 
NativePAGE™ quenching solution: 
4X NuPAGE® LDS sample loading buffer diluted to 1X with ddH2O and 5 mM 





IF (Immunofluorescence) fixing solution: 
4% (w/v) paraformaldehyde solution in 1X PBS. 
 
IF (Immunofluorescence) cell permeabilization solution: 
0.5% (v/v) Triton® X-100 in 1X PBS. 
 
IF (Immunofluorescence) blocking solution: 
10% (v/v) Normal Goat Serum, Ready-to-use (Invitrogen). 
 
10,000X DAPI long term stock solution in ddH2O: 
10 mg of DAPI was dissolved in 1 mL of ddH2O and stored at -20°C. 
 
1000X DAPI working solution in ddH2O:  
A (1:10) dilution in ddH2O was prepared from the 10, 000X DAPI stock solution and 
stored at -20°C. 
 
IF (Immunofluorescence) DAPI staining solution: 
Immediately prior to use, 1000X DAPI was diluted to 1X in PBS.  
 
Ponceau S staining solution: 
0.2% (w/v) Ponceau S, 3% (w/v) trichloroacetic acid, 3% (w/v) sulfosalicylic acid. 
 
50 mM ammonium bicarbonate solution, (NH4HCO3):  
197mg NH4HCO3 in 50mL MilliQ water; 0.2 µm-filtered  
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200mM DTT:  
1.54mg per 50µL of water. 
 
500mM Iodoacetamide:  
1 mg per 10µL of water. 
 
Trypsin digestion solution:  
20 µg of sequencing grade trypsin (Promega) dissolved in 1 mL of  
50 mM ammonium bicarbonate solution. 
 
20 mM DTT solution: 
200 mM DTT diluted (1:10) in 50 mM ammonium bicarbonate solution. 
 
50 mM iodoacetamide solution:  
500 mM Iodoacetamide diluted (1:10) 50 mM ammonium bicarbonate solution. 
 
2.1.3 Plasmids 
pPyCAG-IP/3XFLAG-Nanog       (a gift from Tilo Kunath) 
pCAG-6XHA-Sox2-IP               Maruyama et. al., 2005 







2.1.4 Cell lines  
Cell Line  Description    Reference/Source  
E14tg2a  Wild type, hypoxanthine  Hooper et al., 1987 
phosphoribosyltransferase 
deficient, mouse embryonic stem  
cell line.129/Ola background.  
(Clonal)  
 
TNG   E14Tg2a mouse embryonic stem  Chambers et al., 2007  
cell line in which the endogenous  
Nanog gene has been replaced by  
the eGFP gene. eGFP was inserted  
between the homology arms  
precisely at the Nanog AUG codon.  
eGFP expression is linked through  
an IRES to puromycin resistance  
encoded by the pac gene.    
   
3XFLAG-Nanog E14tg2a stably expressing   This study 
3XFLAG-Nanog from the 
pPyCAG-IP plasmid.  
3XFLAG-Nanog expression is  
linked through an IRES to  
puromycin resistance encoded  
by the pac gene.  (Clonal)  
  
6XHA-Sox2  E14tg2a stably expressing   This study 
6XHA-Sox2 from the 
pCAG-IP plasmid.  
6XHA-Sox2 expression is  
linked through an IRES to  
puromycin resistance encoded  
by the pac gene.  (Clonal)  
  
6XHA-Pik3cd  E14tg2a stably expressing   This study 
6XHA-Pik3cd from the 
pCAG-IP plasmid.  
6XHA-Pik3cd expression is  
linked through an IRES to  
puromycin resistance encoded  





2.1.5 Lentiviral particles for shRNA 
Dharmacon SMARTvector 2.0 lentiviral shRNA vial particles from a pool of 
three different gene targeting sequences for the same gene to ensure successful 
knockdown of the targeted gene. Pre-packaged CUL3, CUL4B and CUL7-targeting 
lentiviral shRNA particles were purchased from Thermo Scientific/Dharmacon 
(distributed by Abgene Ltd., UK). Table 2.1 lists the source clone IDs, as well as, the 
targeting sequences of each for each construct in the pre-packaged shRNA pools 
used. 
Table 2.1 List of pre-packaged lentiviral shRNA viral particles used in this 







Mouse monoclonal anti-FLAG® M2 antibody   Sigma    
Rat monoclonal anti-HA High Affinity antibody   Roche    
Rabbit anti-Nanog antibody      Bethyl  
Monoclonal anti-human/mouse Sox2 antibody   NEB  
Anti-Sox2-Alexa® 555 conjugate antibody    R&D Systems  
Monoclonal anti-human ERRβ/NR3B2 antibody   Perseus Proteomics  
Goat anti-SALL4 antibody      LifeSpan  
Rabbit monoclonal against CUL4B (clone EPR3200)  Origene  
Rabbit anti-human CUL4B monoclonal (EPR3200)       LifeSpan  
Rabbit anti-CUL7 antibody      Bethyl  
Rabbit polyclonal anti-pHH3 antibody    NEB 
Catalogue No.: Source Clone ID: Gene Symbol: Gene Target Sequence: 
VSM5514 SH-062951-01-10 CUL3 GAGATCAAGTTGTACGGTA 
VSM5514 SH-062951-02-10 CUL3 GATTGCCAGAGAGCGGAAA 
VSM5514 SH-062951-03-10 CUL3 TTCAAGAAATCCAGCGTAA 
VSM5514 SH-041281-01-10 CUL4B GGTGAACACTTAACGGCAA 
VSM5514 SH-041281-02-10 CUL4B AACTAATCGGCTTTACGCA 
VSM5514 SH-041281-03-10 CUL4B GGGCTCATATTATAAGTGA 
VSM5514 SH-054741-01-10 CUL7 GGGTGCTCAAGATTCGAGA 
VSM5514 SH-054741-02-10 CUL7 AATTGCCTTGTTGTCCGAA 





Anti-mouse-HRP antibody      GE Amersham 
Anti-rat-HRP antibody      GE Amersham 
Anti-rabbit-HRP antibody      GE Amersham 
Anti-sheep/goat-HRP antibody     GE Amersham 
Anti-mouse-Alexa® 488 antibody     Invitrogen 
Anti-rabbit- Alexa® 488 antibody     Invitrogen 
Anti-mouse- Alexa® 594 antibody     Invitrogen 
Anti-rabbit- Alexa® 594 antibody     Invitrogen 
Anti-mouse- Alexa® 647 antibody     Invitrogen 
Anti-rabbit- Alexa® 647 antibody     Invitrogen 
 
2.1.7 Chemical compounds and small molecules 
Unless otherwise stated, all compounds were purchased from Calbiochem/Merck. 
Compound:  Final concentration in DMSO: 
Nocodazole  [20 µM] 
Br-cAMP  [50 nM] 
PKI (14-22)  [50 µM] 
Ht-31   [50 µM] 
MLN-4924  [1 µM] 
H89   [10 µM] 
Forskolin  [10 µM] 
Wortmannin  [10 µM] 
AurkiIII  [10 µM] 







2.1.8 Culture medium: 
2.1.8.1 Bacterial culture medium 
 Luria-Bertani Medium (LB) (Miller, 1972) Difco Bacto tryptone (10 g/L), 
Difco Bacto yeast extract (5 g/L), NaCl (5 g/L). Prior to autoclaving the pH was 
adjusted to 7.2. Solid LB agar plates were made by adding 2% (w/v) Difco Bacto 
agar to the media. 
 
2.1.8.2 Cell culture medium 
Regular Growth Medium (for 500mL bottle): 
500 mL GMEM      Sigma  
50 mL  HyClone FBS, ES cell defined, 40 nm-filtered Thermo  
5.5 mL  100X L-Glutamine solution    GIBCO 
5.5 mL  100X MEM NEAAs solution    GIBCO 
5.5 mL  100X Sodium pyruvate solution   GIBCO  
1.1 mL  [50mM] 2-Mercaptoethanol solution   GIBCO 
567.6 µL  1000X LIF, >95%     Sigma 
 
2.2 Methods: 
2.2.1 DNA techniques: 
2.2.1.1 Plasmid transformation into DH5α 
50 – 100 ng of plasmid DNA was mixed with 50uL of chemically competent 
DH5α E. coli cells. This mixture was incubated on ice for 30 minutes, then at 42°C 
for 45 seconds and returned to ice for 2 minutes. 500 µL of LB medium containing 
2% (w/v) glucose was added to the transformation mixture and allowed to incubate at 
37°C with agitation at 225 rpm for 1 hour. Cells were then plated onto LB agar plates 
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supplemented with the appropriate selection antibiotic and allowed to grow O/N at 
37°C. Ampicillin was used at a final working concentration of 100 µg/mL. 
 
2.2.1.2 Plasmid isolation from DH5α  
A single colony of E. coli transformed with plasmid DNA (Section 2.2.1.1  
Plasmid transformation into DH5α) was picked and inoculated to 5 mL of LB 
medium containing the appropriate selection antibiotic. This culture was allowed to 
grow O/N at 37°C with agitation at 225 rpm. The following day, bacterial pellets 
were harvested by centrifugation at 10, 000 x g for 2 minutes at 4°C. Plasmid DNA 
was isolated from bacterial cell pellets using the QIAGEN Spin Miniprep kit 
reagents and following the protocol detailed in the QIAprep Miniprep Handbook. 
 
2.2.1.3 Large scale plasmid preparation for transfection into mESCs   
A single colony of E. coli transformed with plasmid DNA (Section 2.2.1.1  
Plasmid transformation into DH5α) was picked and inoculated to 5 mL of LB 
medium containing the appropriate selection antibiotic. This culture was allowed to 
grow O/N at 37°C with agitation at 225 rpm. The following day, 300 µL of the O/N 
bacterial culture was inoculated into a 1L Erlenmeyer flask containing 300 mL of LB 
medium containing the appropriate selection antibiotic. Cultures were grown at 37°C 
with agitation at 225 rpm until an OD of 0.8 was reached. Bacterial pellets were 
harvested by centrifugation at 6, 000 x g for 10 minutes at 4°C. Plasmid DNA was 
isolated from bacterial cell pellets using the QIAGEN Edo-Free Maxi kit reagents 




2.2.2 Culture of mouse embryonic stem cells (mESCs) 
2.2.2.1 Routine culture and passaging of mESCs  
Unless otherwise stated, mESCs were maintained in as feeder-independent 
monolayer cultures on gelatin coated tissue culture flasks as per Williams et al., 1988 
and Smith et al., 1988. 
Cell harvesting and passing protocol: 
Medium was removed from cells cultured in a T25 flask. Medium was rinsed  
from the surface of monolayer by adding 5 mL of 1X D-PBS (GIBCO). PBS was 
aspirated from the flask and 2 mL of 0.05% (w/v) trypsin-EDTA, 1X solution 
(GIBCO) was added. Cells were incubated with 1X trypsin-EDTA solution at RT for 
5 minutes. Cells were dislodged by gently tapping the side of the flask. Trypsin was 
neutralized by adding 2 mL of regular growth medium. Cells were re-suspended into 
a single-cell suspension by pipetting up and down several times with a 5 mL pipette. 
The cell suspension was transferred to a 50 mL centrifuge tube already containing 10 
mL of pre-warmed regular growth medium. Cells were pelleted from suspension by 
centrifugation at 300 x g for 5 minutes at 4°C. The supernatant was aspirated from 
pelleted cells which were then re-suspended cells in 2 mL of growth medium. The 
appropriate volume (see Note 1) of cell suspension was dispensed into a T-25 flask 
coated with gelatin using ESGRO COMPLETE™ Gelatin solution (Millipore) 
containing 10 mL of growth medium. In general, cells were passed when the culture 
reached 80% confluency and the medium and growth factors were replaced every 2 
days. 
1) For routine culture, cells were plated at a [1:4] dilution into the 
appropriate medium.  For over the weekend cultures, cells were plated at 




2.2.2.2 Freezing of mESCs  
Cells grown to 80% confluency in T25 flasks were harvested as per protocol  
detailed in Section 2.2.2.1 Routine culture and passaging of mESCs and  
re-suspended in 2 mL of mESC freezing medium. One mL of mESCs in freezing 
medium was added to a 1.5 mL Cryotube (Corning) and immediately placed on dry 
ice. mESCs were transferred to -80°C for storage. 
 
mESC Freezing Medium (for 10 mL): 
9mL Regular growth medium  
1 mL DMSO      Sigma  
 
2.2.2.3 Transfection of mESCs 
 The day before transfection, cells were harvested and plated into gelatin-
coated 6-well plates at a dilution into fresh regular growth medium to provide a flat 
monolayer of mESCs of 40-50% confluency on the day of transfection. On the day of 
transfection, growth medium was removed and 2 mL of fresh growth medium per 
well of a 6-well plates was added to cells. One µg of plasmid DNA diluted in RT 
OptiMEM™ serum-free medium (GIBCO) was complexed into liposomes for 
transfection using Lipofectamine™ 2000 reagent (Invitrogen) according to 
manufacturer’s instructions. After 4 hours of incubation at 37°C and 7.5% CO2, 2mL 
of regular growth medium was added to each well of the 6-well plate containing 
transfection complexes. Cells were returned to 37°C and 7.5% CO2 and allowed to 
recover overnight. The following day, cells were harvested and plated at a (1:10) 
dilution into gelatin-coated 6-well plates containing 2 mL of PURO selection 
medium containing 1 µg/mL puromycin (InvivoGen). Cells were maintained in 
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selection medium until the appearance of single colonies occurred. The lines 
established from the individual colonies were expanded in culture in order to test for 
expression of the epitope-tagged recombinant proteins. 
 
PURO Selection Medium (for 500mL bottle): 
500 mL GMEM      Sigma  
50 mL   HyClone FBS, ES cell defined, 40 nm-filtered Thermo  
5.5 mL  100X L-Glutamine solution    GIBCO 
5.5 mL  100X MEM NEAAs solution    GIBCO 
5.5 mL  100X Sodium pyruvate solution   GIBCO  
1.1 mL  [50mM] 2-Mercaptoethanol solution   GIBCO 
567.6 µL  1000X LIF, >95%     Sigma 
56.8 µL 1 10 mg/mL Puromycin     InvivoGen 
 
2.2.2.4 Large-scale culture of mESCs for IP-LC-MS/MS studies 
Mouse embryonic stem cells were passaged and maintained as described in  
Section 2.2.2.1 Routine culture and passaging of mESCs. Routine culture and 
passaging of mESCs with the exception of being scaled up to 4 x T-175 flasks per 
twenty 20mm x 150mm tissue culture dishes to be plated. That is, ten 20mm x 
150mm dishes per IP, duplicated for each epitope-tagged bait protein. Cells were 
grown to near 100% confluency on gelatin-coated T-175 flasks. Cells from 1 x T-175 
flask were harvested as described in Section 2.2.2.1 Routine culture and passaging of 
mESCs, resuspended in 5mL of regular growth medium and plated (1:5) into five  
20mm x 150mm Cell
+
 Tissue Culture Dishes containing 30 mL of growth medium. 
After culturing for 48 hours at standard culture conditions, the dishes were 80-90% 




2.2.2.5 Culture of mESCs in hypoxia    
Protocols are the same as those described in Section 2.2.2.1 Routine culture 
and passaging of mESCs with the following exceptions: All hypoxia work was 
performed in the XVivo model G300C hypoxia workstation. All incubators attached 
to the workstation were controlled to 5% O2 and 7.5% CO2 in a completely 
automated fashion using the XVivo O2 control Watview software. For all hypoxia 
experiments in this study, the levels of oxygen and carbon dioxide were fixed at 5% 
and 7.5%, respectively. Additionally, the entire enclosed workspace was maintained 
under the same hypoxic conditions which ensured that all cultures and materials 
within the workstation were constantly maintained in the same low oxygen 
environment. Prior to beginning any hypoxia work, all plastic consumables to be 
used were placed inside the workstation under hypoxic conditions in order to purge 
oxygen from all plastics to come in contact with the cells and/or growth medium and 
washing buffers. All required 500 mL bottles of 1X D-PBS were placed inside the 
workstation with lids unscrewed and resting atop the bottle. This ensures that all 
oxygen in the 1X D-PBS used to wash the cells has been sufficiently purged from the 
solution. All perishable reagents (i.e., regular growth medium, trypsin, etc.) were 
aliquotted in small volumes (not greater than 50 mL) into wide-mouth containers and 
placed in the workspace under hypoxic conditions for a minimum of 3 hours at RT in 
order to equilibrate them to the desired 5% oxygen. Times required for sufficient 






2.2.2.6 Lentiviral transduction of mESCs    
Using the pre-made lentiviral particles described in Section 2.1.5 Lentiviral  
particles for shRNA, the 3XFLAG-Nanog mESC cell line was transduced following 
the protocol described in Embryonic Stem Cells: methods and protocols by Kursad 
Turksen, 2002. Briefly, mESCs were plated on gelatin-coated 6-well plates at a 
density of 5x10
4
 cells/well 24 hours prior to transduction. The following day, 
medium was removed from cells and 5 x 10
7
 TU lentiviral particles were added 
directly to the cells. Following 1 minute incubation at RT, 100 µL of regular growth 
medium containing 10µg/mL of Polybrene was added to cells. mESCs were 
incubated with this mixture for 1 hour at 37°C, 7.5% CO2. 2 mL of regular growth 
medium was added to each well of the 6-well plate and cell were returned to standard 
culture conditions for 24 hours. After 24 hours, the virus-containing medium was 
replaced with fresh regular growth medium and cells were allowed to incubate for a 
further 24 hours. The next day, transduced cells were harvested and plated into 
puromycin selection medium to select for stable integrants.    
 
2.2.2.7 Cell cycle synchronization of mESCs 
Protocol followed as per Savatier et al., 1996 with slight modifications. In  
brief, cells were treated with [20µM] nocodazole overnight. The following morning, 
mitotic cells were shaken off by hitting the flask several times with the palm of hand. 
Cells floating in the medium were then collected by decanting the medium into 50 
mL Falcon tubes. Mitotic cells were pelleted by centrifugation at 500 x g for 5 
minutes at 4°C. The medium was aspirated off the cell pellets which were gently 
resuspended in pre-warmed regular growth medium. Tubes were filled with regular 
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growth medium and centrifuged at 500 x g for 5 minutes at 4°C. Medium was 
discarded and the cells (now free from traces of nocodazole) were gently 
resuspended in 1 mL of regular growth medium. Cells were plated at a density of 2.0 
x 10
5
 cells/well into each well of a 6-well plate. Since mitotic cells require 4-5 hours 
to strongly adhere to the dish, T0 in these experiments represents 4 hours post-
release into nocodazole-free medium. 
 
2.2.3 Protein methods: 
2.2.3.1 Preparation of samples for SDS-PAGE 
Cell pellets were lysed by the addition of an equal volume of cell lysis buffer  
in µL per mg of cell pellet. Pellets were re-suspended by vortexing and sheared by 
pipetting up and down with a P1000 pipette tips. The lysates were allowed to stand 
on ice for 10 minutes and clarified by centrifugation at 12, 000 x g for 5 minutes. 4X 
NuPAGE® LDS sample loading buffer was added to final concentration of 1X with 
100µM DTT to clarified lysates. Samples were boiled for 5 minutes at 100°C and 
vortexed briefly prior to loading onto gel. 
 
2.2.3.2 SDS-PAGE for western blotting 
Protein samples were separated by SDS-PAGE using NuPAGE® 4-12%  
Bis-Tris Gel, 1.0 x 10 well (Invitrogen). Gels were run at 200V for 1 hour at RT in 
1X NuPAGE® MOPS running buffer (Invitrogen) using an XCell SureLock™ 
Electrophoresis Cell (Invitrogen).Following electrophoresis, gels were removed from 
their cassettes and incubated in 1X NuPAGE® Transfer buffer for 20 minutes at RT 
with orbital shaking prior to electrophoretic transfer. 
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2.2.3.3 Electrophoretic transfer of SDS-PAGE separated proteins  
Two pieces of Extra Thick Blot Paper, Protean xi size (Bio-Rad Laboratories, 
Inc.) was cut to roughly 10 cm x 10cm in size (2 per gel to be transferred) and 
nitrocellulose membrane, 0.2 µm (Bio-Rad Laboratories, Inc.) was cut to roughly 9 
cm x 9 cm in size. Gels, blotting paper and membranes were prepared for semi-dry 
electrophoretic transfer by soaking in 1X NuPAGE® Transfer buffer for 20 minutes 
at RT with orbital shaking. Routine electrophoretic transfer was performed at 15V 
for 30 minutes at RT using a Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad 
Laboratories, Inc.).  
 
2.2.3.4 Immunoblotting 
Following semi-dry transfer of proteins to membranes in Section 2.2.3.3 
Electrophoretic transfer of SDS-PAGE separated proteins, membranes were 
incubated in western blot blocking solution for 2 hours at RT with orbital shaking. 
Membranes were washed 3 x 5 minutes at RT with orbital shaking in western blot 
blocking buffer. All primary antibodies solutions were prepared as a (1:1000) 
dilution in western blot antibody buffer. All primary antibody buffer incubations 
were carried out overnight at 4°C with orbital shaking. The next day, membranes 
were washed 3 x 5 minutes at RT with orbital shaking in western blot washing 
buffer. All secondary antibody solutions were prepared as (1:10, 000) dilutions in 
western blot antibody buffer. All secondary antibody solution incubations were 
carried out for 2 hours at RT with orbital shaking. Membranes were washed 3 x 5 
minutes in washed 3 x 5 minutes at RT with orbital shaking in western blot washing 
buffer. Membranes were incubated with 2 mL of SuperSignal™ West Pico/Femto 
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Chemiluminescent Substrate (Pierce) prepared as per manufacturer’s protocol for 1 
min at RT with shaking. Excess substrate was drained from membranes before 
placing them between two clean Niceday transparencies (Office Depot) and securing 
them into a FUJIFilm BAS Cassette2. Membranes were exposed to Amersham 
Hyperfilm ECL High Performance Chemiluminescence film (GE Healthcare) and 
films were subsequently developed using a SRX-101A tabletop film processor 
(Konica, U.S.A.). 
   
2.2.3.5 NativePAGE™ for western blotting    
This technique was performed on samples of immunopurified 3XFLAG- 
Nanog protein complexes isolated under native conditions, eluted by peptide 
competition and concentrated. NativePAGE™ gels are the commercially available 
equivalent to the BN (Blue-Native) PAGE technique developed by Schägger and von 
Jagow, 1991. In both cases, the G-250 dye serves as the charge-shift molecule so that 
the molecular weight native proteins and protein complexes may be determined. 
Eluates of immunopurified 3XFLAG-Nanog and Nanog-containing complexes were 
prepared for native PAGE by adding 4X NativePAGE™ sample loading buffer 
(Invitrogen) to a final concentration of 1X in ddH2O and NativePAGE™ 5% (w/v) 
G-250 Sample additive (Invitrogen) to 1/4
th
 the detergent concentration. The wells of 
a 10-well NativePAGE™ (3-12%) gradient gel (Invitrogen) were washed 2 times 
with dark blue cathode buffer prior to filling the inner buffer chamber completely 
with the dark blue cathode buffer. A total sample volume of 25 µL was loaded into 
each well and 10 µL of NativeMark™ (Invitrogen). After filling the outer buffer 
chamber with 200 mL of anode buffer, gels were run for at 150V for 90 minutes at 
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RT using an XCell SureLock™ Electrophoresis Cell (Invitrogen). Following 
electrophoresis, NativePAGE™ gels were transferred to membranes following the 
protocol for electrophoresis detailed in Section 2.2.3.3. Following transfer, proteins 
were fixed onto the membranes by incubating the membranes in 8% (w/v) acetic 
solution for 10 minutes at RT with orbital shaking. Membranes were washed several 
times in 1X TBS or PBS before proceeding to immunoblotting with anti-FLAG 
antibody as per the protocol detailed in Section 2.2.3.4. 
 
2.2.3.6 Two-Dimensional NativePAGE™ to SDS-PAGE for western blotting  
 
Samples were prepared and electrophoresis performed in the same manner as  
that outlined in Section 2.2.3.5. Following electrophoresis, gels were cut into vertical 
strips (from sample loading well to the bottom of the gel). Each strip was then 
inserted into a 50 mL Falcon tube containing 10 mL of NativePAGE™ reducing 
solution for 30 minutes at RT. The reducing solution was removed and 10 mL of 
NativePAGE™ alkylating solution was added to each strip. Strips were allowed to 
incubate for 15 minutes at RT. This solution was decanted and replaced with 10 mL 
of NativePAGE™ quenching solution. Gel strips were incubated with quenching 
solution for a minimum of 30 minutes at RT to a maximum of overnight at 4°C. 
Following quenching, each gel strip was removed from quenching solution onto a 
petri dish and cut into 14  2.5 mm width slices from the top of the strip (sample 
loading well) to the bottom (approximately 25 kDa band). Gel slices were allowed to 
dry and shrink at RT for 1 hour prior to loading. The wells of a NuPAGE® 4-12% 
Bis-Tris Gel, 1.0 x 15 well (Invitrogen) were rinsed with 1X NuPAGE® LDS sample 
loading buffer containing 100 µM DTT. Each of the 14 gel slices were carefully slid 
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into a well of the 15-well SDS-PAGE gel.  Once all 14 slices and molecular weight 
marker were inserted/loaded onto the SDS-PAGE gel, all wells were overlayed with 
1X NuPAGE® LDS sample loading buffer containing 100 µM DTT. Gel 
electrophoresis, electrophoretic transfer and immunoblotting were performed as per 
Sections 2.2.3.2 - 2.2.3.4. 
  
2.2.3.7 Immunopurification of epitope-tagged proteins from mESCs for LC- 
 MS/MS 
  
Figure 2.1: The IP-LC-MS/MS-based protein-protein interaction mapping platform  
established in this study. A) Workflow diagram of recombinant protein expression and  
immunopurification from mouse ESCs. B) Representative Coomassie-stained gel of purified protein  
complexes. Gel slices excised and digested for LC-MS/MS analysis are indicated by red boxes. C)  






Ten 20 mm x 150 mm Cell
+
 tissue culture dishes (Sarstedt) were harvested  
per IP of 3XFLAG-Nanog, 6XHA-Sox2 and 6XHA-Pik3cd mESC cells lines and 
TNG cell line for control IPs. Prior to beginning the harvest, all IP buffers and 
solutions were filtered using a Nalgene 0.2 µm vacuum filtration unit (NalgNunc 
Intl.) and placed on ice for a minimum of 30 minutes. Dishes to be harvested were 
placed on ice, medium aspirated and washed 2 times with 20 mL of ice-cold  
1X D-PBS. Cells were lysed on ice directly in plate by the addition of 2 mL of IP 
Lysis buffer to one 20 mm x 150 mm Cell
+
 tissue culture dishes. Cells were scraped 
into the lysis buffer using a chilled rubber-bladed cell scraper (Sarstedt). Cells were 
sheared by pipetting up and down using a pipette tip and then transferred to the next 
washed 20 mm x 150 mm dish of washed cells. The cells were then scraped into the 
same 2 mL volume of ice-cold lysis buffer transferred from the first plates. Cells 
were scraped into the lysis buffer and sheared by pipetting in the same manner as for 
the first plate. This procedure was repeated for the first 5 dishes to be harvest. For the 
second set of 5 dishes an additional 2 mL of ice-cold lysis buffer was added and cells 
were scraped and sheared in the same way as the first five dishes. The entire 4-5 mL 
of cell lysate was transferred to ice-cold 2 mL round-bottom tubes (Sarstedt) and 
lysis was allowed to proceed on ice for 30 minutes. Lysates were clarified by 
centrifugation of lysates at 14, 000 x g for 20 minutes at 4°C. Clarified whole cell 
lysate was transferred to fresh 2 mL tubes containing 50 µL of Sepharose CL-4B 
(Sigma) beads pre-equilibrated in cell lysis buffer. Lysates were incubated with 
Sepharose CL-4B resin for 45 minutes at 4°C with nutation. Following this pre-
clearing step, tubes were centrifuged at 1, 000 x g for 5 minutes at 4°C to pellet the 
Sepharose CL-4B resin. Pre-cleared supernatants were transferred to another ice-cold 
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2.0 mL round-bottom tube containing 30 µL of anti-FLAG® M2 agarose (Sigma) or 
anti-HA High Affinity Matrix (Roche). Lysates were incubated with anti-FLAG® 
M2 agarose or anti-HA High Affinity Matrix for 3 hours with nutation. Samples 
were centrifuged at 1000 x g for 5 minutes at 4°C and supernatants discarded. The 
anti-FLAG® M2 agarose and anti-HA High Affinity Matrix beads were washed by 
resuspending the beads in 1 mL of IP Wash buffer 1, transferring the resuspended 
beads into a new, clean 1.5 mL tube (Eppendorf) followed by centrifugation 1000 x g 
for 5 minutes at 4°C. In this manner, resins were washed 3 times in IP Wash buffer 1 
and once in IP Wash buffer 2. At each wash step, the resins were transferred to a 
new, clean, pre-chilled tube. After the 4
th
 and final wash, resins were snap frozen on 
dry ice and stored at -80°C until SDS-PAGE was to be performed.  
    
2.2.3.8 Immunopurification of endogenous proteins from mESCs for  
LC-MS/MS 
 
The protocol used is the same as described in Section 2.2.3.7 with the 
exception that five 20 mm x 150 mm Cell
+
 tissue culture dishes (Sarstedt) were 
harvested per IP and the affinity resins used. For endogenous IPs, antibodies 
recognizing epitopes presented by the native protein were conjugated to Protein A/G 
Plus agarose (Pierce). Affinity resins targeting the endogenous Esrrβ and Sall4 
proteins, the monoclonal anti-Esrrβ antibody (Perseus Proteomics) and the 
polyclonal anti-Sall4 antibody (LifeSpan Biotechnologies) were used. These 
antibodies were coupled to Protein A/G Plus agarose using the Protein A/G agarose 





2.2.3.9 Immunopurification of epitope-tagged proteins from mESCs for  
   NativePAGE and NativePAGE-SDS-PAGE 
 
The protocol used here is the same as the protocol described in Section 
2.2.3.8 with the exception that protein complexes were eluted using 0.2 µg/mL 
3XFLAG® peptide (Sigma) in IP Wash buffer 2. In brief, 3XFLAG-Nanog was 
eluted by resuspending the anti-FLAG® M2 agarose in 500 µL of 0.2 µg/mL 
3XFLAG® peptide solution. These elution mixtures were placed in an Eppendorf 
Thermo mixer set to 2500 rpm for 25 minutes at RT. This elution was repeated one 
more time. Eluates were pooled together and concentrated by centrifugation using an 
Amicon® Ultra-0.5mL, 3K MWCO device (Millipore). 
 
2.2.3.10 λ-phosphatase treatment of immunopurified proteins for SDS-PAGE 
 
3XFLAG-Nanog stable cell line was grown in 10 cm Cell
+
 dishes (Sarstedt) 
and lysed in 1mL of IP lysis buffer containing as per protocol described in Section 
2.2.3.7 Immunopurification of epitope-tagged proteins from mESCs for LC-MS/MS. 
Following final wash, pelleted resins were treated with either λ-phosphatase (NEB) 
buffer containing λ-phosphatase and MgCl2, λ-phosphatase and phosphatase 
inhibitors or no λ-phosphatase (UT Control) as per manufacturer’s instructions. 
Tubes were vortexed for 1 minute every 10 minutes throughout the incubation. The 
reactions were stopped by adding 50 µL of 4X NuPAGE® LDS sample loading 







2.2.4 Mass spectrometry methods: 
2.2.4.1 SDS-PAGE for mass spectrometry 
The protocol is the same as described in Section 2.2.3.2 with the following 
exceptions: The XCell SureLock™ Electrophoresis Cell used for SDS-PAGE for 
LC-MS/MS was cleaned with ethanol, rinsed with ddH2O filtered through a 0.2 µm 
membrane and allowed to air-dry thoroughly before use. All sample loading buffers 
used resuspend resins for sample loading were filtered through 0.2 µm membrane. 
After electrophoresis, gels were placed in a plastic 15 cm x 15 cm plastic petri dish 
filled with 0.2 µm membrane-filtered ddH2O and washed for 15 minutes at RT with 
orbital shaking. This wash was repeated two more times before decanting the water 
and adding 25 mL of SimplyBlue™ SafeStain (Invitrogen) Coomassie stain 
compatible with mass spectrometry. Gels were incubated in the Coomassie stain for 
1 hour at RT with orbital shaking. The stain was removed and 30 mL of 0.2 µm 
membrane-filtered ddH2O containing 2% (w/v) NaCl was added. Gels were 
incubated in this destaining solution overnight at RT with orbital shaking.  The 
following morning, the destaining solution was removed and replaced with fresh 0.2 
µm membrane-filtered ddH2O and allowed to destain for another hour at RT with 
orbital shaking prior to scanning the gel.   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
2.2.4.2 Gel band cutting 
Working in a laminar flow hood, gels were placed on a clean Niceday 
transparency (Office Depot) and the entire sample lane was excised as 5 or 6 large 
blocks using a sterile scalpel. Gel slices were transferred into sterile 2.0 mL round-
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bottom tubes (Eppendorf), large gel slices were further chopped into smaller pieces 
stored at 4°C until digestion with trypsin was to be performed.  
 
2.2.4.3 In-Gel digest 
Gel pieces were shrunk by adding 200 µL of methanol to the tubes and incubating 
for 10 minutes at RT. Methanol was removed and 200 µL of 50 mM ammonium 
bicarbonate solution was added for 10 minutes at RT. Alternating incubation in 
methanol and 50 mM ammonium bicarbonate solution was repeated two more times. 
Gel slices were then reduced by adding 100 µL of 20 mM DTT in 50 mM 
ammonium bicarbonate solution. Gel slices were incubated in this solution for 30 
minutes at 60°C. The DTT-containing solution was removed and 200 µL of methanol 
was added for 10 minutes at RT. Proteins in the gel slices were then alkylated by 
adding 100 µL of 50 mM iodoacetamide in 50 mM ammonium bicarbonate solution. 
Gel slices were incubated in this solution for 1 hour at RT. The iodoacetamide-
containing solution was removed and 200 µL of methanol was added. Gel slices were 
incubated in methanol for 10 minutes at RT or until the gel pieces had shrunken. All 
traces of methanol were removed and gel slices were allowed to dry at RT. To the 
dried gel slices, 20 µL of trypsin solution [20 nM] was added and gel slices were 
incubated in this solution for 30 minutes at 4°C. Enough [50 mM] ammonium 
bicarbonate solution was added to cover the gel slices and gel slices were allowed to 
digest overnight at RT. The following day, gel digest solutions were transferred to a 
new clean tube and 50 µL of 1% (w/v) formic acid solution was added to the sample. 
Samples were incubated for 10 minutes at RT. The solution extracts were then 
transferred to the previous tube and 50 µL of 1% formic acid in (50:50) 
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water/methanol solution was added to the samples. After 15 minutes of incubation at 
RT, the extracts were transferred back to the previous tube and the previous two 
steps were repeated another time. Finally, the solution extracts were dried and 
concentrated using a Speedvac (Thermo Fisher). 
 
2.2.4.4 LC-MS/MS analysis protocol 
Samples were analyzed using an on-line system consisting of a micro-pump 
(1200 binary HPLC system, Agilent, UK) coupled to a hybrid LTQ-Orbitrap XL 
mass spectrometer (Thermo Fisher, UK). The LTQ was automatically controlled 
using Xcaliber 2.0.7 software. Samples were injected into the LTQ-Orbitrap XL by 
capillary picotip columns (10 cm x 360 µm OD x 75 µm ID) with a 15 um tip 
opening size and fitted with borosilicate frits (New Objective, PResearch, UK). Pre-
columns (4 cm x 360 µm OD X 200 µm ID) were used in a vented column pre-
column arrangement (Licklider et al., 2002; Le Bihan et al., 2003). Fused silica 
tubing was purchased from Composite Metal (UK). Digested samples were 
resuspended in 10 µL of reverse phase loading buffer containing 95.7% H2O, 2.5% 
acetonitrile and 0.1% (w/v) formic acid. Eight µL was injected into the HPLC at a 
flow rate of 5 µL/min. After sample loading, the flow rate across the injection 
column was reduced to approximately 100-200 nL/min using the vented column 
arrangement. The peptide mixture was separated by a C18 reverse-phase column 
using a 2 hour elution gradient from 0% - 100% of buffer composed of 90% 
acetonitrile, 10% (v/v) H2O, 0.025% trifluoroacetic acid (w/v) and 0.1% (w/v) formic 
acid. The mass spectrometer was operated in data-dependant mode, with a single MS 
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scan (400-2000 m/z) in FT mode 60K resolution followed by MS/MS scans in the 
linear ion trap on the 5 most abundant ions and dynamic excluded for 120 seconds. 
 
2.2.4.5 Data analysis with MaxQuant software 
Data acquired from the MS/MS runs were searched against a mouse plus 
contaminant IPI database containing 55413 sequences downloaded from 
www.ebi.ac.uk using MASCOT v 2.3 software (Matrix Science Ltd., UK).  
All MS/MS data acquired in this study were searched for the following post-
translational modifications: variable methionine oxidation, STY phosphorylation, 
protein N-terminal acetylation and fixed cysteine carbamidomethylation. The 
precursor mass tolerance was set to 7ppm and MSMS tolerance to 0.4amu. The 
significance threshold (p) was set below 0.05 (MudPIT scoring in Mascot). All LC-
MS runs performed in this study were combined using MaxQuant v 1.0.13.8 
assuming a false positive rate of 0.01 as per protocol described by Cox et al., 2009. 
The MaxQuant output of protein group intensities was calculated as the sum of MS-
peak intensities of identified peptides. This sum was used as a measure of relative 
abundance between samples.  
In these studies, a high confidence interactor was defined as a protein for 
which at least 2 unique peptides were identified. Where the number of peptides 
detected in the sample was 4-fold greater than in the control as well as a peptide peak 






2.2.4.6 Protein network diagram generation using STRING v 9.0 and Cytoscape 
version 2.8.1 
 
The list of high confidence interacting proteins generated by the MaxQuant 
software output, were analyzed for previously reported protein-protein interactions 
using the platform tool STRING v 9.0 (http://www.string-db.org).  Known 
interactors were identified using the mus musculus database and selecting the 
experimental evidence, database and yeast two-hybrid search parameters and, 
importantly, de-selecting the default co-occurence criteria. The STRING v 9.0 med-
high confidence scoring criteria was used to filter the interactions reported. 
 
2.2.5 Immunofluorescence methods: 
2.2.5.1 Immunostaining of mESCs for quantitative confocal microscopy 
Cells were grown on gelatin-coated 8-well Lab-Tek® II Chamber Slide™ 
(ThermoFisher). Growth medium was removed from each well of the 8-well 
chamber slide to be immunostained. Chamber slides washed with 500 µL of room 
temperature 1X PBS (Invitrogen) once for 5 minutes. Cells were fixed by adding  
500 µL of IF fixing solution and incubating for 15 minutes at RT. Cells were washed 
3 times for 5 minutes with 500 µL of 1X PBS. Cells were permeabilized by 500 µL 
of IF permeabilization solution and incubating for 15 minutes at RT. Blocking was 
performed by the addition of 500 µL of IF blocking solution for 1 hour at RT. 
Primary antibodies were diluted (1:100) in IF blocking solution. After 1 hour 
blocking at RT, the blocking solution was removed and 250 µL of primary antibody 
solution and incubated overnight at 4°C. Cells were then washed 3 times for 5 
minutes with IF blocking solution and 500 µL of secondary antibody solution was 
added to each well. All secondary antibody solutions were prepared as [1:500] 
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dilutions in IF blocking solution. Cells were incubated with secondary antibody 
solutions for 1 hour at RT in the dark. Antibody solutions were then removed and 
cells were washed 3 times for 5 minutes in 1X PBS solution at RT. DNA was stained 
by adding 500 µL of IF DAPI staining solution to each well and incubating at RT for 
10 minutes in the dark. The IF DAPI staining solution was removed and slides were 
mounted by the addition of one drop of ProLong® Gold antifade reagent (Invitrogen) 
and gently overlaying a 24mm x 60mm rectangular coverglass (Corning) over all 8 
wells. Slides were stored protected from light until ready to be analyzed by confocal 
microscopy. 
         
2.2.5.2 ROS Assay 
Cells were grown on gelatin-coated 8-well Lab-Tek® II Chamber Slide™ 
(ThermoFisher). Growth medium was removed and replaced with either regular 
growth medium or fresh medium containing the CellROX™ Deep Red Reagent 
(Invitrogen) to a final concentration of 1 µM. Chamber slides with fresh medium 
containing dye were returned to standard culture conditions or hypoxic culture 
conditions for 30 minutes at 37°C. Medium was then removed from each well of the 
chamber slide and washed with 500 µL of room temperature 1X PBS (Invitrogen) 
once for 5 minutes. Cells were fixed by adding 500 µL of IF fixing solution and 
incubating for 15 minutes at RT protected from light. Cells were washed 3 times for 
5 minutes with 500 µL of 1X PBS. In these studies, the ROS assay was performed as 
one part of a multiplexed fluorescence-based assay for quantitation by confocal 
microscopy. Therefore, after performing the three final washes of post cell 
permeabilization, 500 µL of IF blocking solution was added to all wells. Subsequent 
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immunostaining and mounting procedures were performed as described in Section 
2.2.5.1. 
 
2.2.5.3 Immunostaining of mESCs in hypoxic conditions 
The protocols used were the same as those described in Sections 2.2.5.1 - 
2.2.5.2 with the following exceptions: Prior to cell fixation and permeabilization, all 
work was carried out in the XVivo model G300C hypoxia workstation under hypoxic 
conditions defined above. All growth medium, 1X PBS and cell fixation solutions 
were placed in the workstation with lids off for a minimum of 4 hours prior to 
beginning immunostaining procedures. All drug treatments and the CellROX™ Deep 
Red Reagent was added to cells in hypoxic conditions. Following cell fixation and 
permeabilization under hypoxia, all chamber slides were removed from the XVivo 
workstation and the remainder of the procedure was performed in normoxic 
conditions.  
 
2.2.5.4 Quantitative confocal microscopy image acquisition and data extraction 
All confocal microscopic images were acquired using the Leica SP5, Model 
TCS SP5 confocal microscope mounted on the SP5 workstation (Leica Microsystems 
CMS, GmbH) located in the C.O.I.L. The microscope and image acquisition 
parameters were controlled automatically using LAS AF Software program (Leica). 
All microscopy in this study was performed by acquiring 3 z-stacks having a z-step 
size of 0.29 µm and through a minimum z-volume of 12 – 17 µm (depending on 
colony size and height). In xyz acquisition mode, images were acquired in 1024 x 
1024 format at a speed of 400 Hz, and 12-bit bit depth. The size of the images 
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obtained was 246.0 µm x 246.03 µm having a pixel size of 240.50 nm x 240.50 nm x 
293.73 nm. Images were obtained at a 630X total magnification using HCX PL APO 
CS 63.0 x 1.40 objective and the Argon (DAPI), DPSS 561nm (Alexa®488), HeNe 
594nm (Alexa®555 and Alexa®594) and HeNe 633nm (Alexa®647) lasers.  
 
Data was extracted from images by three methods:  
 
1) Using ImagePro v 7.0 software along with Macro1 written by Dave Kelly – 
C.O.I.L. facility manager (See APPENDIX F). Briefly, this Macro measured 
the green and red intensities based on the nuclear outlines produced by the 
thresholding of the DAPI image. The DAPI outlines were used to remove the 
nucleus from the red image. Once the nuclear signal was removed, the rest of 
the red cell had its intensity measured. 
 
2) Using ImagePro v 7.0 along with Macro3 written by Dave Kelly – C.O.I.L. 
facility manager (see APPENDIX G). Briefly, this Macro quantified the 
intensity in the green channel and then counted fluorescent foci in the red and 
far red channels. The DAPI channel was thresholded by the user and then 
used to map the measurements made in the other channels to the nucleus. The 
area of the nucleus was also measured. 
 
3) Using Volocity® v 6.0 software (Perkin Elmer, UK). Briefly, this software 
created outlines of the DAPI signal and used these outlines to map the 
quantified intensities of all 4 channels. In addition, this software measured 




2.2.5.5 Co-localization analysis using Volocity® 6.0 software. 
Using Volocity® (Perkin Elmer) v 6.0 software package, unthresholded co-
localization statistics, Pearson’s co-efficients, as well as, overlapping pixels images 
were generated for all channels of interest from one representative z-stack obtained 
at 0.29 µm step size through the entire cell depth (12-20 µm).  
   
   
     








CHAPTER 3: Pluripotency Factor Protein-Protein Interaction 
Mapping  
    
3.1 Introduction 
Mouse embryonic stem cells (mESCs) possess both the ability for unlimited 
self-renewal in culture and the capacity to maintain their pluripotency indefinitely 
(Smith et al., 2001). These unique abilities are regulated, in part, by the transcription 
factors Nanog, Oct4 and Sox2 (Niwa et al., 2007).  
 Recent studies have shown that Nanog is post-translationally regulated both 
by phosphorylation which stabilizes it and ubiquitination which targets the protein 
for degradation by the 26S proteasome (Moretto-Zita et al., 2010; Ramakrishna et 
al., 2011; Chae et al., 2012). Therefore, the development of a strategy to identify 
those proteins involved in the post-translational modification of Nanog and other 
pluripotency factors would provide valuable insight into how pluripotency in 
regulated in ES cells.  
To date, several IP-LC-MS/MS protein-protein interaction studies of Nanog 
and other key pluripotency factors in mESCs have been published (Wang et al., 
2006; Van den Berg et al., 2008; Liang et al., 2008; Van den Berg et al., 2010; Mak 
et al., 2010; Pardo et al., 2010; Mallanna et al., 2010). Each of these protein 
interaction network datasets were obtained using different cell types, starting 
material (nuclear versus whole cell extracts) and purification methodologies. The 
integration of these networks using Cytoscape reveals that the 10 different 





Image taken from Mallanna and Rizzino, J Cell Physiology 2012. 
Figure 3.1 The published protein–protein interaction datasets for 10 different 
pluripotency factors obtained from mESCs. Using Cytoscape, the IP-LC-MS/MS datasets for 10 
different transcription factors were merged to generate an integrated protein interaction network for 
mESCs. The interactors identified for Nanog, Oct4, Esrrβ, Sall4, Rex1, Dax1, Tcfcp1l1, Zfp281 and 
Nacc1 in mESCs (coloured in blue) (Wang et al.,2006; Liang et al., 2008; Pardo et al., 2010; Van den 
Berg et al., 2010) were integrated with the interactors identified for Sox2  undergoing early-stage 
differentiation (coloured in red) (Mallanna et al., 2010). 
 
Although there are few direct interactions reported between the pluripotency 
factors themselves (Figure 3.1), they do interact with many of the same proteins. 
Furthermore, several of these shared interactors between pluripotency factors 
combine to form complexes which further connect the various interaction networks 
to each other.  This suggests that these 10 essential pluripotency factor proteins are 




Proteins and protein function are regulated in several ways including, but not 
limited to, phosphorylation and ubiquitination. In recent years, Nanog, Oct4 and 
Sox2 have been shown to have their functions modulated by phosphorylation 
(Moretto-Zita et al., 2010; Seki et al., 2010; Jeong et al., 2010). A protein-protein 
interaction network obtained from whole cell extracts would be necessary in order to 
identify the components of phosphorylation-mediated signaling cascades feeding into 
the modulation of these master regulators. 
Another reason why whole cell lysates should be used in IP-LC-MS/MS 
studies is due to the characteristic physical properties of ESCs. That is, their high 
nucleus to cytoplasm ratio (Smith 1992). ESCs having a large nucleus surrounded by 
a small amount of cytoplasm would, in theory, allow for signaling cascades to be 
transduced more rapidly in these cells compared to their differentiated counterparts. 
It follows that the protein interaction landscape described by Mallanna and Rizzino 
(2012) (Figure 3.1) would be tightly regulated by finely tuned balances between 
kinases and phosphatases, ubiquitin ligases and peptidases, acetyltransferases and 
deacetylases, etc. Since many of these reactions may occur within the cytoplasm, it 
should be included in order to identify those proteins involved in the post-
translational modification of pluripotency factors.    
Only one of the protein-protein interaction networks published to date (Figure 
3.1) has been performed on whole cell lysates (Pardo et al., 2010).  The remaining 
studies have all been performed on nuclear extracts. This is presumably because 
these pluripotency factors are transcription factors and transcription factors are 
usually found in the nucleus. However, there is a long list of transcription factors that 




(Yamasaki et al., 2005), FoxO1 (Gan et al., 2005), NF-κB (Mikenberg et al., 2007) 
and the pluripotency factors Oct4B (Liedtke et al., 2007) and Sox2 (Baltus et al., 
2009; Zhao et al., 2011) 
In the study performed by Baltus et al., 2009 it was demonstrated that the 
acetylation of Sox2 results in its translocation to the cytoplasm where it is 
ubiquitinated and targeted for degradation. In light of these findings, elucidating the 
Sox2 protein-protein interaction network using whole cell lysates as opposed to 
nuclear extracts could provide valuable insight into the post-translational regulation 
of this protein. 
Due to the fact that several transcription factors are known to have a life 
outside the nucleus characterizing a protein interaction network under limiting 
conditions such as nuclear extracts although highly specified would provide a deep 
but potentially narrow view of the pluriproteomic landscape. 
In this study, two pluripotency factors known to be modulated by post-
translational regulation were chosen as baits: Nanog and Sox2. Sall4 was chosen due 
to its reported interaction with Nanog (Wu et al., 2006; Zhang et al., 2006). Esrrβ 
and Pik3cd were identified as interactors with Nanog in this study and were chosen 
in order to complete the network. 
 
3.2 Aims of this chapter 
The aim of this chapter is to elucidate a protein-protein interaction network 
centered around Nanog and Sox2 that extends beyond the nucleus of mouse 
embryonic stem cells. This will be accomplished by immunopurifying Nanog and 




analysis on the isolated protein complexes. Additionally, two interactors identified in 
the Nanog purifications will be chosen in order to reciprocate parts of the network. 
The data will be analyzed using STRING and Cytoscape in order to identify the 
connections within the network and uncover those biochemical pathways linking 
extracellular and cytoplasmic signaling events that feed into the regulation of 
pluripotency in mESCs.  One further goal of this chapter is to identify those proteins 
involved in post-translational modifications that interact with these pluripotency 
factors. The identification of either the kinase(s) responsible for phosphorylating 
Nanog or the protein(s) that target it for degradation by the Ubiquitin-Proteasome 
System would provide valuable insight into the molecular mechanisms by which 
pluripotency is maintained.  
 
3.3 Results:  
3.3.1 Nanog protein-protein interaction network 
In order to obtain a protein-protein interaction map for Nanog, a mESC cell 
line stably expressing 3XFLAG epitope-tagged mouse Nanog protein was first 
established. As shown in Figure 3.2, 3XFLAG-Nanog protein complexes were 
immunopurified from whole cell lysates prepared from the E14tg2a/3XFLAG-Nanog 
mESC cell line using anti-FLAG M2 agarose. In order to eliminate any potential 
artifacts introduced due to the use of the puromycin selection antibiotic, an anti-
FLAG M2 agarose IP performed on whole cell lysates prepared from TNG cells 
similarly cultured in 1µg/mL puromycin was used as the control. The entire sample 
lanes were cut and digested ensuring that bias due to differential Coomassie staining 
was not introduced into the results. The results are based on 2 biological replicates of 




biological replicates of anti-FLAG M2 agarose IPs from TNG whole cell lysates 
(Figure 3.2). 
 
Figure 3.2: Immunopurification of 3XFLAG-Nanog protein complexes. Coomassie stained  
gel of 3XFLAG-Nanog protein complexes isolated using anti- FLAG M2 agarose. Gel slices excised 
for digestion and subsequent LC-MS/MS analysis are indicated by red boxes and numbers. 
 
 In order to obtain a protein-protein interaction network consisting of nodes 
(proteins) and edges (interactions) for the Nanog protein in mESCs, the LC-MS/MS 
data acquired from these experiments was analyzed by searching for known 
interactions between the proteins identified using STRING and were graphically 





Figure 3.3: The Nanog protein-protein interaction network generated in this study.  
Cytoscape diagram of the high-confidence Nanog interacting proteins identified by LC-MS/MS.  
Proteins that are reported to interact with each other are clustered together and differentially coloured  
based on the known function of these interacting groups as reported by STRING software. Each  
of the protein clusters is further illustrated in Figures 3.4 and 3.5. 
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In these experiments, 174 high confidence interactors were identified for 
3XFLAG-Nanog and are listed in APPENDIX A. In figure 3.3, the Nanog interaction 
network is shown having 174 nodes and 273 edges. Of the 174 interacting proteins 
identified, 75 were clustered into 11 interacting protein groups having known 
functions. The interacting protein clusters were coloured based on their known 
function ascertained from the STRING protein descriptions output and the bright 
green-coloured nodes represent the other 99 proteins identified to interact with 
Nanog. The circular red line on the Nanog node indicates that this protein interacts 
with itself. This interaction has been well characterized as Nanog self-dimerization 
(Mullin et al., 2008) and is essential for the maintenance of pluripotency (Wang et 
al., 2008). 
 
Figure 3.4: The mRNA transcription initiation, elongation and splicing cluster. Cytoscape 
diagram of the largest cluster of proteins found to interact with Nanog. A) Subgroup of proteins 
linking mRNA transcription initiation with transcript synthesis, B) Subgroup of proteins involved in 
mRNA splicing and metabolism, C) Subgroup of oxidative stress sensing and response proteins. 
 
The largest interacting cluster of proteins identified is shown in Figure 3.4. 
This large cluster consisting of 33 proteins can be further sub-divided into 3 
subgroups. The first subgroup, shown in Figure 3.4 (A), consists of proteins involved 





and Nop58 provide potential links between this subgroup and the mRNA splicing 
subgroup shown in Figure 3.4 (B) Smg5 from the mRNA splicing and metabolism 
subgroup links, via its interaction with Stub1(Lee et al., 2006), to a subgroup of 
proteins involved in oxidative stress sensing and response.  
The remaining 10 interaction clusters identified in this study are shown in 
Figure 3.5 A(i-x). A(i) Shows a large cluster of proteins containing the ligand-
dependent nuclear hormone receptors Esrrβ, Nr5a2 and Nr0B1. Also in this cluster is 
the master pluripotency regulator Sox2 and some of its previously reported 
interactors, Zfp281 and Nacc1. A(ii) Shows a group of proteins involved in 
epigenetic-mediated gene silencing. They are, Rnf2, Phc1 and Cdc73.  A(iii) Shows 
the translation initiation proteins Eif2b2 and Eif2b4. A(iv) Shows a small cluster of 
proteins containing Cbx3, Trim24 and Trim33 which are known to be associated 
with heterochromatin. A(v) Shows the Fam83h, Maged1 and Maged2-containing 
cluster of proteins involved in apoptotic signaling. A(vi) Shows a cluster of 
additional mRNA splicing proteins. A(vii) Shows the novel interactors BRCA2 and 
Ppp2r1b. A(viii) Shows the Pold1 and Pold3 proteins involved in the synthesis of 
DNA. A(ix) Shows a pair of proteins (Nisch and Macf1) thought to be involved in 
cytoskeleton remodeling. A(x) Shows a cluster of proteins containing substrates for 
protein kinase C signaling. Namely, they are: Prkcsh (protein kinase C substrate 
80K-H) and Marcks (myristoylated alanine-rich protein kinase C substrate). 
In order to confirm some of the Nanog interacting proteins observed by mass 
spectrometry, a series of co-immunopreciptation experiments were performed.  In 
Figure 3.5(B), a western blot performed on protein complexes isolated using anti-




is shown. The membrane was probed with antibodies recognizing the endogenous 
Esrrβ, Nr0B1 and Nanog proteins. 
 
 
Figure 3.5: The remaining 10 Nanog interaction clusters and co-immunoprecipitation of 
3XFLAG-Nanog with several identified interactors. (A) Cytoscape diagram of  
the Nanog interacting protein clusters differentially coloured based on the reported functions of these  
interactors using STRING. (B) Western blotting performed on anti-FLAG immunopreciptation of  
3XFLAG-Nanog complexes from mESCs probed with antibodies recognizing the endogenous co- 
purifying nuclear hormone receptors Esrrβ and Nr0B1/Dax1. (C) Western blotting performed on anti- 
FLAG immunopreciptation of 3XFLAG-Nanog complexes from mESCs probed with antibodies  
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In Figure 3.5(C), a western blot performed on protein complexes isolated 
using anti-FLAG M2 agarose beads from the 3XFLAG-Nanog mES cell line and 
TNG cell line is shown. The membrane was probed with antibodies recognizing the 
endogenous Sox2, Akap8, PKAca, PrkaRIIβ and Nanog proteins. 
Several proteins involved in performing various forms of post-translational 
modifications were identified as part of the Nanog protein interaction network. In 
total, 6 kinases, 2 cullins, 5 E3 ubiquitin ligases and 1 F-box protein were identified 
by IP-LC-MS/MS. These protein names, number of peptides identified and peptide 
intensities are summarized in Table 3.1.  
 
 
Table 3.1 Nanog interacting proteins involved in post-translational modifications based 
on n=2 experiments. Summarized are the proteins identified by IP-LC-MS/MS in this study to 
co-purify with Nanog protein. The intensity ratio (sample/control) reported here is an intensity 
measure using protein intensity extracted by MaxQuant software which corresponds to the sum of the 
















Pik3cd 2 2 *
FRAP1
(mTOR) 3 1 *
Sphk2 2 3 *
Mastl 3 6 *
Oxsr1 2 4 *
Prkar1a 2 6 *
Cdk7 2 5 *
CUL4B 7 7 39
CUL7 3 1 *
Trim33 6 6 *
Rnf2 8 32 31
Huwe1 28 8 *
Dtx2 3 8 *
Cdc23 5 8 21
F-box





* Indicates a value of 0 was detected in the control.





3.3.2 Sox2 protein-protein interaction network  
In this set of experiments, the bait protein was the transcription factor Sox2 
having six repeats of the HA epitope tag linked to its amino terminus (Maruyama et 
al., 2005). After generating a mouse embryonic stem cell line stably expressing 
6XHA-Sox2 in an E14tg2a wild-type background, 6XHA-Sox2-containing protein 
complexes were isolated using anti-HA High Affinity matrix, separated on an SDS-
PAGE gel and stained with Coomassie (Figure 3.6). As in the previous section, the 
TNG cell line grown in the presence of 1µg/mL puromycin was used as control 
lysate. The entire sample lanes were cut from the gel and digested with trypsin for 
subsequent LC-MS/MS analysis.   
     
Figure 3.6: Immunopurification of 6XHA-Sox2 protein complexes. Coomassie-stained gel of 
6XHA-Sox2 protein complexes isolated using anti-HA High Affinity matrix. Gel slices excised for 




The results are based on 2 biological replicates of anti-HA High Affinity 
Matrix IPs from 6XHA-Sox2 whole cell lysates compared to 2 biological replicates 
of anti-HA High Affinity Matrix IPs from TNG whole cell lysates. The protein-
protein interaction network obtained for 6XHA-Sox2 in this study consisted of 145 
nodes and 196 edges. The full list of Sox2-interacting proteins identified in this study 
is given in APPENDIX B. In Figure 3.7, 54 of the 145 proteins identified, have been 
clustered into 10 interacting protein groups having known functions. The interacting 
protein clusters were coloured based on their known function and the bright green-
coloured nodes represent the other 91 proteins identified to interact with Sox2.   
All 10 interaction clusters are shown in Figure 3.8 (A-J). (A) Shows a cluster 
of proteins containing Numa1which is a key component of the nuclear mitotic 
apparatus. (B) Shows a cluster containing the Nid2, Lamc1 and Hspg2 proteins 
involved in cell adhesion and migration. (C) Shows the Idh2 and Aprt pair of 
proteins involved in cellular metabolism and energy production. (D) Shows the E3 
ligase Huwe1 and its putative partner Hadh which is involved in lipid metabolism. 
(E) Shows a large cluster of proteins containing the mitotic checkpoint proteins 
BUB1 and CyclinB1. Further links to the mitotic checkpoint and DNA damage repair 
are provided by the presence of Rad50 and ATM kinase within this group. (F) Shows 
a large cluster of proteins containing the proteins Polr2a and Polr2b which are 
involved in transcription initiation and elongation. The kinase Mapk3 (ERK1) was 
identified among this group of proteins, as well as, CUL3 a key component of 
Cullin-RING E3 ligases involved in the regulation of mitosis. (G) Shows a small 
cluster of proteins involved in MafK transcription activation/repression. (H) and (I) 




Shows a pair of proteins containing Pds5a known to be involved in the segregation of 
mitotic chromosomes. 
 
Figure 3.7: The Sox2 protein-protein interaction network generated in this study. 
Cytoscape diagram of the high confidence Sox2 interacting proteins identified by LC-MS/MS. 
Proteins that are reported to interact with each other are clustered together and differentially coloured  
based on the known function of these interacting groups as reported by STRING software. Each of the 
protein clusters are further illustrated in Figure 3.8. 
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MafK transcription activation/repression 
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Figure 3.8: The 10 Sox2 interaction clusters. Cytoscape diagram of the Sox2 interacting 
















A. Nuclear mitotic apparatus components. 
B. Cell adhesion and migration cluster. 
C. Metabolism/energy production cluster. 
D. Lipid metabolism cluster. 
E. Mitotic checkpoint/DNA damage repair cluster. 
F. Transcription initiation/elongation cluster. 
G. MafK transcription activation/repression cluster. 
H. Translation initiation/elongation cluster. 
I. Translation initiation/elongation cluster. 




A multitude of proteins responsible for performing various types of post-
translational modifications were identified as part of the Sox2 protein interaction 
network. Listed in Table 3.2 are the 7 kinases, 2 cullins, 1 E3 ubiquitin ligase, 2 E2 




Table 3.2: Sox2 interacting proteins involved in post-translational modifications based on  
n=2 experiments. Summarized are the proteins identified by IP-LC-MS/MS in this study to co-purify  
with Sox2 protein. The intensity ratio (sample/control) reported here is an intensity measure using  
protein intensity extracted by MaxQuant software which corresponds to the sum of the intensity  






















ATM 2 1 *
Map3k
(ERK1) 3 9 *
BUB1 4 5 28
Melk 17 31 23
Cit 4 2 *
Chka 3 5 *
Sgk223 11 10 *
CUL3 11 17 *
CUL4B 7 8 *
E3 Ub
Ligase Huwe1 9 3 *
Ube2o 5 4 *
Ube2s 2 9 *
Usp34 11 13 113
Usp28 7 2 *
Kinase
Cullins








3.3.3 Esrrβ protein-protein interaction network 
In this study, endogenous Esrrβ protein complexes were immunopurified 
using a monoclonal anti-Esrrβ antibody coupled to Protein A/G agarose beads. The 
entire sample lanes were cut from the gel (Shown in Figure 3.9) and digested with 
trypsin for subsequent LC-MS/MS analysis.  The results are based on 2 biological 
replicates of anti-Esrrβ Protein A/G Plus agarose IPs from E14tg2a whole cell lysates 
compared to 2 biological replicates of anti-mouse IgG agarose IPs from E14tg2a 
whole cell lysates. 
 
Figure 3.9: Immunopurification of endogenous Esrrβ protein complexes. Coomassie-stained 
gel of endogenous protein complexes isolated using anti-mouse-Esrrβ monoclonal antibody coupled to 
Protein A/G Plus agarose beads. Gel slices excised for digestion and subsequent LC-MS/MS analysis 
are indicated by red boxes and numbers. 
 
Of the 187 high confidence interactors identified in the Esrrβ 
immunopurifications (see APPENDIX C), 88 were grouped into 10 protein 
interaction clusters based on reported interactions between these proteins. The 




STRING) and the bright green-coloured nodes represent the other 97 proteins 
identified to interact with Esrrβ (Figure 3.10) 
 
Figure 3.10: The Esrrβ protein-protein interaction network generated in this study. 
Cytoscape diagram of the high confidence Esrrβ interacting proteins identified by LC-MS/MS. 
Proteins that are reported to interact with each other are clustered together and differentially coloured 
based on the known function of these interacting groups as reported by STRING software. Each of the 
protein clusters are further illustrated in Figures 3.11 and 3.12. 
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Translation initiation/elongation 
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Proteinase inhibition/ligand engulfment 
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Figure 3.11: The transcription activation cluster linked to the CPSF complex. Cytoscape 
diagram of a large cluster of Esrrβ interacting proteins. A) Subgroup of proteins containing the Tead 
transcription activation/repression group of proteins and links to mRNA metabolism, B) String of 
proteins involved in mRNA metabolism and synthesis and, C) Cluster of proteins involved in mRNA 
splicing (The CPSF complex). 
 
Shown in Figure 3.11 is the transcription activation cluster linked to the 
cleavage and polyadenylation specificity factor (CPSF) complex. This large group of 
proteins can be sub-divided into 3 sub-groups. Shown in Figure 3.11 (A) is the first 
sub-group which contains Tead1, Tead2, Tead3 and Tead4 which are all components 
of the Tead transcription activation/repression complex. (B) Shows the proteins 
Lin7c, Srrm2 and Pnn which are involved in mRNA metabolism. The association 
between Mpp5 and Amot links one half of this cluster to the Tead complex-
containing cluster in (A) and the interaction between Ythcd1 and Cstf2t links this 
cluster to the CPSF complex-containing cluster. (C) A cluster of proteins involved in 
mRNA splicing (CPSF complex).  Shown in this cluster are all known components 





Figure 3.12: The remaining 9 Esrrβ interaction clusters. Cytoscape diagram of the Esrrβ 
interacting protein clusters differentially coloured based on the reported functions of these interactors 
using STRING.  
 
The remaining 9 interaction clusters are shown in Figure 3.12 (A-I). (A) 
Shown is a large cluster of ribosomal proteins involved in mRNA translation 
initiation and elongation. (B) Shown is a cluster containing the nuclear hormone co-
activator (Ncoa3) connected to the transcriptional repressor Gatad2b. (C) Shown is 
the BRCA2-Hmg20b-RCOR2 cluster. (D) Shown is a cluster containing component 
of the MLL1/MLL complex. (E) Shown is a cluster of cytoskeletal and membrane 
A B 
C D E F 
G H I 
A. mRNA translation initiation/elongation cluster. 
B. Nuclear hormone receptor activation cluster linked to transcriptional repression.  
C. BRCA2 - Hmg20b - RCOR2 cluster. 
D. MLL1/MLL complex components. 
E. Cytoskeletal/membrane  signaling components. 
F. Transcription activation/repression. 
G. Apoptosis induction/inhibition complex. 
H. Proteinase inhibition cluster    




signaling proteins. (F) Shown are Ubtf and Trim27: a pair of proteins involved in 
transcription activation/repression. (G) Shown are Birc6 and Htra2 which are 
components of an apoptosis inhibition/induction complex. (H) Shown is a proteinase 
inhibition cluster of proteins. (I) Shown are the proteins Larp1 and Ptpn14 which are 
involved in the negative regulation of the Pol II transcription complex. 
Listed in Table 3.3 are those proteins involved in performing post-
translational modifications that were identified as part of the Esrrβ protein interaction 
network. Identified in this study were 3 kinases, 1 cullin, 1 E3 ubiquitin ligase and 1 
E3 SUMO ligase. 
 
 
Table 3.3: Esrrβ interacting proteins involved in post-translational modifications based 
on n=2 experiments. Summarized are the proteins identified by IP-LC-MS/MS in this study to co-
purify with Esrrβ protein. The intensity ratio (sample/control) reported here is an intensity measure 
using protein intensity extracted by MaxQuant software which corresponds to the sum of the intensity 




















AurkA 11 32 *
Skiv2l 5 5 *
Riok2 3 6 *
Cullins CUL7 7 4 *
E3 Ub
Ligase Ubr5 14 6 *
E3 SUMO
Ligase Ranbp2 17 7 *





3.3.4 Sall4 protein-protein interaction network 
Using a polyclonal antibody targeting endogenous Sall4 epitopes coupled to 
Protein A/G Plus agarose beads, a Sall4 protein interaction network was established. 
Shown in Figure 3.13 are the endogenous Sall4 protein complexes isolated in this 
study that were cut from the gel and digested with trypsin for subsequent LC-MS/MS 
analysis.  The results are based on 2 biological replicates of anti-Sall4 Protein A/G 
Plus agarose IPs from E14tg2a whole cell lysates compared to 2 biological replicates 
of anti-goat IgG agarose IPs from E14tg2a whole cell lysates. 
  
Figure 3.13: Immunopurification of endogenous Sall4 protein complexes. Coomassie-stained 
gel of endogenous protein complexes isolated using rabbit polyclonal antibody to mouse Sall4 
coupled to Protein A/G Plus agarose beads. Gel slices excised for digestion and subsequent LC-
MS/MS analysis are indicated by red boxes and numbers.  
 
The Sall4 protein-protein interaction network identified in these experiments 
is composed of 104 nodes and 169 edges which are illustrated in Figure 3.14. Of the 
104 high confidence interactors identified in the Sall4 immunopurifications (see 






Figure 3.14: The Sall4 protein-protein interaction network generated in this study. 
Cytoscape diagram of the high confidence Sall4 interacting proteins identified by LC-MS/MS. 
Proteins that are reported to interact with each other are clustered together and differentially coloured 
based on the known function of these interacting groups as reported by STRING. Each of the protein 
clusters are further illustrated in Figures 3.15 and 3.16. 
 
protein clusters were coloured based on their known function and the bright green-
coloured nodes represent the other 51 proteins identified here as interactors with 
Sall4. 
Translation initiation/elongation 
RNA splicing and export   
Epigenetic gene activation/repression cluster 
R NA synthesis 
DNA replication, metabolism and repair 
Mitotic apparatus 







Figure 3.15: The epigenetic gene activation/repression cluster. A) Epigenetic transcriptional 
repression and X-chromosome inactivation cluster, B) Cluster of DNA binding proteins bound with 
Mbd3 and, C) Subgroup containing enzymes responsible for transcriptional repression in connection 
with chromatin remodeling. 
 
Shown in Figure 3.15 is the large epigenetic gene activation/repression 
cluster. This large group of proteins can be further sub-divided into 3 groups. Figure 
3.15(A) Shows a sub-group containing the E3 ubiquitin-protein ligase Rnf2 which is 
involved in the mono-ubiquitination on Lys119 of Histone H2A. This protein acts in 
concert with the other components of this cluster (Wdr5, Cdc73 and Pcgf6) to 
epigenetically silence gene transcription. (B) Shows a cluster containing the majority 
of the NuRD complex members (Gatad2a, Gatad2b, Mbd3, Mta1 and Mta2) involved 
in the recruitment of epigenetic modifying enzymes to specific loci in the nucleus 




A. E3 ubiquitin - protein ligase - containing cluster involved in the mono-ubiquitination of  
Lys-119 on H2A.  
B. DNA binding cluster involved in the recruitment of epigenetic modifying proteins to  
specific loci in the 




modifications. Enzymes involved in both DNA methylation (Dnmt1) and histone 
acetylation (Ep400) are identified here.   
 
Figure 3.16: The remaining 6 Sall4 interaction clusters. Cytoscape diagram of the Sall4 
interacting protein clusters differentially coloured based on the reported functions of these interactors 
using STRING.  
The remaining 9 interaction clusters are shown in Figure 3.16 (A-F). (A) 
Shown is a cluster of proteins involved in translation initiation and elongation. (B) 
Shown is an mRNA splicing and export cluster of proteins containing the essential 
Anaphase Promoting Complex (APC) E3 ligase component Cdc20. (C) Shown is a 
cluster of proteins containing the entire exosome complex which is involved in 
mRNA degradation. (D) Shown are Eprs and Iars proteins which are involved in 
tRNA synthesis. (E) Shown is a pair of proteins which are components of the nuclear 
A B 
C D E F 
A. Translation initiation/elongation cluster. 
B. mRNA splicing and export cluster containing an essential APC E3 ligase 
component. C. Exosom  complex involved in mRNA degradation. 
D. tRNA synthesis cluster. 
E. Nuclear mitotic apparatus cluster. 





mitotic apparatus: Numa1 and Tpx2. (F) Shown is a cluster of proteins containing 
Rfc2, Rfc3, Rfc4 and Rpa1. Together, these proteins form the replication factor C 
complex.  
In Table 3.4 the proteins involved in performing post-translational 
modifications that were identified as part of the Sall4 protein interaction network are 
listed. Identified in this study were 1 kinase, 4 E3 ubiquitin ligases and 1 E3 
ubiquitin ligase substrate recognition component. 
 
 
Table 3.4: Sall4 interacting proteins involved in post-translational modifications based on 
n=2 experiments. Summarized are the proteins identified by IP-LC-MS/MS in this study to co-purify 
with Sall4 protein.  The intensity ratio (sample/control) reported here is an intensity measure using 
protein intensity extracted by MaxQuant software which corresponds to the sum of the intensity 




3.3.5 Pi3kcd protein-protein interaction network 
In this set of experiments, the bait protein used was the kinase Pik3cd with 
six repeats of the HA epitope tag on its amino terminus (Takahashi et al., 2003). A 
stable stem cell line was generated which constitutively expresses 6XHA-Pi3kcd in 
an E14tg2a wild-type background. Figure 3.17 shows the 6XHA-Pik3cd-containing 
protein complexes isolated using anti-HA High Affinity matrix. Once again, because 














Kinase Riok1 5 10 *
Mib2 3 3 *
Ubr5 7 2 *
Rnf2 4 16 *
MycBP2 12 3 *
BRAP 21 38 *
Substrate
Recognition Cdc20 5 13 *






prepared from the TNG cell line also cultured in the presence of puromycin were 
used as a control cell line for these experiments. The results are based on 2 biological 
replicates of anti-HA High Affinity matrix IPs from 6XHA-Pik3cd whole cell lysates 
compared to 2 biological replicates of anti-HA High Affinity IPs from TNG whole 
cell lysates. 
 
Figure 3.17: Immunopurification of Pik3cd protein complexes. Coomassie-stained gel of 
Pik3cd protein complexes isolated using anti-HA High Affinity matrix. Gel slices excised for 
digestion and subsequent LC-MS/MS analysis are indicated by red boxes and numbers.  
 
The Pik3cd interaction network consists of 95 nodes and 387 edges which are 
illustrated in Figure 3.18. Of the 95 high confidence interactors identified in the 
6XHA-Pik3cd immunopurifications (APPENDIX E), 44 were grouped into 5 protein 
interaction clusters based on the reported interactions between these proteins using 
STRING software (Figure 3.19). The interacting protein clusters were coloured 
based on their known function and the bright green-coloured nodes represent the 






Figure 3.18: The Pik3cd protein-protein interaction network generated in this study. 
Cytoscape diagram of the high confidence Pik3cd interacting proteins identified by LC-MS/MS. 
Proteins that are reported to interact with each other are clustered together and differentially coloured 
based on the known function of these interacting groups as reported by STRING. Each of the protein 
clusters are further illustrated in Figure 3.19. 
Epigenetic transcriptional silencing/Histone methylation 
Protein folding and stability 
Translation initiation/elongation 
RNA metabolism and transport 
Pik3cd  interactors 






Figure 3.19: The 5 Pik3cd interaction clusters. Cytoscape diagram of the Pik3cd interacting 
protein clusters differentially coloured based on the reported functions of these interactors using 
STRING.  
  
All 5 interaction clusters are shown in Figure 3.19 (A-E). (A) shown is a 
cluster of proteins containing the Pik3cd regulatory subunits Pik3r2, Pik3r3 as well 
as, Grb2 and Irs2. (B) Shown is a cluster of proteins involved in RNA metabolism 
and transport. (C) Shown is a large cluster of ribosomal proteins responsible for 
translation initiation and elongation. (D) Shown are the proteins mSin3a, Ash2l and 
Ube2i which are known for their involvement in epigenetic transcriptional silencing 
and histone methylation. (E) Shown are Vpb1 and Pfdn2 which are involved in 
protein folding and the targeting of proteins to cytosolic Chaperonin. 
A B 
C D E 
A. Pik3cd cluster containing Pik3cd regulatory units and previously identified interactors. 
. B. RNA metabolism and transport cluster. 
C. Translation initiation/elongation cluster. 
D. Epigenetic transcriptional silencing and histone methylation cluster. 




Proteins involved in performing post-translational modifications that were 
identified as part of the Pik3cd protein interaction network are listed in Table 3.5 




Table 3.5 Pik3cd interacting proteins involved in post-translational modifications based 
on n=2 experiments. Summarized are the proteins identified by IP-LC-MS/MS in this study to co-
purify with Pik3cd protein. The intensity ratio (sample/control) reported here is an intensity measure 
using protein intensity extracted by MaxQuant software which corresponds to the sum of the intensity 



























AK2 3 14 *
Pik3r3 11 25 *
Pik3r2 14 21 *
E3 Ub
Ligase Stub1 5 21 *
E2 Ub 
Ligase Ube2i 2 5 *






3.3.6 Integration of the interaction networks  
All 5 protein interaction networks were merged using Cytoscape in order to 
highlight shared interactors between the networks within a larger integrated network 
(Figure 3.20). This integrated network consists of 614 proteins which have been 
detected in high confidence (Materials and Methods, Section 2.2.3.5).  After analysis 
using STRING, 1374 protein-protein interactions were found to occur within the 
integrated networks.  
In total, 34 proteins providing links between the Nanog protein network and 
one other bait protein’s network were identified in this study. An additional 35 
proteins provide connections between one other bait protein network and another bait 
protein network. These connections are illustrated in Figures 3.21 through 3.29. 
The interactors shared between the Nanog and Esrrβ protein interaction 
networks are shown in Figures 3.21 and 3.22. The 9 proteins identified in this study 
as being part of both protein networks are shown in Figure 3.21. A cluster of 
interacting proteins, components of which are found in both networks is illustrated in 
Figure 3.22. The light blue-coloured nodes in this figures shows those proteins that 
were identified only in the Nanog network.  In total, 13 proteins link the Nanog and 
Esrrβ networks to each other. 
Figure 3.23 shows the 5 proteins found in both the Nanog and Sox2 protein 
interaction networks.  
In Figure 3.24, the 5 proteins connecting the Nanog and Sall4 protein 
interaction networks together are illustrated. (A) Shows the 2 individual proteins 
found in both networks, (B) Shows the interactors shared by Nanog and Sall4 that 




both networks are coloured green while those specifically part of the Nanog or Sall4 
interaction networks are coloured blue or purple, respectively. 
Figure 3.25 illustrates the individual proteins found in both the Nanog and 
Pik3cd protein interaction networks. 
In this study, the Nanog, Esrrβ and Sox2 protein interaction networks were 
found to converge on a novel protein complex shown in Figure 3.26. The red arrows 
in this figure indicate the direction of the bait protein and the blue lines indicate with 
which bait protein the shared interactors (in green) were also identified. The pink 
coloured node in this complex indicates that this particular protein was identified 
only in Esrrβ immunopurifications. 
 Importantly, individual proteins linking 3 networks together were also 
identified in this study. Figure 3.27 shows that the Cdc73 protein was identified in 
Nanog, Pik3cd and Sall4 protein interaction networks. The Cdc73 node is coloured 
orange indicating a link between the Nanog network and the two other networks. 
In Figure 3.28, shows that the nuclear mitotic apparatus protein, Numa1 was 
identified in the Sox2, Esrrβ and Sall4 immunopurifications. The Numa1 node 
coloured bright blue in this figure reveals the link between these three pluripotency 
factors. 
A large central cluster containing 62 proteins having a large degree of 
connectivity to all of the 5 networks elucidated in these studies is shown in Figure 
3.29. This cluster is composed mainly of ribosomal proteins involved in mRNA 
translation initiation and elongation. Additionally, this cluster contains proteins 
involved in mRNA splicing and metabolism, ribosome biogenesis, nonsense-





Figure 3.20: The integration of all 5 protein-protein interaction networks generated in this 
study. Cytoscape diagram connecting all of the protein interaction networks identified by IP-LC-
MS/MS in this study. Bait proteins are coloured yellow and the nodes for each of the baits are 
differentially coloured. The figure legend indicates the colour scheme used to illustrate the individual 
networks as well as those nodes that provide links between the networks.  
Nanog interaction network 
Esrrβ interaction network 
Sox2 interaction network 
Sall4 interaction network 
Nodes linking one network with two other networks 
Nodes linking  Nanog network with two other networks 
Nodes linking one network with one other network 
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Figure 3.21: Direct connections between the Nanog and Esrrβ protein-protein interaction 
networks. A section of the network (Figure 3.20) illustrating a direct link between the Nanog and the 
















        
Figure 3.22: Connectivity between the Nanog and Esrrβ protein-protein interaction 
networks. A section of the network (Figure 3.20) illustrating a cluster of proteins linking the Nanog 
and the Esrrβ protein-protein interaction networks. Components of the cluster identified as interactors 
in both the Nanog and Esrrβ networks are shown in bright green. Red arrows indicate the direction of 








Figure 3.23: Connectivity between the Nanog and Sox2 protein-protein interaction 
networks. A section of the network (Figure 3.20) illustrating the proteins identified by IP-LC-MS/MS 
as being part of both the Nanog and the Sox2 protein-protein interaction networks (bright green). Red 


















Figure 3.24: Connectivity between the Nanog and Sall4 protein-protein interaction 
networks. A section of the network (Figure 3.20) illustrating (A) the proteins identified in both the 
Nanog and the Sall4 protein-protein interaction networks by IP-LC-MS/MS (bright green). (B) Shown 
is a cluster of proteins in which components were identified as interacting with Nanog (light blue), 












Figure 3.25: Connectivity between the Nanog and Pik3cd protein-protein interaction 
networks. A section of the network (Figure 3.20) illustrating the proteins identified by IP-LC-MS/MS 
as being part of both the Nanog and Pik3cd protein-protein interaction networks (bright green). Red 

















Figure 3.26: Connectivity between the Nanog, Esrrβ and Sox2 protein-protein interaction 
networks. A section of the network (Figure 3.20) illustrating a cluster of proteins linking the Nanog, 
Esrrβ and Sox2 protein-protein interaction networks. Components of the cluster providing direct links 
between Nanog and the two other bait proteins are shown in bright green. The pink coloured node 
indicates that this protein was identified only as an interactor with Esrrβ. Red arrows indicate the 










Figure 3.27: Connectivity between the Nanog, Sall4 and Pik3cd protein-protein interaction 
networks. A section of the network (Figure 3.20) illustrating the protein identified in the Nanog, Sall4 
and Pik3cd protein-protein interaction networks by IP-LC-MS/MS (bright orange). Proteins providing 













Figure 3.28: Connectivity between the Esrrβ, Sall4 and Sox2 protein-protein interaction 
networks. A section of the network (Figure 3.20) illustrating the protein identified by IP-LC-MS/MS 
in the Esrrβ, Sall4 and Sox2 protein-protein interaction networks (bright blue). Red arrows indicate 
the direction of the bait protein nodes. 
 
 
Figure 3.29: Connectivity between all 5 protein-protein interaction networks generated in 
this study. A section of the network (Figure 3.20) illustrating a large cluster of 63 proteins identified 









3.3.7 Comparison with the previously reported interaction networks of Orkin, 
Van den Berg and Pardo 
In Figure 3.30, a Venn diagram comparing the Nanog protein-protein 
interaction dataset obtained in these studies with the Nanog dataset published by 
Stuart Orkin’s lab in 2006 is shown. The Orkin dataset reports 18 proteins interacting 
with the Nanog protein in contrast to the 174 reported in this study. 
 
 
Figure 3.30: Comparison of Nanog protein interactors identified by IP-LC-MS/MS in this 
study with the published Orkin Nanog dataset. Venn diagram showing the overlap between the 
high confidence interactors with the Nanog dataset reported by Orkin.  
 
A comparison between the published protein-protein interaction datasets 
obtained for Esrrβ and Sall4 in this study with the datasets previously published by 
Van den Berg in 2008 is shown in Figures 3.31 and 3.32. In Figure 3.31, a Venn 
diagram shows an overlap of only 8 proteins between the two different Esrrβ IP-LC-
MS/MS datasets.  A further 179 proteins are unique to the dataset acquired in this 
study and 74 are unique to the Van den Berg dataset. In Figure 3.32, a Venn diagram 





additional 28 proteins are unique to the Van den Berg study and 91 are unique to this 
study.  
 
Figure 3.31: Comparison of Esrrβ protein interactors identified by IP-LC-MS/MS in this 
study with the published Van den Berg Esrrβ dataset. Venn diagram showing the overlap between 
the high confidence interactors with the Esrrβ dataset reported by Van den Berg.  
 
 
Figure 3.32: Comparison of Sall4 protein interactors identified by IP-LC-MS/MS in this 
study with the published Van den Berg Sall4 dataset. Venn diagram showing the overlap between 
the high confidence interactors with the Sall4 dataset reported by Van den Berg.  
 
In figure 3.33, the entire IP-LC-MS/MS protein interaction datasets for all 5 




diagram showing the overlap between all 3 networks. (B) Table summarizing the 
different baits used in all 3 studies. 
 
Figure 3.33: Comparison of the entire protein interaction dataset from these studies with 
published datasets generated using the same number of baits. A) Venn diagram showing the 
overlap between the entire Roy High Confidence dataset with the entire datasets from Orkin and Van 
den Berg, B) Table listing the bait proteins used to obtain the Roy, Orkin and Van den Berg datasets.  
 
The protein interactions observed in this study were obtained from whole cell 
lysates versus nuclear extracts (used by Orkin and Van den Berg). Therefore, it was 
thought that comparison with a dataset that was also obtained using whole cell 
lysates might provide a greater overlap of interactors. To address this question, a 
comparison was made with the published IP-LC-MS/MS dataset for Oct4 obtained 
from whole cell lysates of mESCs published by Pardo in 2010 (Pardo et al., 2010).  
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Figure 3.34: Comparison of the entire protein interaction dataset from these studies with 
those of Orkin, van den Berg and Pardo. A) Venn diagram showing the overlap between the entire 
Roy High Confidence dataset with the entire dataset published by Orkin, Van den Berg and Pardo. B) 







In Figure 3.34 (A) Venn diagram showing that the dataset acquired in this 
study has an overlap of 24 proteins with the Pardo dataset, 38 proteins with the Van 
den Berg dataset and 16 proteins with Orkin dataset. While this comparison did not 
account for the overall lack of overlap in the datasets, it did reveal an interesting 
interactor shared by this study and Pardo’s dataset. The table in Figure 3.34 (B) 
reveals that CUL4B is an interactor that is unique to the datasets acquired using 




In this chapter, the mass spectrometry data presented were obtained using 
previously published immunopurification protocols and tandem MS/MS 
methodology (Luke-Glaser et al., 2007; Olma et al., 2009). Modifications were made 
to these published protocols and are further detailed in the text below. In most cases, 
epitope-tagged pluripotency factors expressed stably from the pPyCAGIP plasmid 
were immunopurified from mouse embryonic stem cells using epitope-specific 
antibodies. In the case of two baits (Esrrβ and Sall4), however, commercially 
available antibodies to endogenous epitopes were employed at the 
immunopurification step. The datasets presented here are unique from the previously 
published datasets from Van den Berg and Orkin (Van den Berg et al., 2010; Wang 
et al., 2006) in that all immunopurifications have been performed on whole cell 
lysates rather than nuclear extracts. Additionally, the chelating agent EDTA which is 
often used as a phosphatase inhibitor during immunopurifications, was omitted from 
all buffers. The rationale for this exclusion is that EDTA, while it inhibits 
phosphatases, it can also inhibit kinases. The use of whole cell lysates and the 




phosphorylate the bait proteins and identify signalling pathways that may regulate 
the stability and function of these pluripotency factors. The omission of EDTA from 
lysis buffer, however, requires that lysates are pre-cleared with an inert matrix (Chen 
et al., 2007) briefly prior to the incubation with the immunoaffinity matrix. 
In order to minimize the potential contribution of the gelatin matrix proteins 
to the samples, cells were instead transferred to non-gelatinized Cell
+
 tissue culture 
plates manufactured by Sarstedt one day prior to harvest for immunopurifications. 
Another advantage of using a gelatin-free culture environment is that it allowed for 
rapid lysis of cells on the dish as opposed to cell lysis following lengthy 
centrifugation steps in order to remove gelatin contamination. This resulted in an 
improved number of peptides identified for bait and prey proteins in samples and 
allowed for purification of epitope-tagged baits to be performed on a scale of 10 x 
15cm plates per sample and for endogenous immunopurifications to be performed on 
a scale of 5 x 15 cm plates per sample. 
 
3.4.1 The Nanog Protein-Protein interaction network 
Nanog is often referred to as a ‘safeguard’ for pluripotency (Chambers et al., 
2007) due to the fact that its expression at high levels inhibits differentiation of 
mESCs. Conversely, mESCs can differentiate only when Nanog expression levels 
are low. This defining characteristic of Nanog as a ‘gate-keeper’ to pluripotency is 
why it was chosen as the primary bait protein as the primary bait protein around 
which the protein interaction network in this study was centered.  
Among the 33 proteins shown in Figure 3.4, were Dkc1 (Dyskerin), Smg5 




decay and telomere maintenance (Ruggero et al., 2003; Ohnishi et al., 2003). These 
three proteins further strengthen link between Figure 3.4 (A) and (B).  
In Figure 3.5 part A(i) the nuclear hormone receptors and Sox2-containing 
cluster of proteins identified in this study is illustrated. This cluster links hormone-
dependent transcriptional activation/repression with two master regulators of 
pluripotency: Nanog and Sox2.  
Figure 3.5 part A(ii), reveals a cluster of 6 proteins involved in epigenetic  
silencing and gene repression through chromatin remodelling interacting with 
Nanog. Phc1, for instance, is a key component of the Polycomb group (PcG) multi-
protein PRC1 Polycomb-group repressive complex 1 (Satijn et al., 1997). The PRC1 
complex acts via chromatin remodelling and modification of histones; it mediates 
mono-ubiquitination of histone H2A 'Lys-119', rendering chromatin heritably 
changed in its expressibility (Satjin and Otte, 1999). Another essential component of 
the PRC1 complex is ring finger protein 2 (Rnf2). Rnf2 is an E3 ubiquitin-protein 
ligase that mediates mono-ubiquitination of Lys-119 on histone H2A, thereby 
playing a central role in histone code and gene regulation. H2A 'Lys-119' 
ubiquitination gives a specific tag for epigenetic transcriptional repression and 
participates in X chromosome inactivation of female mammals (Lee et al., 2001). 
 Figure 3.5(B) demonstrates that protein complexes purified from the 
3XFLAG-Nanog mES cell line contain endogenous Esrrβ and Nr0B1/Dax1 proteins. 
This confirms the identification of these two nuclear hormone receptors as being part 





 Additionally, Figure 3.5(C) reveals that 3XFLAG-Nanog protein complexes 
co-purify with the endogenous Sox2 protein, as well as, several components of the 
endogenous PKA signaling pathway. This provides further confirmation that the 
master regulator Sox2 and those PKA signaling proteins identified by LC-MS/MS in 
this study are indeed part of the Nanog protein interaction landscape in mESCs. 
Unique to this study is the identification of BRCA2 as a high confidence 
interactor with Nanog. BRCA2 is best known for its involvement in double-strand  
break repair and/or homologous recombination which. To our knowledge, BRCA2 
has never been reported to be associated with Nanog and was identified here with 7 
peptides.  
Also unique to this study was the identification of CUL4B and CUL7 cullin 
proteins co-purifying with Nanog. This study is the first to report the potential post-
translational regulation of Nanog by Cullin-RING-ligase (CRL)-mediated 
ubiquitination. The involvement of these proteins in the control of Nanog protein 
levels is explored in Chapter 4: Exploring the Post-Translational Modification of 
Pluripotency Factors Using Chemical Compounds and Small Molecules. 
 
3.4.2 The Sox2 Protein-Protein interaction network 
Sox2 is a High Mobility Group domain-containing transcription factor 
that is essential for pluripotency (Masui et al., 2007). Since Sox2 was identified in 
Nanog purifications as a high confidence interactor, reciprocal Sox2 IP-MS/MS 
experiments were performed.  




levels in both sample and control immunopurifications. Similarly, Esrrβ was 
identified as a interactor close to but above control levels. The DNA damage repair 
protein BRCA2 was not identified in these experiments. However, several other 
DNA damage repair proteins including Rad50, ATM, MMS19, Faap100 and Brip1 
(BRCA1 interacting protein) were identified as high confidence interactors in these 
purifications. The fact that DNA damage repair proteins are also identified in this 
interaction network suggests that the metabolism and repair of DNA might be an 
essential function of these key pluripotency factors.  
Further to this end, the double-strand break (DSB) DNA damage repair 
proteins Rad50 and ATM kinase both co-purified with Sox2 as high confidence 
interactors in this study. RAD50 is a component of the MRN complex, which plays a 
central role in DSB DNA repair, DNA recombination, maintenance of telomere 
integrity and meiosis. One possible explanation for the presence of RAD50 in this 
network may be a requirement for its ability to bind broken DNA ends and hold them 
in close proximity (Dolganov et al., 1996) in order for enzymes involved in DNA 
repair to act upon them. 
Many of the proteins identified in this study to be involved in the DNA 
damage checkpoint within cells are also components of, or are functionally linked to, 
the mitotic checkpoint of the cell cycle. For example, Bub1 (Budding Inhibited by 
Benzimidazoles 1) which is involved in the enforcement of the mitotic cell cycle 
checkpoint, is associated with the kinetochore and has a role in regulating the exit 
from mitosis and normal mitotic timing in cells (Meraldi et al., 2004). 
To further support the notion that Sox2 might be involved in the regulation of 




dataset. In total, 6 proteins which are essential to the regulation and timing of mitosis 
were identified in this study. Namely, they are: Pds5a, Bub1, Melk, CyclinB1, Kntc1 
and ERK1. The Sox2 protein’s interaction with these proteins might be hinting at a 
novel role for the Sox2 protein in the control of mitotic entry and exit in ES cells in a 
manner which supports the maintenance pluripotency of these cells. 
 
3.4.3 The Esrrβ Protein-Protein interaction network 
Esrrβ is a nuclear hormone receptor that has been shown to bind to the Oct4 
promoter activating Oct4 transcription and sustaining self-renewal (Zhang et al., 
2008; Van den Berg et al., 2008). Since Esrrβ was identified consistently in Nanog 
purifications as a high confidence interactor in this study, reciprocal Esrrβ IP-LC-
MS/MS experiments were performed. Although Nanog was identified as a low 
confidence interactor in these immunopurifications, Cytoscape analysis of the Esrrβ 
protein interaction network revealed 13 shared interactors with the Nanog protein 
interaction network. Therefore, it is possible that Nanog and Esrrβ do not directly 
interact with each other but rather co-purify with each other due to their associations 
with other proteins.  
Another unique aspect this present study was the identification of the 
RCOR2-BRCA2-Hmg20b-Ppp2r1b cluster of proteins. Components of this cluster 
are identified the Nanog, Esrrβ and Sox2 protein interaction networks. The possible 
function of this particular complex has not been elucidated and suggests once again 






3.4.4 The Sall4 Protein-Protein interaction network 
Sall4 (Sal-like 4) is a zinc finger transcription factor which activates Oct4 
expression and is required for the maintenance of pluripotency (Zhang et al., 2006; 
Yuri et al., 2009). Although not identified as a high confidence interactor in the 
experiments presented here, Sall4 has been previously reported to interact with 
Nanog (Wu et al., 2006; Liang et al., 2008). In an attempt to isolate and characterize 
a potential subset of low abundance Nanog and Sall4-containing complexes, 
reciprocal Sall4 IP-LC-MS/MS experiments were performed. In these experiments, 
Nanog, Esrrβ and Sox2 were not identified as either high or low confidence 
interactors. However, the Sall4 protein interaction network is highly connected to the 
Nanog protein interaction network by 8 proteins. These network-connecting proteins 
are: Pcgf6, Rnf2, L3mbtl2, Eml4, Kiaa1551, Cdc73, Serbp1 and Mga. 
One of the largest clusters of interactors in the Sall4 network is the epigenetic 
gene activation/repression cluster shown in Figure 3.15. This cluster also contains the 
greatest number of shared interactors with Nanog. They are: Pcgf6, Rnf2, L3mbtl2 
and Cdc73 and are all involved with epigenetic silencing (Lee et al., 2001; Wang et 
al., 2004; Akasaka et al., 2002; Guo et al., 2009; Rozenblatt-Rosen et al., 2005) . 
This suggests that the Sall4 and Nanog proteins may not directly physically interact 
but rather that they can co-purify due to each protein’s independent association with 
a shared protein complex within ES cells. 
The second largest cluster of interactors in the Sall4 IPs is the entire 
Replication factor C complex RFC illustrated in Figure 3.16(F). The RFC complex is 




DNA repair and telomere maintenance (Wang et al., 2000). Therefore, this cluster 
also links the Sall4 protein interaction network to DNA damage repair in mESCs. 
Unique to Sall4 purifications in this study, is the identification of proteins 
involved in Raf/MEK inhibition, Table 3.4. MycBP2 and its known interactor BRAP 
(BRCA1-associated protein). BRAP (also known as IMP and Rnf52) has been shown 
to impede Raf/MEK kinase signal propagation (Matheny and White, 2006). 
Inhibition of MEK kinase has been identified as a means of maintaining 
pluripotency/preventing differentiation of ES cells (Ying et al., 2008). Therefore, the 
interaction of the pluripotency factor Sall4 with this protein known to inhibit 
mitogenic signaling provides a valuable clue as to how Sall4 may contribute to the 
stabilization of the pluripotent ES cell state. 
 
3.4.5 The Pik3cd Protein-Protein interaction network 
Pik3cd (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit 
delta, or p110delta) is a kinase involved in lipid metabolism and immune response 
regulation (Kim et al., 2007). For reasons that are unknown, this isoform of PI3K is 
most abundantly expressed and active in both leukocytes and embryonic stem cells 
(Takahashi et al., 2003). Since Pik3cd was identified in Nanog purifications with 2 
peptides satisfying the high confidence interactor criteria used in this study (defined 
in Chapter 2: Materials and Methods, Section 2.2.3.5), reciprocal Pik3cd IP-MS/MS 
experiments were performed. 
In these experiments, 2 peptides of Nanog were also identified in the 6XHA-
Pik3cd eluates, however, they did not satisfy the high confidence criteria used in this 




Among the remaining 95 interactors is Fkbp3 (FK506-binding protein 3) an 
immunophilin which play a role in immuno-regulation and basic cellular processes 
involving protein folding and trafficking. This encoded protein is a cis-trans prolyl 
isomerase that binds the immunosuppressants FK506 and rapamycin (Ochocka et 
al.,2009) suggesting that treatment with rapamycin may alter or inhibit the 
characteristic metabolism conferred to ES cells because of their over-expression of 
Pik3cd rather than Pik3ca or Pik3cb which are over-expressed in cancer cells. 
 
3.4.6 Integration of the protein interaction networks 
The high confidence datasets of each individual network were then merged  
together using Cytoscape (Figure 3.20) resulting in an integrated protein-protein 
interaction network  centered around the pluripotency factors investigated in this 
study. By taking this approach to visualise the data it became possible to identify key 
interacting proteins shared by Nanog and other protein baits. This analysis allowed 
for the identification of both individual proteins as well as groups of proteins (i.e., 
complexes) that link the Nanog interaction network to the other pluripotency factor 
networks. 
One protein identified as connecting the Pik3cd, Sall4 and Nanog protein 
interaction networks is Cdc73. This protein is part of a complex (Figure 3.27) which 
mediates chromatin remodelling and epigenetic gene silencing (Zhu et al., 2005). 
The identification of the Cdc73-containing chromatin remodelling/gene silencing 
complex connecting the Nanog, Pik3cd and Sall4 networks would suggest a 
mechanism of maintaining pluripotency which extends beyond simply the activation 




remodelling of chromatin within the nucleus which allows for the repression of genes 
that would cause the cells to commit to various lineages. Facilitating this process, is 
the Sall4-interacting protein, BRAP, which would allow for an open state of 
chromatin to exist in ES cells in the absence of mitogenic signalling.   
As illustrated in Section 3.3.6 Integration of the Interaction Networks, the 
integrated interaction network reveals numerous connections between the Nanog 
network and the networks of the other 4 bait proteins used in this study. In addition, 
several connections are observed between the other 4 bait protein networks with each 
other. Taken together, this reveals that a multitude of contact points exist between the 
individual protein interaction networks and would imply that a well-integrated series 
of protein interaction-mediated mechanisms exist at the core pluripotency. 
Furthermore, the large number of proteins involved in post-translational 
modifications identified in this study suggests that the network of protein interactions 
governing pluripotency is both highly integrated and tightly regulated. 
 
3.4.7 Comparison with the published datasets of Orkin, Van den Berg and 
Pardo 
The protein interaction network published by Stuart Orkin’s lab in 2006 
(Wang et al., 2006) was built around the same number of bait proteins (5 baits 
proteins) used in this study.  The only bait protein in common with the ones used in 
these studies is Nanog. Comparison of the Nanog IP-LC-MS/MS presented in 
Section 3.3.2 with Orkin’s Nanog data shows a stark contrast between Orkin’s 18 
Nanog interactors and the 174 determined by the Nanog IP-LC-MS/MS experiments 




Orkin published dataset and the entire dataset acquired in these studies is limited to a 
mere 16 proteins.  
The overlap between the entire Van den Berg dataset and the dataset 
presented here is improved to 40. However, 15, 68 and 532 proteins remain unique to 
the Orkin, Van den Berg and this study’s dataset, respectively. Whether these 
discrepancies are due to the different methods of expression employed by each study 
and/or the use of nuclear extracts as the starting material for the IP-LC-MS/MS 
experiments remains unclear.  
In Figure 3.34, it is shown that although the Pardo dataset was acquired for 
only one bait protein (Oct4), it shows an overlap of 24 proteins. Interestingly, Figure 
3.34(B) shows that the Pardo dataset also identifies CUL4B as an interactor with the 
protein interaction landscape for Oct4. Whether or not the use of whole cell lysates 
explains the identification of CUL4B both by Pardo and in this study remains to be 
determined. Since CUL4B can be detected both in the nucleus and the cytoplasm 
(Tripathi et al., 2005), and Sox2 is exported to the cytosol following it acetylation 
(Baltus et al., 2009), the IP-LC-MS/MS strategy employed here may have provided a 
clue as to how this protein is regulated. 
 
3.5 Future Work 
The harvesting and purification methodology developed and employed in this 
study provided a different view of how several key pluripotency factors are regulated 
post-translationally. This interaction dataset provides the field of regenerative 
medicine with many valuable targets for the modulation of these pluripotency factor 




Future work to investigate chemical compounds and small molecules that 
inhibit or activate the functions of the proteins listed in Tables 3.1-3.5 should be 
performed. Assessment and quantification of the effects of such perturbations on the 
identified Nanog-Sox2 interaction might provide key insights into this functional 
significance of this interaction. Additionally, quantification of Nanog and Sox2 
protein levels in response to the inhibition of the cullin proteins identified would 
reveal how the protein levels of these master pluripotency may be regulated.  The 
discovery of a molecule that could reversibly stabilize these master pluripotency 
factors and/or their interactions with each other studied here would provide 
researchers with a new-found control over the maintenance of pluripotency. Chapter 
4: Exploring the Post-Translational Regulation of Pluripotency Factors Using 
Chemical Compounds and Small Molecules will explore this concept further.  
Another major finding in this chapter is the strong links between each of the  
pluripotency factors and DNA damage proteins. Future work to better characterize 
the functional significance of these connections within mESCs should be 
investigated. Since DNA damage has been reported to cease under hypoxic 
conditions (Di Carlo et al., 2004), an integrated protein-protein interaction network 
established under hypoxic conditions may provide insight into the dataset obtained in  
this chapter. Such a network may provide an even further clarified view of  
pluripotency protein interaction networks by answering the following: Do the  
interactions observed here under normoxic conditions also occur at physiologically  
relevant oxygen tensions? Are these interactions regulated in the same way by the  
same set of post-translational modifications? Do interactions between master  
pluripotency factors and DNA damage repair proteins still occur in the absence of  




damage-inducing environment? The answers to these questions may provide valuable  








CHAPTER 4: Exploring the Post-Translational Modification of  






Nanog levels have been shown to fluctuate in mESCs resulting in a 
heterogeneous population where some cells express high levels while others express 
very little to none (Chambers et al., 2007).   An initial study revealed that mESCs 
lacking Nanog lost pluripotency and tended to differentiate into extra-embryonic 
endoderm lineages upon prolonged culture (Mitsui et al., 2003). Alternatively, the 
over-expression of Nanog completely blocks differentiation of mESCs and allows 
them to remain pluripotent in culture without the requirement of LIF (Chambers et 
al., 2003; Chambers et al., 2004). As a result of these combined properties, Nanog 
has become regarded as being ‘the gate-keeper’ of pluripotency.  
In the years following, it has been well-documented that Nanog protein levels 
are modulated both by phosphorylation which causes self-dimerization and stabilizes 
it and also by ubiquitination which results in its degradation by the 26S proteasome 
(Mullin et al., 2008; Wang et al., 2008; Moretto-Zita et al., 2010; Ramakrishna et al., 
2011; Chae et al., 2012). However, neither the kinase phosphorylating Nanog nor the 
E3 ligase(s) ubiquitinating it and targeting it for proteasomal degradation have been 
identified to date.  
The identification of chemical compounds or small molecules that could 
elevate the levels of phosphorylated Nanog thereby, stabilizing its transcriptional 
activity would provide a non-genetic means of blocking differentiation.  One 
approach to elevating Nanog protein levels in cells would be to identify the E3 ligase 
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responsible for its degradation and inhibit its function. Recently, a small molecule 
named MLN4924 has been reported as an inhibitor of the enzyme NAE1, efficiently 
blocking the Neddylation of all cullin proteins and blocking the degradation of CRL 
substrate proteins (Soucy et al., 2009). If the master regulators of pluripotency were 
found to be substrates of CRLs, MLN4924 may provide a reversible and dose-
dependent method of stabilizing pluripotency. Understanding how proteins that 
confer pluripotency to ES cells are both stabilized and degraded will reveal the 
biochemical mechanisms by which the stem cell state is established, maintained, and 
eventually lost. The ability to control and modulate the stability of pluripotency itself 
through the use of small molecules could provide researchers with valuable tools for 
future fundamental research, as well as, potentially advance the field of regenerative 
medicine. 
Conversely, the identification of the kinase responsible for phosphorylating 
Nanog and inhibition of its function would result in opening the door toward 
differentiation. Such a compound may allow for all cells in a given culture to be 
homogeneously primed for differentiation. These cells could then be differentiated 
into the lineage of choice by subsequent treatments. This could provide a powerful 
reagent for cell-based therapeutics to treat degenerative diseases.  
In addition to ES cells, Nanog has also been detected in several tumour cell 
types including germ cell tumours, testicular, lung, oral, gastric and prostate cancers 
(Hoei-Hansen et al., 2005; Hart et. al., 2005;  Jeter et al., 2009; Chiou et al., 2008; 
Chiou et al., 2010). It has been found to play a key role in tumour development by 
conferring pluripotent stem cell characteristics to tumour cells (Jeter et al., 2011; 
Chiou et al., 2010). In the field of oncology, Nanog is currently being used as a 
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diagnostic biomarker. Its presence is indicative of the most invasive forms of cancer 
and a poor prognosis (Meng et al., 2010; Jeter et al., 2011; Tsai et al., 2011). 
Therefore, the discovery of a chemical compound or small molecule that could 
prevent the phosphorylation of Nanog and thereby destabilize it would induce 
differentiation of highly metastatic cancer cells. This compound would result in the 
development of new reagents to combat the most aggressive types of cancer.  
 
4.1.1 Proteins involved in post-translational modifications identified in this 
study 
 
In Chapter 3, protein-protein interaction networks were obtained for five 
different pluripotency factors. Among the identified interactors, were several proteins 
responsible for performing various types of post-translational modifications and they 
are summarized in Table 4.1.  
With regards to the degradation of proteins, the cullin proteins that have been  
identified in this study to potentially interact with pluripotency factors are of 
particular interest. CUL3 was identified in Sox2 purifications, CUL4B was identified 
in both Nanog and Sox2 purifications and CUL7 was identified to co-purify with 











 Bait Protein: 
Protein Class: Nanog Sox2 Esrrβ Sall4 Pik3cd 
Kinases 
 
Pik3cd ATM AurkA Riok1 Pik3r3 
FRAP1 ERK1 Skiv2l  Pik3r2 
Sphk2 BUB1 Riok2  Ak2 
Mastl Melk    
Oxsr1 Cit    
Prkar1a Chka    
Cdk7 Sgk223    
Cullins 
CUL4B CUL4B CUL7   
CUL7 CUL3    
E3 ligase 
Trim33  Ubr5 Ubr5 Stub1 
Rnf2   Rnf2  
Huwe1 Huwe1  Mib2  
Dtx2   MycBP2  
Cdc23   BRAP  
E2 conjugating 
 Ube2o   Ube2i 
 Ube2s    
Ub peptidase 
 Usp28    
 Usp34    
SUMO E3 ligase   RanBP2   
Table 4.1: Proteins involved in post-translational modifications identified in this study. 




4.1.2 Chemical compounds and small molecules used to study the regulation of 
Nanog and other pluripotency factors 
 
As highlighted in Table 4.1, it is possible that multiple pluripotency- 
conferring proteins are targeted for degradation by different CRLs. Further 
exploration and identification of which CRL is degrading which protein is necessary 
in order to reveal how these proteins might be stabilized and their abundances 
controlled without the need for genetic manipulation. 
This Chapter will investigate the perturbation of the protein modifying  
enzymes identified in Chapter 3 using a variety of molecules purposefully chosen 
based on the identification of their previously published target proteins by IP-LC-
MS/MS in this study. A summary of the molecules selected for use in this Chapter 
are listed and their properties summarized in Table 4.2. 
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Table 4.2: Chemical compounds and small molecules used to study the regulation of 
Nanog and Sox2. Summarized information regarding the structural, chemical and functional 
properties of compounds used in this study. Data presented here has been extracted from the 
manufacturers websites with the exception of Ht-31 for which some information can be found under 
US patent number 6610657 (Promega Corp.). 
*3i inhibitor cocktail as described by Ying et al., 2008. Surpassed by 2i (MEK-1/2 and GSK-3β) 
inhibitor cocktail by Silva et al., 2008.  






Known targets Target(s) identified 
by IP-LC-MS/MS 
H89 C20H20BrN3O2S · 















Forskolin C22H34O7 410.50 Adenylyl cyclase 
Activator, increases 












MLN4924 C21H25N5O4S 443.52 Nedd8-activating 
enzyme inhibitor. 
Inhibits all CRL activity. 









1320  The AKAP-binding 
domain of Prkar2a. 
Inhibits the interaction 
between PKA regulatory 








1321.50 PKA  Prkaca (PKA 
catalytic subunit) 

















































resulting in inhibition of 
phospho-ERK1 & 2  
 













Aurki III C23H20N4O3 400.4 AurkA  
AurkB  
AurkA 
Nocodazole C14H11N3O3S 301.32 Inhibits microtubule 
dynamics. Arrests cell 
cycle at the G2/M 
phase. 
Used here to 




4.2       Aims of this chapter 
The aim of the work in this chapter was to further explore the post- 
translational protein modifying enzymes identified in the previous chapter to interact 
with the five pluripotency factors characterized in this study. The combined approach 
of chemical compound/small molecule inhibition and native gel analysis of Nanog 
protein complexes was employed to investigate the signaling pathways controlling 
the stability of Nanog-containing protein complexes. Furthermore, this approach will 
provide a means to assess the stability of the Nanog interaction with Sox2 and 
determine its involvement in maintaining the pluripotent state. Co-localization 
studies will be performed in an attempt to visualize whether or not the interactions 
observed by IP-LC-MS/MS in this study (Chapter 3) naturally occur within the intact 
cells.  The development of several multiplexed fluorescence based quantitative 
confocal microscopy assays, will allow for the determination of Nanog and Sox2 
protein levels in response to various perturbations including the inhibition of CRLs. 
The use of the NAE1 inhibitor MLN4924 will be used, as well as, shRNA 
knockdown of CUL3, CUL4B and CUL7 in order to identify the CRL that may 
responsible for targeting Nanog and Sox2 for degradation. Confocal microscopy will 
be used to examine whether or not CUL4B co-localizes with Nanog and Sox2 and 
whether or not this interaction occurs within the cytoplasm or the nucleus. This will 
address the issue raised in Chapter 3 about whether or not IP-LC-MS/MS studies 
performed on whole cell lysates accounts for the identification of the CUL4B protein 
in both the dataset reported by Pardo et al. in 2010 and in this study.    Furthermore, 
the effects of inhibiting CUL3, CUL4B and CUL7 on the cell cycle of mESCs will 
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be studied in order to determine at which point in the cell cycle Nanog is being 
targeted for degradation.  
 
4.3 Results: 
4.3.1 Effects of various chemical compounds and small molecules on the 
Nanog protein 
 In this experiment, the 3XFLAG-Nanog stable cell line was treated with the  
inhibitors listed in Table 4.2 in order to determine if their respective targets were  
responsible for the phosphorylation of Nanog protein in mESCs (Yates and  
Chambers, 2005).   
In order to confirm that this increased molecular weight band detected by the 
anti-FLAG M2 antibody was indeed a phosphorylated form of the Nanog protein, a 
λ-phosphatase treatment was performed on immunoprecipitated 3XFLAG-Nanog 
protein complexes. In Figure 4.1 (A), it is shown that treatment with λ-phosphatase 
results in the disappearance of the higher molecular weight band detected by the anti-
FLAG M2 antibody.  
In Figure 4.1 (B), an increase in phospho-Nanog levels is observed 
following a 12 hour treatment of mESCs with PKI (14-22), Ht-31, MLN4924, 
AurkiIII and nocodazole. In comparison, 3i cocktail caused only a marginal increase 
in phospho-Nanog levels. Conversely, the band corresponding to phospho-Nanog 
completely disappears following treatment with H89, Forskolin and Wortmannin. 
Interestingly, treatment with Nocodazole, known to synchronize cells at the G2/M 
stage of the cell cycle causes the accumulation of phospho-Histone H3 as well as an 





Figure 4.1: Effects of various chemical inhibitors on the Nanog protein in mouse 
embryonic stem cells. A) Western blot on lysates prepared from 3XFLAG-Nanog stable cell line  
treated with various inhibitors for 12 hours. Arrows point to the Nanog protein and a modified Nanog.  
B) anti-FLAG western blot on FLAG M2 agarose- purified 3XFLAG-Nanog protein. Nanog protein 
bound to beads were either untreated (UT) or subjected to phosphatase inhibitor (PPI) and  
λ-phosphatase treatment. Arrows point to Nanog and phospho-Nanog proteins. C) Effects of  
the compounds H89 and MLN4924 on Nanog phosphorylation status after 12 and 24 hours of  
treatment. Arrows indicate Nanog and phospho-Nanog bands. anti-phospho-HH3 was used as a  
mitotic marker and anti-actin as a loading control. 
 
 
In Figure 4.1 (C), it is shown that the opposing effects of MLN4924 and H89 
treatment on the abundance of phospho-Nanog levels are consistent after 12 and 24 
hours of treatment in this study.  
 
4.3.2 Effects of various perturbations on Nanog-containing protein complexes  
 In order to determine the how the disappearance of phospho-Nanog affects 
the formation of Nanog complexes, 3XFLAG-Nanog complexes were  
immunopurified from mESCs cultured in normoxia, at physiologically relevant  
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oxygen tensions treated with H89 and separated by native gel electrophoresis.  
Figure 4.2 (A) shows that the molecular weight of the most prominent 3XFLAG-
Nanog-containing complexes decreases from well above 1.2 MDa to between 1 MDa 
and 0.75 MDa in cells treated with H89. Furthermore, the complexes appear as a 
relatively uniform smear across the molecular weight range indicating a lack of 
resolution by the native gel of assembled 3XFLAG-Nanog complexes. Figure 4.2 (B 
– D) shows the distribution of 3XFLAG-Nanog complexes after two-dimensional 
Native-to-SDS PAGE.  In ES cells grown in standard culture conditions (B), a broad 
range in the distribution of complexes exists with the most abundant complexes 
having a molecular weight of between 1 MDa and 0.5 MDa. At physiologically 
relevant oxygen tensions (C), a significant decrease in modified 3XFLAG-Nanog 
was observed. Strikingly, in Figure 4.2 (D), following H89 treatment those 
complexes within the 1 MDa to 0.5 MDa size range were no longer the most 
abundant complexes in mES cells. Instead, those complexes between 0.242 MDa and 







Figure 4.2: Native and Native-to-SDS-PAGE western blot analysis of Nanog containing 
protein complexes. anti-FLAG western blot performed on M2 agarose purified 3XFLAG-Nanog 
protein complexes isolated from mES cells subjected to various perturbations and separated on A) 
NativePAGE gradient native gel. NativePAGE-to-SDS-PAGE analysis was performed on 3XFLAG- 
Nanog-containing complexes isolated from mES cells cultured in: B) Normoxia, C) 24 hours hypoxia  
(5% O2), and D) 24 hours treatment with 10µM H89.      
 
In order to examine how the elevation of phospho-Nanog affects 
the formation of Nanog complexes, native gel analysis was performed on  
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immunopreciptates from cells under various perturbations, including  
treatment with MLN4924 and Ht-31.  
Figure 4.3 shows a comparison of the molecular weight distribution of 
3XFLAG-Nanog complexes in response to various forms of phospho-Nanog 
stabilization. The most abundant Nanog complexes are within the range of >2.0 MDa 
to 0.75 MDa in size. The effects of the various chemical treatments are apparent at 
the lower molecular weight range of the gel corresponding to the size of the dimeric 
form of Nanog. Here we see that culture in hypoxic conditions as well as the small 
molecules Ht-31 and Forskolin increase the levels of dimeric Nanog whereas 
MLN4924 and Wortmannin (a PI3K inhibitor) seemingly decrease the levels of 
dimeric Nanog. 
It was then determined what effect phospho-Nanog and possibly Nanog 
dimerization has on Nanog protein-protein interactions in ES cells. Since Sox2 was 
identified as an interactor with Nanog by the IP-LC-MS/MS studies performed in 
Chapter 3, the interaction between these two proteins in the presence and absence of 
phospho-Nanog was examined. In Figure 4.4 (A), shown is a representative native 
gel analysis of the molecular weight distribution of Nanog protein complexes in 
response to various inhibitor treatments.  (B) to (G) show the distribution of Nanog 
and Sox2-containing protein complexes in mESCs after the same treatments 
subjected to Native-to-SDS PAGE analysis. 
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Figure 4.3: Size distribution of Nanog-containing protein complexes in response to various  
perturbations. anti-FLAG western blot on BN-PAGE separated immunopurified 3XFLAG-Nanog-
containing complexes in response to various perturbations. A) 30 second exposure time and, B) 10 
second exposure time of the same gel. Red boxes outlining both the most abundant species of Nanog 
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In Figure 4.4 (A), an anti-FLAG (Left-hand panels) and an anti-Sox2 (Right-
hand panels) western blot on BN-to-SDS-PAGE separated 3XFLAG-Nanog 
complexes are shown. Figure 4.4 (B), shows that in standard culture conditions, 
Nanog and Sox2 interact only in the highest molecular weight complexes near the 
resolution limit of the gel, approx. 20 MDa. (C) Shows that the protein complex 
distribution profile in physiologically relevant conditions is exactly the same as 
normoxia but has a decreased mean molecular weight between 1.2 to 1.0 MDa. (D) 
Shows that treatment with Ht-31 results in all Nanog complexes containing the Sox2 
protein. These complexes have a mean molecular weight distribution similar to 
hypoxia, between 1.2 to 1.0 MDa. (E) Shows that treatment with Forskolin results in 
Nanog and Sox2-containing protein complexes forming at > 1.2 MDa to near 20 
MDa (the resolution of the gel). In addition, all complexes are heavily modified in 
this condition. (F) Shows that treatment with MLN4924 results in all complexes 
containing both Nanog and Sox2 across the molecular weight range observed. In 
addition, the protein complexes in the mean molecular weight range (>1.2 MDa to 
0.8 MDa) contain equal amounts of both Nanog and Sox2 protein. (G) Suggests that 





Figure 4.4: The effects of chemical compounds and small molecules on the interaction 
between Nanog and Sox2. A) anti-FLAG and anti-Sox2 western blotting of BN to SDS-PAGE 
separated immunopurified 3XFLAG-Nanog-containing protein complexes. BN to SDS-PAGE western 
blotting for Nanog (anti-FLAG) and anti-Sox2 of protein complexes isolated from 3XFLAG-Nanog 
stable cell line cultured for 12 hours in: B) Normoxia, C) Hypoxia, D) 50 µM Ht-31, E) 50 µM 








4.3.3 Quantitation of Nanog, Sox2 and CUL4A/B proteins in response to 
inhibition of the PKA signaling pathway   
 In this experiment the levels of Nanog, Sox2 and CUL4A/B proteins in the  
entire cell was measured in response to various perturbations. 3XFLAG-Nanog  
mESCs subjected to various treatments were triple immunostained for all three  
proteins. Figure 4.5 shows overlay images of 3XFLAG-Nanog, endogenous Sox2  
and endogenous CUL4A/B proteins in mESCs. While the 3XFLAG-Nanog protein is  
predominantly nuclear, Sox2 and CUL4A/B proteins are mostly cytoplasmic. The  
Sox2 protein is distributed through both the cytoplasm and the nucleus, the  
CUL4A/B signal is detected almost exclusively in the cytoplasm.  
Relative fluorescence measurements were extracted from raw confocal data 
using Macro1 (see APPENDIX F). Briefly, this Macro quantifies the relative 
fluorescence units (RFUs) in the red channel, as thresholded by the user and maps 
the reading from the green channel onto the areas of fluorescence measured in  
the red channel. The Macro performs this function on every slice in the entire z-stack  
of images acquired. The user assigns which fluorescence channel (green, red or far  
red) is to be measured as the red and green channels defined by the macro script.  
 In Figure 4.6 (A), the RFU measurements were extracted with Nanog being   
assigned as the red channel and CUL4A/B assigned as the green. In Figure 4.6 (B), 
the RFU measurements were extracted with Sox2 being assigned as the red channel  
and CUL4A/B assigned as the green. Data was treated as a multiplexed fluorescence- 
based assay where the mean intensities averaged from 3 z-stacks were converted into  
percentage relative fluorescence. Therefore, the results are represented in terms of a  




Figure 4.5: Immunostaining for Nanog, Sox2 and CUL4A/B in mESCs subjected to various 
perturbations. Immunofluorescent overlays of the 3XFLAG-Nanog stable cell line subjected to 
various treatments for 12 hours and immunostained for Nanog (yellow), Sox2 (red) and CUL4A/B 






Figure 4.6: Effects of chemical inhibition on total cellular Nanog, Sox2 and CUL4A/B 
protein levels. A) Total cellular Nanog relative to CUL4A/B protein levels. B) Total cellular Sox2 
relative to CUL4A/B protein levels. For all graphs, the relative fluorescence averaged from 3 separate 
mESC colonies was calculated using Normoxia UT Control fluorescence as the denominator. 1 St. 
Dev. above the mean % relative fluorescence is shown. The significance compared to Normoxia UT 
control was determined using a one-way ANOVA test and is indicated with asterisks above error bars. 




Figure 4.6 (A) Shows the quantitation of total Nanog protein levels relative to  
the total CUL4A/B protein levels. Of all 5 treatments tested in this experiment, only 
hypoxia resulted in an increase in either total Nanog or total CUL4A/B protein levels 
by 49% and 280%, respectively. 
Figure 4.6 (B) Shows the quantitation of total Sox2 protein levels relative to  
the total CUL4A/B protein levels. Once again, only hypoxia revealed an effect on the 
protein levels of either Sox2 or CUL4A/B. That is, an increase of 341% in Sox2 
protein levels and an increase of 406% in CUL4A/B protein levels. 
 In order to quantify nuclear Nanog protein levels relative to Sox2 protein 
levels, data was extracted from the same set of z-stack images shown in Figure 4.5 
using Macro3 (see APPENDIX G). Briefly, once the DAPI signal has been 
thresholded by the user, this Macro traces outlines around the DAPI signal (nuclear 
area) and measures the fluorescence intensity (RFU) in the green channel mapped 
onto the DAPI signal. The extraction method was performed in two steps. The first 
extraction with the Nanog channel (far red) set as the green channel and the second 
one where the Sox2 channel (red) was set as the green channel.  
 Figure 4.7 (A) Shows overlay images of Nanog and Sox2 proteins following 
various treatments. (B) Shows the quantitation of nuclear Nanog and Sox2 protein 
levels, as well as, nucleus area measurements in response to the various treatments. 
No significant changes in nuclear Nanog protein levels were observed in any of the 
conditions tested. An increase in nuclear Sox2 levels was detected in response to 
hypoxia, Ht-31 and PKI (14-22) amide treated cells by 87%, 38% and 38%, 





Figure 4.7: Effects of chemical inhibition on nuclear Nanog and Sox2 protein levels in 
function of nucleus size. A) Immunofluorescent image overlay of Nanog (yellow), Sox2 (red) and 
DAPI (blue). Scale bar is 48 µm. B) Nuclear Nanog relative to nuclear Sox2 protein levels and 
nucleus size. For all graphs, the relative fluorescence was calculated using Normoxia UT Control 
fluorescence as the denominator. The significance compared to Normoxia UT control was determined 
using a one-way ANOVA test and is indicated with asterisks above error bars. Where: * = p-value < 








4.3.4 Co-localization of Nanog, Sox2 and CUL4A/B proteins  
 In this experiment the co-localization co-efficients of Nanog, Sox2 and  
CUL4A/B protein were determined using Volocity 6.0.  
 
Figure 4.8: Cellular localization and co-localization of Nanog, Sox2 and CUL4A/B proteins 
in mouse embryonic stem cells. (A) Nanog and Sox2 co-localization (Pearson’s = 0.643), (B) Nanog 
and CUL4A/B co-localization (Pearson’s = 0.439), (C) Sox2 and CUL4A/B co-localization 
(Pearson’s = 0.738) and (D) CUL4A/B and DAPI co-localization (Pearson’s = 0.472). Scale bar is 30 
µm. Co-localizing pixels are shown in yellow, CUL4A/B in green, Sox2 in red and DAPI blue. 
 
 
In Figure 4.8 (A) Shown is Nanog and Sox2 protein co-localization in the  
nucleus. (B) Shows Nanog and CUL4A/B protein co-localization in the nucleus. Co- 
localization was increased at mitotic spindles as chromosome segregation occurred  
during anaphase and telophase. (C) Shows co-localization between Sox2 and  
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CUL4A/B occurring in the cytoplasm. A dramatic change was observed during 
anaphase and telophase where they co-localized in the nucleus at mitotic spindles. 
(D) Shows a poor co-localization between CUL4A/B and the DAPI signal until 
mitosis where they co-localized strongly, on condensed chromosomes. 
 
4.3.5 Effects of the chemical compound MLN4924 on the protein levels of 
various pluripotency factors 
 In this experiment, the 3XFLAG-Nanog mES stable cell line was treated  
with the chemical compound MLN4924 in order to determine if inhibiting CRL  
activity would increase the levels of Nanog, Sox2 and Esrrβ proteins.  Figure 4.9 (A)  
shown is an anti-FLAG western blot demonstrating an increase in the levels of  
phospho-Nanog following 12 and 24 hours of CRL inhibition compared to untreated  
cells and H89-treated cells. (B) Shown is an anti- Esrrβ western blot performed on  
mESCs treated for 12 and 24 hours with MLN4924. Inhibition of CRL function did  
not have any effect on Esrrβ protein levels. (C) Shown is a western blot to detect  
Sox2 and CUL4A/B protein levels in response to CRL inhibition after 12 and 24  
hours. MLN4924 treatment resulted in increases in both Sox2 and CUL4A/B protein  








Figure 4.9: Effects of inhibiting Cullin Ring Ligase (CRL) activity with the compound 
MLN4924 on Nanog, Sox2 and Esrrβ proteins. A) anti-FLAG western blot showing  Nanog and 
phospho-Nanog proteins in the 3XFLAG-Nanog stable cell line treated with MLN4924 versus H89 
treatment. B) anti-Esrrβ western blot showing levels of Esrrβ protein in response to cullin inhibition. 
(C) Western blot showing Sox2 and CUL4A/B proteins following treatment with MLN4924. Anti-











4.3.6 Effects of individual cullin-specific shRNA on the interaction of Nanog 
with Sox2 and Esrrβ 
 The increase in phospho-Nanog caused by the pan-Cullin inhibitor MLN4924  
was further dissected using a more targeted cullin inhibition approach. To  
this end, stable cell lines were created expressing shRNA targeted to CUL3, CUL4B,  
CUL7, as well as, a scrambled control sequence. In order to examine how this  
increase in phospho-Nanog affects Nanog protein interactions, 3XFLAG- 
Nanog protein was immunopurified from the shRNA-expressing stable cell lines and  
examined for the presence of Nanog, Sox2 and Esrrβ.                       
 
 
Figure 4.10: The effect of specific knockdown of individual cullins on Nanog interaction 
with Sox2 and Esrrβ. (A) anti-FLAG IP western blot showing Nanog protein levels purified from ES 
cells in response to the inhibition of CUL3, CUL4B and CUL7 proteins (B) anti-Esrrβ blot showing 
the levels of Esrrβ protein co-purifying with Nanog protein in response to cullin inhibition. (C) anti-
Sox2 western blot showing the levels of Sox2 protein co-purification with Nanog protein in response 
to culling inhibition, and (D) levels of IgG light chain used as a loading control. 
 
Figure 4.10 (A) Shows that knockdown of CUL3, and to a slightly lesser  
extent, knockdown of CUL4B resulted in an increase in the level of Nanog being  
immunoprecipitated. (B) Shows the amount of Esrrβ that co-purified with Nanog  
remained unaffected by the knockdown of CUL3, CUL4B or CUL7. (C) Shows the  
amount of Sox2 protein co-purified with Nanog increased in response to all cullin  
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knockdowns and was highest in response to CUL4B and CUL7 shRNA in normoxia. 
Unexpectedly, after 16 hours in hypoxic conditions, Nanog was barely detectable in 
control cells and both Sox2 and Esrrβ completely disappeared in CUL7 shRNA.  
 
4.3.7 Quantitation of Nanog and phospho-Histone H3 protein levels in 
response to cullin inhibition 
In order to confirm whether or not the increase in the amount of Nanog 
protein purified from CUL3 and CUL4B knockdown cell lines was due to an 
increase in Nanog protein levels in these cells, a multiplexed quantitative confocal 
microscopy assay was performed. In this experiment Nanog protein levels were 
measured in response to various forms of cullin inhibition. Since CUL3 inhibition 
has been reported to delay entry into mitosis, as well as, increase in the levels of 
intracellular reactive oxygen species (ROS), both ROS and the phospho-Histone H3 
(pHH3) levels were quantified as well. All image analysis was performed using 
Volocity 6.0.  
Figure 4.11 shows the fluorescent overlay images of Nanog (shown in red), 
pHH3 (shown in green) and ROS (shown in yellow). In these images it is shown that 
treatment with MLN4924 causes an apparent increase in nucleus size accompanied 
by a lack of pHH3 staining. Another interesting observation made in this experiment 
was that the ROS staining was primarily restricted to the cytoplasm in all mESC cell 
lines examined.  
In order to quantify the levels of Nanog, pHH3 and ROS from these images, 
the mean fluorescence intensities averaged from 3 independent colonies was 
extracted using Volocity 6.0 and the relative percentage fluorescence was calculated 
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using CTRL shRNA as the denominator.  Figure 4.12 (A) shows that treatment of 
mESCs with MLN4924 resulted in a 69% increase in Nanog protein levels, a 65% 
decrease in pHH3 protein levels and a 39% increase in nucleus size. Interestingly, the 
knockdown of CUL3 resulted in a 101% increase in Nanog protein levels but had no 
significant effect on pHH3, or nucleus size. Figure 4.12 (B) shows that neither cullin 
inhibition, nor increased Nanog protein levels had a significant effect on the levels of 
either total or nuclear ROS foci.  
 
Figure 4.11: Immunostaining for Nanog, pHH3, and ROS in response to various forms of 
Cullin inhibition in mES cells. Overlay images of shRNA knockdown cell lines with CellROX dye 
for the detection of reactive oxygen species (yellow) and immunostained for Nanog (red) and pHH3 




Figure 4.12: Quantitation of Nanog, pHH3, Nuclear ROS, Total ROS and cell size in 
response to knockdown of specific cullin proteins in ES cells. A) Nuclear Nanog protein levels 
relative to nucleus size and pHH3 protein levels. B) Nuclear Nanog protein levels relative to nuclear 
ROS foci and total cellular ROS foci. The % relative fluorescence was calculated using UT Control 
fluorescence as the denominator.1 St. Dev. above the mean % relative fluorescence is shown. The 
significance compared to UT control shRNA cell line was determined using a one-way ANOVA test 
and is indicated with asterisks above error bars. Where: * = p-value < 0.05 and ** = p-value < 0.01.  
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4.3.8 Quantitation of Nanog protein levels in response to CUL7 knockdown 
 In order to address the question of whether or not the inhibition all CRLs by 
the MLN4924 compound might antagonize the effects of CUL3-specific inhibition, 
Nanog protein levels were quantified in response to CUL7-specific knockdown in 
mESCs.  The effects of CUL7 knockdown on Nanog protein levels were examined 
because it was identified in Chapter 3 of this study as part of the Nanog protein 
interaction network. Since both CUL3 and CUL4B knockdown resulted in an 
increase in Nanog levels, it was wondered if CUL7 might be responsible for the 
observed undesirable effects of MLN4924. That is, the moderate increases in Nanog 
protein levels and the enlargement of the nucleus.  
Figure 4.13 (A) shows overlay images of Nanog (green) and DAPI (blue). 
Figure 4.13 (B) shows a 53% decrease in Nanog protein levels (within 1 St. Dev. 
compared to control cells) in response to CUL7-specific inhibition in mESCs. No 
significant changes in nucleus size (Area) were detected. 
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Figure 4.13: Specific knockdown of CUL7 and its effects on Nanog protein levels in ES cells. 
A) anti-FLAG immunofluorescent staining for Nanog protein (green) and DAPI (blue). Scale bar is 48 
µm. B) Nanog protein levels relative to nucleus size in response to CUL7 inhibition. The % relative 
fluorescence was calculated using UT Control fluorescence as the denominator. 1 St. Dev. above the 
mean % relative fluorescence is shown. The significance compared to UT control shRNA cell line was 
determined using a one-way ANOVA test and is indicated with asterisks above error bars. Where: * = 
p-value < 0.05. 
 
 
4.3.9 Quantitation of Sox2 protein levels in response to CUL4B inhibition 
 In Chapter 3, the CUL4B isoform was identified as an interactor with both 
Nanog and Sox2 proteins by IP-LC-MS/MS. In Figure 4.8 (Section 4.3.4), it was 
shown that the Sox2 protein and the CUL4A/B proteins co-localize. Furthermore, 
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this co-localization was shown to occur primarily in the cytoplasm until mitosis 
where this association was detected on mitotic spindles and condensed 
chromosomes. This suggests that the Sox2 protein is targeted by CUL4A/B-based 
CRL for degradation in a cell cycle-dependent manner in mES cells. 
  To test this hypothesis, Sox2 and CUL4A/B protein levels were quantified in 
response to CUL4B-specific knockdown using confocal microscopy. Data was 
extracted from these images using Macro3 and the mean relative fluorescence 
averaged from 3 z-stacks was used to calculate the percentage relative fluorescence.  
Figure 4.14 (A) Shows overlay images of Sox2 (red) and CUL4A/B (green). 
Once again, as in Figure 4.8, the CUL4A/B protein is primarily cytoplasmic while 
Sox2 is distributed through both the cytoplasm and the nucleus. Conversely, in 
response to CUL4B-specific inhibition, the fluorescence signal for both the Sox2 
protein and CUL4A/B was primarily nuclear. 
Figure 4.14 (B) Shows quantitation of the Sox2 and CUL4A/B proteins, as 
well as, measurement of nucleus size (Area) in response to CUL4B-specific shRNA 
compared to control. In this experiment, Sox2 protein levels were increased by 188% 
in response to CUL4B knockdown.  The level of immunofluorescence detected after 
immunostaining using an antibody recognizing both isoforms of CUL4 (CUL4A and 
CUL4B) proteins was increased by 286% in response to CUL4B knockdown. 
Additionally, the CUL4B shRNA-expressing cell line showed a 32% decrease in 




Figure 4.14: Quantitation of Sox2 protein levels in response to CUL4B knockdown in ES 
cells. A) Control (CTRL) shRNA and CUL4B shRNA stable cell lines immunostained with anti-
CUL4A/B (green), anti-Sox2 antibody (red) and with DAPI (blue).Scale bar is 48 µm. B) Sox2 
relative to CUL4A/B proteins levels and nucleus size in response to CUL4B inhibition. The % relative 
fluorescence was calculated using UT Control fluorescence as the denominator. 1 St. Dev. above the 
mean % relative fluorescence is shown. The significance compared to UT control cells was 
determined using a one-way ANOVA test and is indicated with asterisks above error bars. . Where:  
* = p-value < 0.05;** = p-value < 0.01; *** = p-value < 0.001, and **** = p-value < 0.0001. 
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4.3.10 Co-localization of Sox2 with CUL4A/B and Nanog proteins in response 
to CUL4B inhibition 
 In Figure 4.15, a dramatic shift in the cellular localization of both the Sox2  
protein and the protein being recognized by the CUL4A/B antibody (in this case,  
 CUL4A) was observed in response to CUL4B knockdown. In this experiment,  
yellow co-localizing pixel overlays, as well as, Pearson’s co-efficients were  
generated using Volocity 6.0.    
Figure 4.15 (A), shows co-localization of Sox2 protein and DAPI  
increased in response to CUL4B knockdown. Similarly, the co-localization of  
CUL4A/B signal with DAPI was also increased when CUL4B-specific shRNA was  
expressed. The co-localization between Sox2 and CUL4A/B (CUL4B) signal was  
also increased in CUL4B shRNA cells. Additionally, this co-localization occurred  
exclusively in the nucleus in response to CUL4B shRNA. Taken together, these  
results indicate that Sox2 and CUL4B proteins interact in the cytoplasm where Sox2  
protein levels are regulated by a CUL4B-based CRL.  
 Figure 4.15(B) Shows an enlarged view comparing Sox2 and CUL4A/B  
protein co-localization in response to CUL4B shRNA compared to untreated control  
cells. Red arrows point out cells at different stages in the cell cycle. In untreated  
control cells, Sox2 and CUL4A/B co-localization was observed in the cytoplasm  
until mitosis when the signals co-localized at mitotic spindles and condensed  
chromosomes. In response to CUL4B shRNA, however, the Sox2 and CUL4A/B  
signals co-localization occurred strictly in the nucleus. Upon entry into mitosis by the  
CUL4B shRNA-expressing cells, Sox2 and CUL4A/B signals co-localized in the  
nucleus, at mitotic spindles and condensed chromosomes as in control mES cells.  
 Figure 4.15 (C) Shows that the co-localization between the Nanog and Sox2  
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proteins was also increased in response to CUL4B shRNA compared to control cells. 
 
Figure 4.15: Co-localization of Sox2 with CUL4A/B and Nanog in response to CUL4B 
knockdown in ES cells.   A) Co-localization of DAPI & CUL4A/B in response to CUL4B shRNA 
compared to UT control cells (Pearson’s = 0.715 and 0.422, respectively). Co-localization of Sox2 
protein and DAPI in these cells (Pearson’s = 0.575 and 0.428, respectively).  Co-localization between 
Sox2 protein & the CUL4A/B in response to CUL4B shRNA compared to UT control cells (Pearson’s 
= 0.865 and 0.642, respectively). B) Enlarged image with red arrows indicating the cellular 
localization of Sox2 in association with CUL4A/B (Left panel) and the primary cellular localization 
of both the Sox2 and CUL4A/B signal is nuclear in response to CUL4B shRNA (Right panel). C) 
Co-localization of Nanog and Sox2 proteins in response to CUL4B shRNA (Right panel) compared 
to control cells (Left panel) (Pearson’s = 0.856 and 0.351, respectively). Scale bar is 24 µm. 
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4.3.11 Cell cycle analysis of Nanog protein expression in response to the 
knockdown of CUL3, CUL4B and CUL7 
In Figure 4.15, it was shown that Sox2 co-localized with the CUL4A/B  
proteins during the late stages of mitosis at mitotic spindles and condensed  
chromosomes. Therefore, it was investigated whether or not Nanog was also being  
targeted for degradation by its putative CUL3-based CRL at a specific stage of the  
cell cycle. In order to study Nanog protein levels throughout the cell cycle, a mitotic  
shake-off experiment was performed as per the protocol developed by Savatier et al.,  
1996. As noted by Savatier, ES cells require one hour post-adhering to flasks in order  
to begin cycling once again and, therefore, T0 in this experiment represents 2 hours  
post-harvest.  In Figure 4.16, western blotting was performed on whole cell lysates  
prepared from cells harvested at various time-points throughout this experiment.  
Comparisons of Nanog protein expression levels were determined relative to the  
mitotic cyclin, Cyclin B1.  
 Figure 4.16 (A) shows Nanog protein expression in CUL3 shRNA- 
expressing cells were detectable 8 hours earlier and was dramatically increased at 24  
hours post-release into medium compared to control cells. CUL4B shRNA- 
expressing cells was similar in the timing Nanog expression to CUL3 knockdown.  
However, the same dramatic increase in Nanog protein levels at T24 in CUL3  
knockdown cells was not observed in response to CUL4B knockdown. CUL7  
shRNA-expressing cells had the identical Nanog expression profile as control cells. 
Figure 4.16 (B) shows the expression profiles of CUL3, Nanog and CyclinB1  
as a function of cell cycle in parental 3XFLAG-Nanog mESCs. At T24, the levels of  
both CUL3 and CyclinB1 proteins drop dramatically and Nanog protein is  
expressed. Figure 4.16 (C) shows that CUL3 knockdown alters the expression of  
both CyclinB1 and Nanog. Cyclin B1 levels were overall much lower in these cells  
which caused problems for detection. However, the Cyclin B1 profile was similar to  
control cells while Nanog expression was detected 8 hours earlier than in control  
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cells (T16), and was dramatically increased at T24 compared to control cells. 
Figure 4.16 (D) shows that in response to CUL4B knockdown, an equal amount of  
Nanog protein was detectable at T16 and T24 post-release from nocodazole  
treatment.  
 
Figure 4.16: Nanog protein expression throughout the cell cycle in response to specific 
knockdown of CUL3, CUL4B and CUL7. A) anti-FLAG western blots Nanog protein levels post 
release from nocodazole synchronization in mitosis. B) Western blot showing the levels of Nanog 
protein relative to CUL3 and Cyclin B1 proteins in control cells. C) Western blot showing the levels 
of Nanog protein relative to CUL3 and Cyclin B1 proteins in response to CUL3 shRNA. D) Western 
blot showing the levels of Nanog protein relative to CUL3 and Cyclin B1 proteins in response to 




4.4.1 Effects of various chemical compounds on the Nanog protein 
   
 As previously discussed in Chapter 3 – Section 3.4.1, Nanog is considered the  
‘gate-keeper’ of pluripotency. It safeguards pluripotency by preventing ES cells from 
differentiating when Nanog levels are high and provides a window of opportunity for  
differentiation to occur when its levels are low (Mitsui et al., 2003; Ivanova et al.,  
2006; Chambers et al., 2007). When the Nanog protein is phosphorylated, it self- 
dimerizes and is stabilized (Ramakrishna et al., 2011; Chae et al., 2012). Nanog is  
then able to exert it effects: increased cell proliferation, impose LIF-independence in  
culture and preserve pluripotency (Mullin et al., 2008; Wang et al., 2008). Several  
molecules were identified in this study as being able to increase Nanog  
phosphorylation above UT control cells. Namely, they are: PKI (14-22), Ht-31,  
MLN4924, AurkiIII and nocodazole. Additionally, a few others were identified  
which cause the disappearance of the phospho-Nanog protein band:  H89 and  
Wortmannin. These results revealed for the first time to my knowledge, a method of  
controlling phospho-Nanog protein levels.  
 
 
4.4.2 Effects of various perturbations on Nanog-containing protein complexes  
 
In this section, native gel analysis of Nanog protein complexes purified from 
cells treated with H89 demonstrated that the disappearance of the phospho-Nanog 
protein band (Figure 4.1) de-stabilizes Nanog complexes in mESCs. Further analysis 
by 2D Native-to-SDS-PAGE confirmed the de-stabilization of Nanog complexes by 
this compound. Although the results are quite interesting and H89 is advertised and 
sold as a PKA inhibitor, H89 has well documented off-target effects. In fact, this 
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compound has been shown to inhibit 8 other kinases. They are: MAPKAP-K1b, 
MSK1, PKBα, SGK, S6K1, ROCK II, AMPK, and CHK1 (Davies et al., 2000; 
Lochner et al., 2006). For this reason, a more specific method of inhibiting PKA was 
required in order order to confirm the results obtained using H89. One specific 
method of PKA inhibition is by the cell permeable peptide sequence (14-22) derived 
from heat-stable protein kinase inhibitor (PKI). PKI is an endogenous inhibitor of 
PKA and peptide derivatives thereof  have been shown to effectively and specifically 
inhibit PKA activity both in vitro and in vivo (Glass et al., 1989; Walsh et al., 1991). 
Therefore, a commercially available cell-permeable version of this peptide was tested 
alongside H89. As shown in Figure 4.1, treatment of 3XFLAG-Nanog mESCs with 
PKI (14-22) did not confirm the results obtained with H89. Conversely, the specific 
inhibition of PKA with this molecule greatly increased phospho-Nanog levels. 
Therefore, the depletion of phospho-Nanog by H89 treatment appears not to be due 
to the compound’s reported activity as a PKA inhibitor but rather by inhibiting one 
or more of its other ‘off-target’ kinases.  
In addition to the fact that H89 inhibits 8 other kinases, Davies et al., 2000 
showed that three kinases MSK1, S6K1 and ROCKII are inhibited with an IC50 of 
120 nM, 80 nM, 270 nM, respectively. These values are close to or below that 
reported for H89 inhibition of PKA, 135 nM.  Using chemical compounds or small 
molecules that specifically inhibit each of these kinases, the depletion of phospho-











Figure 4.17: The molecular keys that lock and unlock the gateway to pluripotency. The chemical 
compounds and small molecules shown in this study to increase or decrease phospho-Nanog levels in 
ES cells. Where increased phospho-Nanog induces self-dimerization and stabilizes Nanog function: 
maintains the pluripotent state. Conversely, decreased phospho-Nanog levels prevents dimer 
formation, pluripotency is lost and cells are susceptible to differentiation.  
 
 Figure 4.17 shows that Nanog dimerization mediated by phospho-Nanog can 
be either stabilized or inhibited using small molecules. In the yellow boxes are the 
compounds identified in this study to modulate phospho-Nanog levels. The red 
arrows indicate the direction in which the compounds listed in the yellow boxes are 
driving Nanog phosphorylation and stabilization. The red question mark above the 
list of kinases driving the reaction toward de-stabilization, indicates that it is 
currently not known which one or combination of these kinases is responsible for the 
multi-site phosphorylation of Nanog. Therefore, inhibitors to each of these kinases 
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both individually and in combination should be tested for their effects on phospho-
Nanog levels. 
 
4.4.3 Quantitation of Nanog, Sox2 and CUL4A/B proteins in response to 
inhibition of the PKA signaling pathway 
 
 Since two of the molecules shown to increase phospho-Nanog levels in this 
study inhibit PKA’s ability to phosphorylate its substrates, these compounds were 
further tested for the effects on the levels of Nanog, Sox2 and CUL4A/B proteins. In 
this section an attempt was made to further dissect the PKA signaling pathway by 
quantitating both the total cellular, as well as, the nuclear levels of these 3 proteins.  
 The specific inhibitor of PKA activity, PKI (14-22) was employed as well as 
the specific inhibitor of AKAP signaling, Ht-31 (Carr et al., 1991; Wang et al., 
2006). Forskolin, an activator of adenylyl cyclase was employed alongside a more 
specific method of elevating intracellular cAMP levels using cell-permeable Br-
cAMP. This comparison was made in order to address whether the disappearance of 
phospho-Nanog caused by Forskolin (Figure 4.1) was due to its ability to elevate 
cAMP levels by activating adenylyl cyclase (Seamon et al., 1981; Insel et al., 2003). 
All 4 molecules were compared to both UT normoxia control cells as well as UT 
cells cultured in hypoxia. The comparison with hypoxia was done in order to 
determine whether or not the use of small molecules to increase phospho-Nanog 
levels was able to recapitulate physiologically relevant growth conditions in ES cells.  
 By extracting the data using two different macros (Macro1 and Macro2), it 
was possible to quantify the levels of Nanog, Sox2 and CUL4B proteins throughout 
the entire cell as well as specifically in the nucleus. Using Macro1, no significant 
changes in the total levels of these proteins was detected in response to any of the 
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small molecule and peptide treatments employed. In hypoxic conditions, however, 
the total levels of all three proteins were significantly increased (Figure 4.6).  
The quantitation of nuclear Nanog, Sox2 and CUL4A/B protein levels 
revealed that specific PKA pathway inhibition elevated Sox2 levels in mES cells 
(Figure 4.7). However, hypoxia-cultured cells showed the greatest increase in nuclear 
Sox2 levels compared to any of the treatments tested. Interestingly, the cell 
permeable peptide inhibitors PKI and Ht-31 (potent elevators of phospho-Nanog 
levels) increased levels of nuclear Sox2 protein significantly above controls. None of 
the treatments tested had any significant effect on nuclear Nanog protein levels. 
Therefore, an increase in phospho-Nanog levels does not increase overall Nanog 
protein levels. Taken together with the results shown in Figure 4.1, this data indicates 
that PKI (14-22) and Ht-31 do not increase overall Nanog protein levels but, instead, 
induce a possible equilibrium between the phosphorylated and unphosphorylated 
forms.  
Considering, the significant increase in nuclear Sox2 levels combined with 
the fact that Ht-31 treatment also enriches for the formation of Nanog-Sox2 protein 
complexes suggests that both the phosphorylation of Nanog, it predicted dimerization 
(Ramakrishna et al., 2011; Chae et al., 2012) as well as the Nanog-Sox2 interaction 








4.4.3.1 Model: The molecular keys that unlock the gateway to pluripotency 
 
 
Figure 4.18: The molecular keys that lock and unlock the gateway to pluripotency. In this model, 
the PKI (14-22) and Ht-31 prevent PKA from phosphorylating Sox2 thereby stabilizing the Sox2 
protein and its interaction with the phospho-Nanog/Nanog dimer. The interaction of Sox2 with the 
dimerized form of Nanog is required to prevent the disappearance of phospho-Nanog possibly via 
ubiquitination and targeting it for degradation.  When the Nanog dimer and its interaction with Sox2 
are stabilized, the doorway leading to differentiation is closed.  
  
  
This model is based on the data presented thus far in this study. Although 
Sox2 has never been reported to be phosphorylated by PKA, it has been reported to 
be phosphorylated by PKB/Akt1 on Threonine 118 (Jeong et al., 2010). Comparison 
of the phosphorylation motifs recognized by PKA and PKB/Akt1 reveals that the two 
recognition sequences are highly similar (Table 4.3). 
 
Table 4.3 The substrate recognition sequences of PKA and PKB/Akt1. Phospho-motif 





* Indicates can be Serine or Threonine
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In this particular case, the site identified by Jeong et al., 2010 to be 
phosphorylated by PKB/Akt1 can also be phosphorylated by PKA. In this study, the 
PKA-anchoring proteins Akap8 and Akap8l, were both identified as interactors with 
Nanog by IP-LC-MS/MS, as well as, Sox2.  Furthermore, the amino acid that Jeong 
et al, 2010 reported as being phosphorylated on Sox2 (Threonine 118) lies within the 
High Mobility group (HMG) domain which is conserved in all Sox proteins. 
Previous studies on Sox9 have shown that this protein is phosphorylated within its 
HMG domain at Serine 181 by PKA (Huang et al., 2000; Malki et al., 2005). 
Alignment of the Sox9 and Sox2 HMG domains reveals that Serine 181 in the Sox9 
protein corresponds to Threonine 118 in the Sox2 protein (Figure 4.19).   
 
Figure 4.19: The PKA and PKB/Akt1 phospho-motif within the conserved HMG domain of 
Sox9 and Sox2. The PKA recognition sequence identified in Sox9 is also found in the Sox2 protein 
sequence. Red box indicates the PKA phospho-motif found in both proteins. Red letters indicate the 
residues being phosphorylated by PKA. 
 
 
It has also been reported that PKA inhibition prevents the phosphorylation of 
Oct4 and further activates Oct4 mediated transcription (Saxe et al., 2009). Therefore, 
the observed increases in nuclear Sox2 protein levels could also be attributed, at least 







Sox9  159  ERLRVQHKKDHPDYKYQP RRR S VKNGQAE    187 
Sox2    97  KRLRALHMKEHPDYKYRP RRK TKTLMKKD  125 
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4.4.4 Co-localization of Nanog, Sox2 and CUL4A/B  
 
 Introduced in Chapter 3 was the decision to perform the IP-LC-MS/MS study 
using whole cell lysates rather than nuclear extracts. This decision was partly based  
on the documented life of Sox2 outside the nucleus (Li et al., 2007; Baltus et al.,  
2009).  
In this study CUL4B was identified as an interactor with both Sox2 and 
Nanog by IP-LC-MS/MS. This interaction was also observed by Pardo et al., 2010 in 
their interaction network for Oct4. Since Pardo et al., 2010 also performed their IP-
LC-MS/MS study on whole cell lysates, it was hypothesized that this interaction was 
occurring in the cytoplasm rather than the nucleus.  
 In order to test this hypothesis, the 3XFLAG-Nanog cell line was  
immunostained for Nanog, Sox2 and CUL4A/B. Co-localization of these proteins  
was determined by confocal microscopy. In Figure 4.8, it was shown that Sox2 and  
Nanog co-localization occurred in the nucleus. This suggests that a life beyond the  
nucleus is most likely restricted to the Sox2 protein.  
Sox2 and CUL4A/B co-localization was detected in the cytoplasm until  
mitosis when their co-localization was observed at mitotic spindles and surrounding 
condensed chromosomes. This observation provides insight into why Nanog was not 
reciprocated in Sox2 IP-LC-MS/MS experiments.  
In the case of Nanog and CUL4A/B, co-localization occurred solely in the  
nucleus. As was the case for Sox2, this co-localization was also observed at mitotic 
spindles and surrounding the condensed chromosomes. Furthermore, CUL4A/B co-




 It is important to point out that due to the lack of a CUL4B-specific antibody,  
the antibody used in this study recognizes both isoforms of CUL4; CUL4A and  
CUL4B. Thereby, making it impossible to distinguish which of the one or both  
isoforms are co-localizing with Nanog and Sox2 in control cells when both isoforms 
 are being expressed.    
 From the results in this experiment it would appear as though the hypothesis  
is correct: the identification of CUL4B by IP-LC-MS/MS in this study and the Pardo 
 et al., 2010 was due to whole cell lysates being used as opposed to nuclear extracts 
and this interaction occurs in the cytoplasm. However, this is counter-intuitive since 
CUL4B has been reported to be a nuclear protein whereas CUL4A is both nuclear 
and cytoplasmic (Guerrero-Santoro et al., 2007; Zou et al., 2009). The 
immunostaining in this experiment shows that the majority of the CUL4A/B protein  
is cytoplasmic with very little detectable nuclear fluorescence. That is, until mitosis  
where it translocates to the nucleus to condensed chromosomes and mitotic spindles. 
This cell cycle-dependent localization is characteristic of CUL4 and has been  
previously shown for both CUL4A and CUL4B isoforms (Higa et al., 2006; Jin et  
al., 2006; Guerrero-Santoro et al., 2008). 
 Despite this, only peptides specific to the CUL4B sequence were detected by  
LC-MS/MS in the Nanog and Sox2 IPs. Therefore, in order to confirm our  
hypothesis, further investigation into whether or not the primarily cytoplasmic  
staining is indeed due to CUL4B was done (see Sections 4.4.10 and 4.4.11 ). The  
knockdown of CUL4B expression levels in mESCs resulted in the almost complete  
disappearance of the CUL4A/B antibody signal in the cytoplasm. Therefore, this  
confirms that CUL4B is expressed most abundantly in the cytoplasm of mESCs  
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stably expressing high levels of the Nanog protein. In contrast, CUL4A is  
predominantly localized in the nucleus  of these cells. 
 
4.4.5 Effects of the chemical compound MLN4924 on the protein levels of 
various pluripotency factors 
 
 In Chapter 3, three cullin proteins were identified as interacting with  
pluripotency factors by IP-LC-MS/MS. In Section 4.3.1, a compound that inhibits all  
Cullin-RING Ligase (CRL) activity in cells, the NAE1 inhibitor MLN4924, was  
identified as one of several compounds able to stabilize phospho-Nanog protein  
levels. Since CRL substrates are typically phosphorylated prior to being  
ubiquitinated by their respective CRLs (Hershko et al., 1998; Glickman et. al., 2002;  
Lu et al., 2009), the observed increase in phospho-Nanog levels following treatment  
with MLN4924 supports the notion of CRL-mediated degradation of Nanog.  
 In addition to Nanog, Sox2 and Esrrβ were also found to interact with cullin 
proteins. Both CUL4B and CUL3 were found to interact with Sox2 and CUL7  
was detected in the Esrrβ purifications (Chapter 3). In order to determine if the Sox2  
and Esrrβ proteins might also be substrates for CRL-mediated degradation, their  
levels were examined in response to MLN4924 treatment.  
The levels of phospho-Nanog were increased following treatment with 
MLN4924 for 12 and 24 hours. Esrrβ protein levels were unaffected after 12 hours 
and 24 hours of treatment with the compound. However, a significant effect on Sox2 
protein levels was observed. The levels of Sox2 protein increased following 12 hour 
treatment with MLN4924 and were further increased after 24 hours. At the same 
time, CUL4A/B protein levels also increased over time. This effect can be attributed 
to the MLN4924. Since this compound has been shown to specifically inhibit the 
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NAE1 enzyme in both mammals and plants (Soucy et al., 2009; Milhollen et al., 
2009; Hakenjos et al., 2007), the increase in CUL4A/B protein levels can be 
explained by their documented ability to undergo auto-ubiquitination (Groisman et 
al., 2003; Hrecka et al., 2007; Jackson et al., 2009). The inhibition of CUL4-based 
CRLs activity would, therefore, prevent both CUL4 isoforms from self-destruction 
and stabilize CUL4A/B protein levels as well as their substrates.  
 
4.4.6 Effects of individual cullin-specific shRNA on the interaction of Nanog 
with Sox2 and Esrrβ 
 
 The purification of the Nanog protein from ES cells stably expressing CUL3,  
CUL4B and CUL7 shRNA was performed in order to determine whether or not its  
interaction with the Sox2 and Esrrβ proteins was due to Nanog being degraded by the  
same CRL as these proteins (Section 4.3.6).  
 In this experiment, the amount of Nanog protein being purified from ES cells  
was increased when CUL3 or CUL4B were knocked down. This implies an overall  
increase in the amount of Nanog protein in ES cells when these genes were  
knocked known. The greatest increase in the amount of Nanog protein being purified  
occurred when CUL3 was knocked down. This increase was significant compared to  
cells stably expressing a control scrambled shRNA construct and strongly suggests  
that CUL3 may be responsible for the degradation of Nanog . 
Esrrβ was found to co-purify with Nanog at the same levels regardless of  
which cullin was knocked down. This result indicates that the Esrrβ interaction with 
Nanog is not due to their being degraded by the same ligase and therefore Esrrβ can 
be considered a true interaction with the Nanog network.  
 In the case of Sox2, an increasing amount of protein was observed to co- 
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purify with Nanog in response to CUL3, CUL4B and CUL7 shRNA, respectively.  
This result indicates that Sox2 is an interactor with Nanog and, this interaction is not 
the result of both proteins co-localizing with (as demonstrated in Section 4.3.4) and  
being degraded by CUL4B.    
 
4.4.7 Quantitation of Nanog and phospho-Histone H3 protein levels in 
response to cullin inhibition 
 
 It was demonstrated in Section 4.3.7 that treatment with MLN4924 increases  
the levels of a phosphorylated form of the Nanog protein, however, total levels of  
Nanog appeared relatively equal. In this experiment, Nanog protein levels were  
quantified and revealed that MLN4924 increases Nanog protein levels by 30%.  
Therefore, the increase in phospho-Nanog due to CRL inhibition does correspond to  
an increase in total Nanog protein levels within the cells. Furthermore, this indicates  
that there may be more than one phospho-Nanog protein exists in mESCs: one which  
stabilizes Nanog dimerization and pluripotency and another possibly differentially  
phosphorylated form of Nanog which is being targeted for ubiquitination by a CRL.  
 In Section 4.3.6, the amount of Nanog protein purified from ES cells in  
response to CUL3 and CUL4B inhibition was increased. The results from this 
experiment indicate that Nanog protein levels are further increased by the specific 
inhibition of CUL3 by shRNA. This suggests that Nanog is being degraded by a 
CUL3-based CRL. In response to CUL4B-specific knockdown, the mean percentage 
relative fluorescence detected for Nanog was increased to a similar level as with 
MLN4924. However, this result was not significant within 1 Std. Dev. of the mean 
compared to CTRL cells.  This result implies that although Nanog levels are 
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increased in response to CUL4B knockdown, this effect is not due to CUL4B 
targeting Nanog for degradation.   
A significant decrease in phospho-Histone H3 levels was observed in  
response to MLN4924. This implies that when ES cells are treated with MLN4924 
they may be prevented from entering mitosis. Another observed effect of MLN4924 
on ES cells was a significant increase in nucleus diameter by 10% above control. 
Although this increase may sound slight, the observed effects of cell nucleus 
morphology were not. Figure 4.11 shows the significantly enlarged nuclei of ES cells 
in response to MLN4924 treatment.  
The effects of MLN4924 observed here can be explained by recently 
published studies. Firstly, this compound prevents CUL4-based degradation of Cdt1 
in S-phase. This results in DNA re-replication, checkpoint activation and apoptosis in 
cancer cells (Lin et al., 2010; Milhollen et al., 2011). This explains the decrease in 
phospho-HH3 levels observed in this study as cells would be arrested in S-phase and 
prevented from entering mitosis. Furthermore, this also explains the observed 
increase in nucleus size as DNA re-replication and apoptosis would both contribute 
to the swelling of the nucleus. Additionally, MLN4924 has been shown to stabilize 
the cell cycle inhibitor p21and inhibit proliferation in tumour cells (Jia et al., 2011). 
Although the levels Nanog are increased by MLN4924 treatment it cannot  
overcome one or more of the above-mentioned effects. Altogether, the toxic effects 
that have been reported in the literature for MLN4924 with rapidly proliferating 
cancer cells can explain why the compound does not increase Nanog levels as greatly 
as seen for CUL3-specific inhibition. They also explain the adverse effects that 
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MLN4924 treatment has on ES cells, the swelling of the nucleus and preventing 
entry into mitosis.  
 
4.4.8 Quantitation of Nanog protein levels in response to CUL7 knockdown 
  
 Another cullin protein which was identified as an interactor with Nanog and 
Esrrβ (Chapter 3) was CUL7. In order to further confirm that a CUL3 CRL is 
degrading Nanog, it was required to quantify the effects of CUL7 inhibition on 
Nanog protein levels. Additionally, it was postulated in Section 4.3.7: Quantitation of 
Nanog and phospho-Histone H3 protein levels in response to cullin inhibition, that 
although MLN4924 increases Nanog protein levels, its inhibition of all CRLs may be 
working in opposition to its inhibition of the CRL responsible for degrading Nanog. 
This is confirmed by the recent studies (Lin et al., 2010; Milhollen et al., 2011; Jia et 
al., 2011), with regards to the inhibition of CUL4 CRLs. However, the role of CUL7 
CRL-specific inhibition in antagonizing the increase in Nanog levels in ES cells has 
not been determined.   
 In this experiment, the levels of Nanog protein were decreased by 18% 
compared to CTRL shRNA-expressing cells. This effect can be attributed to the 
accumulation of p53, the well-known substrate of CUL7 CRLs (Andrews et al., 
2006; Kasper et al., 2006; Kim et al., 2007; Sarikas et al., 2008). The repression of 
Nanog’s expression by p53 is well-documented in the literature (Lin et al., 2005; 
Solozobova et al., 2009; Zbinden et al., 2010; Brandner et al., 2010;  Kuijk et al., 
2010; Moon et al., 2011). These experiments suggest that the increased Nanog levels 
by MLN4924’s inhibition of CUL3 CRL activity is being counter-balanced at the 
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transcriptional level by the accumulation of p53 which results from inhibiting CUL7 
CRL function.  
 
  
4.4.9 Quantitation of Sox2 protein levels in response to CUL4B inhibition 
 
 There were two questions to be answered by performing this experiment:  
1) Is Sox2 a substrate for CUL4B isoform-specific CRL degradation? and 2) Is the  
primarily cytoplasmic protein being recognized by the CUL4A/B antibody used in  
this study CUL4B or CUL4A? 
 The first question was answered by the quantitation of Sox2 protein levels in  
response to CUL4B-specific inhibition using shRNA. In this experiment, we see that  
Sox2 protein levels were increased by 163% above control cells. Also, the levels of  
CUL4A protein (recognized by the CUL4A/B antibody used) were increased by  
262% above controls. In addition, the localization of the CUL4A/B signal was 
primarily nuclear as opposed to cytoplasmic as seen in the control. This increase in  
Sox2 and CUL4A proteins coincided with a 25% increase in nucleus size.  
 These results indicate that Sox2 is indeed the substrate of a CUL4B isoform- 
specific based CRL. In addition, this interaction was identified by IP-LC-MS/MS in  
Chapter 3 of this study due to the use of whole cell lysates as the starting material for  
the purifications performed. The identification of CUL4B in Nanog IPs is, therefore,  
the likely to be the result of Nanog’s interaction with Sox2 observed in this study.  
Although Nanog staining is primarily nuclear, all 3 proteins do co-localize on mitotic  
spindles and condensed chromosomes during mitosis as shown, to my knowledge for  
the first time in this study (Figure 4.8).  
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The fact that this degradation occurs primarily in the cytoplasm of ES cells, 
reveals that CUL4B is differentially localized in ES cells. It cannot be ruled out that 
this altered localization might be a consequence of the ectopic expression of Nanog 
in these cells which, as a result, stably express high levels of the Nanog protein.  
The increase in CUL4A signal (as indicated by the CUL4A/B antibody in 
CUL4B shRNA-expressing cells) can be attributed to an increase in the expression of 
the CUL4A isoform in response to the stable knockdown of CUL4B. Although the 
CUL4A and CUL4B isoforms have always been thought to be functionally redundant 
(Higa et. al., 2006a; Jin et al., 2006; Higa et al., 2006b; Olma et al., 2009), recent 
studies have shown that CUL4B isoform-specific CRLs have been characterized 
(Nakagawa et al., 2011; Li et al., 2011; Green and Gozani, 2011).  
 The identification in this study of a CUL4B isoform-specific CRL degrading  
Sox2 in embryonic stem cells is both novel and intriguing. As previously mentioned,  
these two isoforms have always been regarded as having redundant function in cells.  
However, they are isoforms which are encoded by separate genes with the CUL4B  
gene being encoded on the X-chromosome (Kerzendorfer et al., 2007). Mutations in  
the CUL4B gene cause X-linked mental retardation and an increased sensitivity to  
double stranded DNA breaks (Zou et al., 2007; Kerzendorfer et al., 2010). Recently,  
a CUL4B isoform-specific CRL targeting Wdr5 for degradation was reported  
(Nakagawa et al., 2011). Wdr5 is a component of the H3K4 methyltransferase  
complex involved in epigenetic repression of transcription and was also identified of  
the interaction network (Chapter 3 of this study). Taken together, with the CUL4B  
isoform-specific CRL identified here to degrade Sox2, an argument could be made  
that in ES cells CUL4B is the preferentially expressed isoform of CUL4. This  
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suggests that there are potentially several novel and currently uncharacterized 
CUL4B isoform-specific CRLs that are both specific and unique to ES cells.  
  
 
4.4.10 Co-localization of Sox2, Nanog and CUL4A/B protein levels in response 
to CUL4B inhibition 
 
 This experiment revealed that in the 3X FLAG Nanog cell line CUL4B 
 staining is primarily cytoplasmic with the exception of mitosis where once again,  
both proteins co-localized on mitotic spindles and on condensed chromosomes. In  
response to CUL4B-specific inhibition, Sox2 staining is entirely nuclear with only  
faint staining in the cytoplasm. The elevated CUL4A/B signal (now mostly attributed  
to CUL4A) is also primarily nuclear. Once again, however, both CUL4A and Sox2  
proteins co-localize at mitotic spindles and condensed chromosomes. These results  
imply that Sox2 does indeed co-localize with the CUL4B isoform in the cytoplasm of  
ES cells but may associate with either CUL4A or CUL4B at condensed  
chromosomes and on mitotic spindles.  This would explain why cells expressing only  
the CUL4A isoform are still able to progress through mitosis and do not undergo cell  
cycle arrest. This study illustrates that the CUL4A and CUL4B isoforms are not  
entirely functionally redundant as once thought. Where redundancy was found in this  
study was at mitotic spindles and condensed chromosomes. During mitosis it appears  
as though, in the absence of CUL4B, the CUL4A protein is acting upon their shared  
substrates in order to allow for cell cycle progression.   
It is now becoming accepted that these isoforms have unique and specific 
functions which, in the case of CUL4B, involves the regulation of ES cell-expressed 
proteins which include: Wdr5 (Nakagawa et al., 2011), Peroxiredoxin III (Li et al., 
2011), DNA damage repair proteins (Kerzendorfer et al., 2010), chromatin 
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remodeling (Green and Gozani, 2011) and the master pluripotency regulator, Sox2 
(to my knowledge only identified in this study). 
 
4.4.11 Cell cycle analysis of Nanog protein expression in response to the 
knockdown of CUL3, CUL4B and CUL7  
 
 Mitotic shake-off experiments revealed differences the cell cycle-related  
expression profiles obtained for Nanog in response to CUL3 and CUL4B  
knockdown. Post-release into regular growth medium, the expression of Nanog  
begins at T24 in control cells. In response to CUL3 knockdown, Nanog expression  
began at T16 which is 8 hours earlier than control cells. Furthermore, at T24, a  
dramatic increase in Nanog levels was seen in CUL3 shRNA-expressing cells. In  
response to CUL4B knockdown, Nanog expression also began at T16 and persisted  
at T24. In contrast to CUL3 knockdown cells, however, a dramatic increase in Nanog  
levels did not occur at T24 in the CUL4B knockdown cells. Instead, Nanog levels  
were equivalent at T16 and T24 post-release. CUL7 knockdown cells had the same  
timing of Nanog expression as control cells at T24. Taken together, these results  
further confirm the hypothesis that Nanog is degraded by a CUL3 CRL.  
 In control cells we saw that Cyclin B1 levels began to accumulate atT4 post- 
release and peaked at T16. This indicates that cells began to enter mitosis 4 hours  
after being released into growth medium. The peak in Cyclin B1 levels, indicating  
the cells had entered metaphase, occurred at T16 post release. A dramatic decrease in  
Cyclin B1 levels was seen at T24 which indicates that cells had exited mitosis. At  
this same time point, Nanog protein was detected for the first time post-release.  
CUL3 knockdown resulted in Nanog expression being detectable in low  
173 
 
amounts at T16 post-release and were dramatically increased at T24. Due to Nanog’s 
documented role in promoting the G1/S transition in ES cells, (Zhang et al., 2009; 
Ma et al., 2009). This suggests that the cells began to enter S phase 8 hours earlier 
than in control cells.  
Unfortunately, the detection of Cyclin B1 in the CUL3 and CUL4B  
experiments was so weak that no observations could be made confidently about the 
effects this altered Nanog expression profile may have on CyclinB1 level in these 
cells. 
 Although others have reported Nanog to be ubiquitinated and degraded by the 
26S proteasome (Moretto-Zita et al., 2010; Ramakrishna et al., 2011), this study is  
(to my knowledge) the first to identify that Nanog is specifically degraded by a  
CUL3 CRL in ES cells. Taken together, the results obtained in Sections 4.3.4 –  
4.3.12 of this study combine to form to the models being proposed in the following  






















4.4.11  Model of Cell Cycle-dependent CUL4A/B CRL-mediated degradation of 












Figure 4.22   Model of CUL4B isoform-specific CRL-mediated Ubiquitination/ degradation  
of cytoplasmic Sox2. Cytoplasmic Sox2 is reversibly targeted by a CUL4B isoform-specific CRL 
(identified in this study) for ubiquitination and subsequent degradation. Question mark indicates that 
the WD40 domain-containing protein linking CUL4B to Sox2 is currently unknown. This reaction is 
reversed by the ubiquitin peptidases responsible for de-ubiquitinating Sox2 resulting in its being 









4.5 Future work: 
4.5.1 Molecules identified in this study to close the molecular gateway toward  
 differentiation.  
 
 Two molecules were identified in this study to increase phospho-Nanog 
levels and increase its interaction with Sox2 in embryonic stem cells are: Ht-31 and 
PKI (14-22). As described in section 4.4.3, they are both commercially available cell 
permeable peptides that inhibit PKA signaling by two distinct and highly specific 
mechanisms. In this study, it was shown that these two peptides have the ability to 
increase the levels of phospho-Nanog which results in its self-dimerization (Mullin et 
al., 2008).  This self-dimerization is necessary to maintain pluripotency and increase 
Nanog’s transcriptional activity (Wang et al., 2008). This is the first report of 
molecules capable of increasing phospho-Nanog levels and stabilizing it. 
These peptides should be tested for their ability to maintain ES cells in a 
pluripotent state for longer time periods in culture both with and without LIF present 
in the culture conditions. Short-term culture in the presence of these molecules 
revealed that they out-perform the well-known 3i medium in their ability to increase 
phospho-Nanog levels. Therefore, these molecules should be tested for their ability 
to maintain ES cells in long-term culture and in direct comparison with 3i medium 
(Ying et al., 2008). 3i medium requires the complete removal of FBS from medium, 
which is not required in this case. While the 3i system is currently the gold standard 
for maintaining pluripotency in ES cells, it has its drawbacks. For example, 
switching from standard culture conditions to serum-free 3i medium means that all 
previously obtained results may not be comparable or reproducible. Due to its cost, 
3i medium’s widespread use is restricted to low-scale culture of ES cells in academic 
research labs.  
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The advantage of using these cell permeable peptides is that, unlike 3i 
medium, they work in standard culture conditions (Figure 4.1) and can simply be 
added to standard culture medium currently being used by any lab. 
 
4.5.2 Molecules identified in this study to open the molecular gateway toward  
 differentiation.  
 
 In this study the chemical compound H89, which is widely marketed as PKA 
inhibitor, was shown to deplete the levels of phospho-Nanog and cause Nanog 
complex dissociation and degradation. When compared with a highly specific form 
of PKA inhibition using the cell permeable peptide PKI (14-22), however, the exact 
opposite effect was observed. That is, specific inhibition of PKA increased phospho-
Nanog levels.  
 It has been well documented that H89 inhibits up to 8 other kinases in 
addition to PKA. They are: MAPKAP-K1b, MSK1, PKBα/Akt1, SGK, S6K1, 
ROCK II, AMPK, and CHK1 (Davies et al., 2000; Lochner et al., 2006). MSK1, 
S6K1 and ROCKII are inhibited with an IC50 of 120 nM, 80 nM, 270 nM, 
respectively. In the cases of MSK1 and S6K1, they are actually inhibited more 
strongly than PKA itself which has an IC50 of 135 nM. Inhibitors to all 8 kinases, 
and combinations thereof, should be tested for their ability to deplete phospho-Nanog 
levels and induce differentiation.  The identification of such a compound would not 






4.5.3 Investigating the Sox2 interaction with dimerized Nanog.  
  
 In this chapter, the interaction between Sox2 and the dimerized form of 
Nanog (phospho-Nanog) is demonstrated in mESCs. Also shown in this study is that 
this interaction is enriched for when Nanog is stabilized by an increase in phospho-
Nanog levels. This implies that Sox2 interacts with the phosphorylated and 
dimerized forms Nanog with a higher affinity than its unmodified counterparts. This, 
in turn, results in higher nuclear Sox2 levels (shown in this study).  
 Taken together, these results suggest that Sox2 is part of the protein complex 
along with Nanog that maintains pluripotency. However, the functional significance 
of this interaction should be further studied. For example, Sox2 shRNA should be 
employed and the levels of phospho-Nanog determined. A decrease in phospho-
Nanog levels would imply that the interaction with Sox2 somehow stabilizes the 
Nanog dimer. Conversely, an increase would imply that Sox2 somehow attenuates 
Nanog dimerization.  
 
4.5.4 Identification of the BTB/POZ domain containing protein that interacts  
 with Nanog and targets it for ubiquitination. 
 CUL3 was shown for the first time in this study as being involved for the 
degradation of Nanog. CUL3 binds directly to its specific substrate proteins via a 
BTB/POZ domain containing protein. In order to identify the BTB/POZ domain-
containing protein that forms the CUL3 CRL degrading Nanog, a search for all 
BTB/POZ domain-containing interactors identified in the Nanog interaction network 
in this study should be performed. Each of the identified BTB/POZ domain 
containing proteins should then be tested for its ability to co-purify with Nanog. 
Subsequently, an in vitro ubiquitination assay using purified CUL3, Nanog and the 
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yet to be determined BTB/POZ domain containing protein should be performed. 
Additionally, the mitotic shake-off experiment should be repeated in order to 
accurately determine which stage of the cell cycle Nanog is being degraded by CUL3 
in conjunction with the unknown BTB-POZ domain-containing protein. 
 
4.5.5 Identification of the CUL4B substrate-specific adaptor protein that  
 targets Sox2 for ubiquitination. 
 
 For the first time in this study, the CUL4B isoform of CUL4 was identified as  
being involved in the degradation of Sox2. The best known CUL4 E3 ligases are 
multi-subunit complexes containing CUL4, ROC1/RBX1 and DDB1. DDB1 binds to 
a WD40 repeat containing protein which serves as the substrate-specific adaptor 
protein. These ligases are involved in DNA damage repair and cell cycle progression. 
Although ROC1/RBX1 was identified by mass spectrometry in this study as an 
interactor with Sox2, DDB1 was not identified significantly above the control IP 
following the high stringency selection criteria used in this study. This could be due 
to the fact that the criteria used in this study to define interactors may have been too 
stringent.  
In addition, since CUL4B was observed to be primarily cytoplasmic in ES 
cells and translocated to the nucleus only upon entry into mitosis, where CUL4A is 
capable of substituting for CUL4B function. This observation leads to the following 
hypothesis: That Sox2 is degraded in the nucleus by a CUL4A/B –ROC1-DDB1-
WD40 domain-containing protein X during mitosis. In order to identify protein X, 
the Sox2 interaction data set from this study should be searched for all WD40 repeat 
containing proteins. Each protein identified would then be tested for their ability to 
co-purify with Sox2. Once identified, an in vitro ubiquitination assay using purified 
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Sox2, ROC1/RBX1, DDB1 and the yet to be identified WD40 repeat-containing 
protein should be performed. If this is unsuccessful an IP-LC-MS/MS should be 
performed on HA-Sox2 cells synchronized in mitosis in an attempt to enrich for this 
low abundant ligase. 
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CHAPTER 5: Thesis Summary/Conclusion 
  
5.1      The IP-LC-MS/MS Protein-Protein Interaction Networks in mESCs 
The data presented in this thesis originated from a desire to identify post-
translational mechanisms that govern pluripotency. This was achieved by employing 
an IP-LC-MS/MS strategy developed specifically for the identification of proteins 
that interact with Nanog, Sox2, Esrrβ and Sall4. By employing this strategy, novel 
protein interactions unique to this study were observed. This has provided a very 
different view of the protein interaction landscape in mESCs compared to that from 
the 10 previously reported studies summarized by Mallana and Rizzino, 2012.  
While high salt buffers are commonly used when extracting transcription 
factors and nuclear proteins from cells, these high ionic strength conditions also 
disrupt weak protein-protein interactions. Since the goal of this study was to identify 
the weak and typically transient interactions that occur between a kinase or 
phosphatase and its target, lower ionic strength buffers (250 mM NaCl) were 
employed at all steps during immunopurifications. Although lower salt containing 
buffers were used, Benzonase as well as the physical shearing of cells with pipette 
tips were employed to ensure adequate lysis of both cells and nuclei.  
The interaction networks described in this thesis have extended our view of 
the protein-protein interactions in which these pluripotency factors engage with a 
variety of kinases, phosphatases and E3 ubiquitin ligases, indicating enzymes that 
may be modulate the abundance or activity of pluripotency factors. As a result, the 
protein interaction networks identified in this study have perhaps laid the foundation 
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for future work to identify means by which the stabilization or destabilization of 
pluripotency may be achieved. 
  
5.2 Nanog Interacting Proteins 
 The protein interaction network ascertained for Nanog under the lower ionic 
strength conditions used in this study contains several novel interactors including 
Sox2, Esrrβ, Pik3cd, BRCA2 and CUL4B. Additionally, several proteins responsible 
for performing various types of post-translational modifications were identified to 
interact with Nanog. In total, 7 kinases, 2 cullins, 5 E3 ubiquitin ligases and 1 F-box 
protein were identified. The Nanog protein interaction network presented in this 




 BRCA2, a known tumour suppressor protein whose best characterized 
function is its involvement in error-free repair of double-stranded DNA breaks 
through homologous recombination and the (Duncan et al., 1998; Sarkisian et al., 
2001; Yoshida and Miki, 2004), was also found to be an interactor. This is an 
entirely novel aspect of the present study and suggests a role for Nanog in the 
maintenance of the genomic integrity of ES cells. Furthermore, this hints that the 
gateway to pluripotency may be mediated, in part, by DNA damage and repair. 
 It has been previously reported that both DNA damage and differentiation 
significantly decrease when cells are grown under hypoxic conditions (Di Carlo et  
al., 2004; Moore and Lemishka, 2006; Pires et al., 2010) due to a decrease in the  
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production of Reactive Oxygen Species (ROS) (Evans and Cooke, 2004; Bertram  
and Hass, 2008; Guachalla and Rudolph, 2010) . In addition, a recent body of  
literature (Larsen et al., 2010a; Larsen et al., 2010b; Milyavsky et al., 2010) points to  
the requirement for adult stem cells to damage their own DNA in order to reveal 
genetic elements deeply buried within the structure of DNA and allow transcriptional  
programs associated with differentiation to become activated (Fernando and  
Megeney, 2007; Abdul-Ghani and Megeney, 2008; Larsen et al., 2010b; Milyavsky  
et al., 2010). Could this also be true for embryonic stem cells? 
 The observed Nanog-BRCA2 interaction in this study lays the foundation for 
a rather appealing hypothesis to be tested in future work. 
 
5.2.2 The Nanog-BRCA2 Hypothesis 
BRCA2 was identified as an interactor with Nanog in normoxic conditions 
(Chapter 3 of this study) when levels of DNA damage-inducing ROS are high. 
Therefore, it was hypothesized that this interaction would be less pronounced in 
hypoxia when ROS-induced DNA damage levels are lowered. This hypothesis is 
illustrated in Figure 5.1. The red arrows indicate that the Nanog-BRCA2 interaction 
is either promoted (required) or inhibited (no longer required). The red question mark 
indicates that it is not known whether or not the Nanog-BRCA2 interaction is 





Figure 5.1: Model of Nanog interaction with BRCA2 in order to facilitate DNA damage 
repair and prevent differentiation of ES cells. In this model, Nanog and BRCA2 participate in 
DNA damage repair due to oxidative stress. In physiological conditions, this interaction is no longer 
needed as DNA damage ceases due to lowered oxygen tension.  
 
 
5.2.3 The BRCA2 and Hmg20b complex  
 In addition to its role in DNA damage repair, BRCA2 is also known to 
regulate entry into mitosis through its interaction with Hmg20b. Hmg20b was first 
identified as BRAF35 (BRCA2 Associated Factor 35), the DNA-binding component 
of a complex it forms with the BRCA2 protein. Together, Hmg20b and BRCA2 were 
shown to be involved in cell cycle progression at the G2/M transition (Marmorstein 
et al., 2001). Hmg20b is also part of a complex devoid of BRCA2 in which it 
associates with several histone deacetylase proteins and participates in the repression 
of neuronal-specific genes through chromatin remodeling (Hakimi et al., 2002; 
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Hakimi et al., 2003; Iwase et al., 2004). In Chapter 3, both BRCA2 and its 
interacting partner Hmg20b (in the Esrrβ protein interaction network) were identified 
as part of the integrated interaction network in this work. The identification of both 
BRCA2 and Hmg20b may indicate a role for the Nanog-BRCA2 interaction in cell 
cycle progression, chromatin remodeling, neuronal gene-specific transcriptional 
repression and DNA repair. Further investigation of this complex and its association 
with Nanog may uncover unknown functions of these proteins in the maintenance of 
pluripotency.   
 
5.3 Modulation of Nanog and Sox2 Using Small Molecules and Cell 
Permeable Peptides 
 
 In Chapter 4 of this work, a chemical biology approach was taken in order to 
identify interrogate the potential action of the identified kinases and Cullin-RING 
ligases (CRLs) on Nanog. Novel to this work is the identification of several small 
molecules capable of either elevating phospho-Nanog levels (MLN4924, PKI (14- 
22) amide, AurkiIII, Ht-31 and Nocodazole) or depleting phospho-Nanog levels 
(H89, Wortmannin and Forskolin) in mESCs.  
 Since phosphorylation of Nanog has been reported to stabilize Nanog and  
induce Nanog-Nanog dimer formation (Moretto-Zita et al., 2010), it is postulated  
here that some of the compounds identified in this study may stabilize phospho- 
Nanog levels, induce dimer formation and close the gateway to differentiation. This 
will require to be demonstrated by further experimentation in which mESCs treated 
with the phospho-Nanog elevating compounds identified here are induced to 
differentiate. A delay in the induction of mESC differentiation would functionally 




Although the IP-LC-MS/MS studies performed by both Pardo (Pardo et al., 
2010) and Van den Berg (Van den Berg et al., 2010) identified Akap8 (Protein 
kinase A anchoring protein) as part of their protein interaction networks, neither 
study identified the kinase itself. Novel to this study was the identification of several 
components of the PKA signaling pathway as part of the integrated protein 
interaction network. Among them were, Akap8 and the regulatory subunits of PKA 
itself. Using small molecules and sequence-specific cell permeable peptides, it was 
shown in this study that the specific inhibition of components of the PKA signaling 
pathway modulates both Nanog and Sox2 proteins in mESCs.  
While preparing to defend this thesis, a work by Yamimizu et al., 2012 was 
published in Cell Stem Cell. In this work, Yamamizu and colleagues demonstrate 
that specifically inhibiting PKA using PKI (14-22) amide delays differentiation of 
mESCs by maintaining elevated Nanog transcript levels. However, the ability of PKI 
(14-22) to elevate phospho-Nanog protein levels in mESCs currently remains novel 
to this thesis.  
  
5.4 Modulation of Nanog and Sox2 by Inhibiting Cullin RING Ligase 
Activity in mESCs 
 
 Among the compounds identified to elevate phospho-Nanog levels in this  
work was the pan-Cullin RING Ligase inhibitor, MLN4924. This raises the  
possibility that there may be several phosphorylated forms of Nanog that exist in  
mESCs. That is, phospho-Nanog proteins which are stabilized and may form Nanog- 
Nanog dimers and other forms which are ubiquitinated by an unidentified CRL and  
subsequently degraded by the 26S proteasome. 
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 In an effort to identify the exact CRL involved in the degradation of  
Nanog, each cullin protein identified as being part of the integrated protein  
interaction network in this study was inhibited using shRNA. Specific shRNA  
inhibition of CUL3 resulted in a 100% increase in Nanog levels as well as causing  
Nanog protein to be expressed 8 hours earlier than in control shRNA cells following  
release from mitotic arrest.  These results are the first demonstration that Nanog may  
be targeted by a CRL E3 ubiquitin ligase in a cell cycle-dependent manner. 
 Also in this work, it is shown that Sox2 protein levels are increased by 190%  
in response to CUL4B inhibition by shRNA. Taken together with the observed  
timing of Nanog expression in the CUL4B shRNA cells, it would appear that Sox2 is  
also being degraded in a cell cycle-dependent manner similar to Nanog. This is the  
first demonstration that Sox2 may be degraded  by a CRL E3 Ubiquitin ligase. 
 
5.5 Co-localization of Nanog, Sox2 and CUL4A/B in mESCs 
 
 In Chapter 4 it was shown that Nanog and Sox2 proteins co-localize with  
each other and that this co-localization appears to be strongest during mitosis on  
mitotic spindles and condensed chromosomes. Furthermore, it is shown in this work  
that Sox2 and CUL4A/B immunostaining occurs primarily in the cytoplasm with the  
exception of mitosis, where both protein localize to the nucleus.  
While a cytoplasmic localization for Sox2 has been reported by others, (eg.,  
Baltus et al., 2009), it remains possible that this immunostaining is non-specific. For  
example, it is possible that the blocking steps performed during immunostaining  
were unsuccessful and incomplete resulting in high levels of background staining in 
the cytoplasm. It is also possible that the primary or secondary antibodies themselves 
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recognize other epitopes than those they were intended to bind. This explanation 
seems highly unlikely since the immunostaining experiments on the 3XFLAG-Nanog 
cell line as well as the CUL4B shRNA cell line were performed using exactly the 
same protocol, primary and secondary antibodies.  
 One way to address concerns regarding the specificity of the antibodies used 
would be to perform the same immunostaining experiments on the CUL4B shRNA 
cell line and the parental control line using a Sox2 antibody both with and without a 
Sox2 epitope blocking peptide. The disappearance of Sox2 signal from the cytoplasm 
and/or mitotic spindles will indicate that the immunofluorescence signal in the 
cytoplasm and at mitotic spindles is indeed indicative of Sox2. Another control for 
non-specific interaction of the Sox2 antibody used would be to perform Sox2 
immunostaining on a Sox2 shRNA cell line. If a large amount of 
immunofluorescence is detected in the cytoplasm in this cell line, it would clearly 
indicate a lack of specificity by the antibody employed in this study. In order to 
determine the non-specific interactions by the secondary antibodies used in this 
study, cells should be incubated with the secondary antibodies alone. This type of 
experiment will reveal whether or not the fluorescent signals observed in this work 
are the result of the secondary antibodies binding to components of the blocking 
reagent employed. 
Yet another experimental control would be to perform anti-HA 
immunostaining on the 6XHA-Sox2 cell line developed in this study. 
Immunostaining could be performed both in the presence and absence of the 6XHA 
peptide. This experiment would reveal the cellular localization of the 6XHA-Sox2 
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protein used to ascertain the Sox2 protein interaction network by IP-LC-MS/MS in 
this study. 
With regards to the cytoplasmic immunostaining observed for CUL4A/B in 
this study, further experiments should be performed using the CUL4B-specific 
antibody developed by Guerrero-Santoro et al., 2006. Additionally, by 
immunostaining for CUL4B in the presence of the CUL4B blocking peptide that 
Guerrero-Santoro et al., 2006 used, the disappearance of CUL4B signal will indicate 
where the CUL4B protein is localized in mESCs. 
 While some future work remains to be performed with regards to 
immunofluorescence controls, the identification here that the specific inhibition of 
the CUL4B isoform elevates Sox2 levels provides a novel insight into the post-
translational regulation of this pluripotency factor. Furthermore, the data presented in 
Chapter 4 of this thesis provides evidence that the abundance of Nanog and Sox2 
proteins may be modulated by non-genetic means in mESCs. The novel pathways 
and chemical inhibitors identified in this work have further extended of knowledge 
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